<div id="page0" style="width:595.3pt;height:793.7pt">
<p style="top:64.3pt;left:56.7pt;line-height:10.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.5pt;color:#131313">REVIEW ARTICLE</span></p>
<p style="top:105.9pt;left:51.0pt;line-height:17.4pt"><span style="font-family:XssngvAdvTTb8864ccf.B,serif;font-size:17.4pt;color:#131313">Platelet-rich plasma for the treatment of bone</span></p>
<p style="top:124.8pt;left:51.0pt;line-height:17.4pt"><span style="font-family:XssngvAdvTTb8864ccf.B,serif;font-size:17.4pt;color:#131313">defects: from pre-clinical rational to evidence in the clinical</span></p>
<p style="top:143.8pt;left:51.0pt;line-height:17.4pt"><span style="font-family:XssngvAdvTTb8864ccf.B,serif;font-size:17.4pt;color:#131313">practice. A systematic review</span></p>
<p style="top:179.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:XssngvAdvTTb8864ccf.B,serif;font-size:10.0pt;color:#131313">Alice Roffi</span><sup><span style="font-family:XssngvAdvTTb8864ccf.B,serif;font-size:7.0pt;color:#131313">1</span></sup><sup><span style="font-family:WswsfsAdvP0005,serif;font-size:8.0pt;color:#131313"> </span></sup><span style="font-family:WswsfsAdvP0005,serif;font-size:8.0pt;color:#131313">&amp;</span><span style="font-family:XssngvAdvTTb8864ccf.B,serif;font-size:10.0pt;color:#131313"> Berardo Di Matteo</span><sup><span style="font-family:XssngvAdvTTb8864ccf.B,serif;font-size:7.0pt;color:#131313">1,2</span></sup><sup><span style="font-family:WswsfsAdvP0005,serif;font-size:8.0pt;color:#131313"> </span></sup><span style="font-family:WswsfsAdvP0005,serif;font-size:8.0pt;color:#131313">&amp;</span><span style="font-family:XssngvAdvTTb8864ccf.B,serif;font-size:10.0pt;color:#131313"> Gopal Shankar Krishnakumar</span><sup><span style="font-family:XssngvAdvTTb8864ccf.B,serif;font-size:7.0pt;color:#131313">1</span></sup><sup><span style="font-family:WswsfsAdvP0005,serif;font-size:8.0pt;color:#131313"> </span></sup><span style="font-family:WswsfsAdvP0005,serif;font-size:8.0pt;color:#131313">&amp;</span><span style="font-family:XssngvAdvTTb8864ccf.B,serif;font-size:10.0pt;color:#131313"> Elizaveta Kon</span><sup><span style="font-family:XssngvAdvTTb8864ccf.B,serif;font-size:7.0pt;color:#131313">1</span></sup><sup><span style="font-family:WswsfsAdvP0005,serif;font-size:8.0pt;color:#131313"> </span></sup><span style="font-family:WswsfsAdvP0005,serif;font-size:8.0pt;color:#131313">&amp;</span></p>
<p style="top:191.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:XssngvAdvTTb8864ccf.B,serif;font-size:10.0pt;color:#131313">Giuseppe Filardo</span><sup><span style="font-family:XssngvAdvTTb8864ccf.B,serif;font-size:7.0pt;color:#131313">3</span></sup></p>
<p style="top:248.9pt;left:51.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Received: 31 October 2016 /Accepted: 7 November 2016 /Published online: 26 November 2016</span></p>
<p style="top:258.0pt;left:51.0pt;line-height:8.5pt"><span style="font-family:PssjrlAdvPi3,serif;font-size:8.5pt;color:#131313">#</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> The Author(s) 2016. This article is published with open access at Springerlink.com</span></p>
<p style="top:282.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:XssngvAdvTTb8864ccf.B,serif;font-size:10.0pt;color:#131313">Abstract</span></p>
<p style="top:294.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:10.0pt;color:#131313">Purpose</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313"> The treatment of large bone defects represents a sig-</span></p>
<p style="top:306.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">nificant challenge for orthopaedic surgeons. In recent years,</span></p>
<p style="top:318.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">biologic agents have also been used to further improve bone</span></p>
<p style="top:331.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">healing. Among these, platelet-rich plasma (PRP) is the most</span></p>
<p style="top:343.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">exploited strategy. The aim of the present study was to sys-</span></p>
<p style="top:356.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">tematically review the available literature to identify: 1) pre-</span></p>
<p style="top:368.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">clinical in-vivo results supporting the rational of PRP use for</span></p>
<p style="top:381.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">bone healing; 2) evidence from the clinical practice on the</span></p>
<p style="top:393.6pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">actual clinical benefit of PRP for the treatment of fractures</span></p>
<p style="top:406.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">and complications such as delayed unions and non-unions.</span></p>
<p style="top:418.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:10.0pt;color:#131313">Methods</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313"> A systematic review of the literature was performed</span></p>
<p style="top:430.6pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">on the application of PRP in bone healing, using the following</span></p>
<p style="top:443.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">inclusion criteria: pre-clinical and clinical reports of any level</span></p>
<p style="top:455.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">of evidence, written in English language, published in the last</span></p>
<p style="top:467.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">20 years (1996</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:10.0pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">2016), on the use of PRP to stimulate long-</span></p>
<p style="top:480.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">bone defect treatment, with focus on fracture and delayed/</span></p>
<p style="top:492.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">non-unions healing.</span></p>
<p style="top:504.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:10.0pt;color:#131313">Results</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313"> The search in the Pubmed database identified 64 arti-</span></p>
<p style="top:517.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">cles eligible for inclusion: 45 were preclinical in-vivo studies</span></p>
<p style="top:529.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">and 19 were clinical studies. Despite the fact that the overall</span></p>
<p style="top:542.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">pre-clinical results seem to support the benefit of PRP in</span></p>
<p style="top:554.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">91.1 % of the studies, a more in depth analysis underlined a</span></p>
<p style="top:567.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">lower success rate, with a positive outcome of 84.4 % in terms</span></p>
<p style="top:282.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">of histological analysis, and even lower values considering</span></p>
<p style="top:294.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">radiological and biomechanical results (75.0 % and 72.7 %</span></p>
<p style="top:307.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">positive outcome respectively). This was also mirrored in the</span></p>
<p style="top:319.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">clinical literature, where the real benefit of PRP use to treat</span></p>
<p style="top:331.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">fractures and non-unions is still under debate.</span></p>
<p style="top:343.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:10.0pt;color:#131313">Conclusion</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313"> Overall, the available literature presents major</span></p>
<p style="top:356.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">limitations in terms of low quality and extreme heterogeneity,</span></p>
<p style="top:368.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">which hamper the possibility to optimize PRP treatment and</span></p>
<p style="top:381.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">translate it into a real clinical benefit despite positive preclin-</span></p>
<p style="top:393.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">ical findings on its biological potential to favour bone healing.</span></p>
<p style="top:425.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:XssngvAdvTTb8864ccf.B,serif;font-size:10.0pt;color:#131313">Keywords</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313"> Bone defect </span><sup><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">. </span></sup><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">Bone healing </span><sup><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">. </span></sup><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">Fracture </span><sup><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">. </span></sup><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">Growth</span></p>
<p style="top:437.7pt;left:306.2pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">factors </span><sup><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">. </span></sup><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">Non-union </span><sup><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">. </span></sup><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">PRP</span></p>
<p style="top:480.9pt;left:306.1pt;line-height:11.0pt"><span style="font-family:XssngvAdvTTb8864ccf.B,serif;font-size:11.0pt;color:#131313">Introduction</span></p>
<p style="top:506.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">The treatment of large bone defects represents a significant clin-</span></p>
<p style="top:519.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">ical challenge for orthopaedic surgeons [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96">1</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">,</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96"> 2</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">]. The well-</span></p>
<p style="top:531.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">orchestrated regenerative ability of bone to heal is hampered,</span></p>
<p style="top:544.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">in the case of complex defects, by the lack of a template for</span></p>
<p style="top:556.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">regeneration and, eventually, it requires surgical intervention</span></p>
<p style="top:568.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">[</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96">3</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">]. Autografts and allografts are considered to be the major</span></p>
<p style="top:581.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">bone substitutes, however they each have their own limitations</span></p>
<p style="top:593.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">regarding availability, donor site morbidity and chronic pain,</span></p>
<p style="top:606.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">leading to not always optimal results [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96">4</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">]. In order to overcome</span></p>
<p style="top:618.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">these issues, several bone substitute materials have been devel-</span></p>
<p style="top:631.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">oped and applied in the clinical practice [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96">5</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">,</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96"> 6</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">]. To further im-</span></p>
<p style="top:643.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">prove the success rates, co-adjuvant agents have also been pro-</span></p>
<p style="top:656.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">posed, which may enhance implant osseointegration potential</span></p>
<p style="top:668.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">and restore bone tissue function [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96">7</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">]. Among these, growth fac-</span></p>
<p style="top:681.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">tors (GFs) are expressed during different phases of tissue healing</span></p>
<p style="top:693.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">and may represent a key element in promoting tissue regenera-</span></p>
<p style="top:705.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">tion [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96">8</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">]. In fact, GFs delivered through orthopaedic devices have</span></p>
<p style="top:606.0pt;left:51.0pt;line-height:8.5pt"><span style="font-family:TbvbwgAdvTT4ff65459,serif;font-size:8.5pt;color:#131313">*</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> Berardo Di Matteo</span></p>
<p style="top:615.9pt;left:66.5pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">berardo.dimatteo@gmail.com</span></p>
<p style="top:645.1pt;left:51.0pt;line-height:6.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:6.0pt;color:#131313">1</span></p>
<p style="top:646.8pt;left:65.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Nano-Biotechnology Laboratory, Rizzoli Orthopaedic Institute, Via</span></p>
<p style="top:656.8pt;left:65.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">di Barbiano 1/10, 40136 Bologna, Italy</span></p>
<p style="top:670.0pt;left:51.0pt;line-height:6.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:6.0pt;color:#131313">2</span></p>
<p style="top:671.7pt;left:65.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">I Orthopaedic and Traumatologic Clinic, Rizzoli Orthopaedic</span></p>
<p style="top:681.7pt;left:65.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Institute, Via Pupilli 1, 40136 Bologna, Italy</span></p>
<p style="top:694.9pt;left:51.0pt;line-height:6.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:6.0pt;color:#131313">3</span></p>
<p style="top:696.7pt;left:65.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Biomechanics Laboratory, Rizzoli Orthopaedic Institute, Via di</span></p>
<p style="top:706.6pt;left:65.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Barbiano 1/10, 40136 Bologna, Italy</span></p>
<p style="top:32.9pt;left:51.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">International Orthopaedics (SICOT) (2017) 41:221</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">237</span></p>
<p style="top:44.4pt;left:51.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">DOI 10.1007/s00264-016-3342-9</span></p>
<img style="position:absolute;transform:matrix(.31190364,0,-0,.30984629,637.36007,17.14801)" src="data:image/png;base64,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">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,670,48.666669)" src="data:image/png;base64,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">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,671.6667,49.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAA4AAAANCAYAAACZ3F9/AAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAoUlEQVR4nKXSCRKDIBBEUe9/xyQsA8imcoKOEzWlZCviAX71o4au
lIJxmjAMA1LOiDHBh4Dee1jXw1gLbQykJgilcBUSl5tA9wjHNUwZIcY5CnA9Rw40
R4oIUmkIWYe7RQ55kUPrOJwXiRd/hPEZLlSyW/iVmhqp1Rv9Fq5U1U51O6p+Rx2R
D9TtFKepdJL6urhQI1PDX9TqHC3UUFM//Jw7n3Gi6v8uu+IAAAAASUVORK5CYII=">
<img style="position:absolute;transform:matrix(.31995113,0,-0,.3019969,659.53506,63.748064)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAACYAAAAECAIAAABtO9rEAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAABKklEQVR4nG2QTauCQBiF/ZsuWriL/oFtrt608rNSCsFPEA0CNwoS
tohoU4tAXIgLXbRx0a/oMHIhuJ3NzDtz3vO8M1Sapr7v8zzPMAxN0+PxmGVZjuP4
P3Ef+vmmT8PQ8kuEzXQ6nUwmo9EIscvlcr/fH49H6nq9guo4zmKxgGk+n8uyLEkS
SlEUZ0RD/9chPs9hg1kQBIQAoCiKqqqIQqlpWhiGRVHc73eqrmssKJIkiaIoCALb
trfb7Xq9hg94NA94gWj2TzjELXJhAwCY1WplmqZlWZ7nIfNwOGRZdrlcyrJs25bq
+77ruqqqbrfb+XzO8xzsOI4H9m63MwwDeF3XkYXBZSKJCBuFCMMBs9lsMCtIruvi
TSDh/06nEz7y8Xg0TfN8Pl+v1xv6dgZFXPTL+gAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(.31998969,0,-0,.28959964,659.49588,63.668016)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAACYAAAAFCAIAAACmZwlhAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAsUlEQVR4nGNoqKmqLi9NS07ycHWxsbL08fJMTU4sKy6sra4ESpGN
aivLSwvzkxPivD3c7Wys/Xy8cjLSa6vKgVIMQFxTWZ6fkxUbFRkVHpaRmlxeXFRX
VUGJfVBbqyrKigrSk5OiI8IS42OL8/MgxoKsrK+urCwrKS7IKynMryovrafMf8gI
YnJJQT7Qx8CwrAcLMsDlgE6oq66sp5JlCFtrqurAhsN9woAkXU1dy3AhADOVDFwu
cjTeAAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(.31998969,0,-0,.30733408,659.49588,58.548006)" src="data:image/png;base64,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">
<img style="position:absolute;transform:matrix(.31998969,0,-0,.31200043,659.49588,59.828016)" src="data:image/png;base64,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">
<img style="position:absolute;transform:matrix(.31998969,0,-0,.3158573,659.49588,28.18806)" src="data:image/jpeg;base64,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">
<img style="position:absolute;transform:matrix(.31998969,0,-0,.30879925,659.49588,58.128046)" src="data:image/png;base64,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">
<img style="position:absolute;transform:matrix(.31998969,0,-0,.274665,659.49588,47.008039)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAACYAAAAGCAIAAAAg83vPAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAeklEQVR4nOXPMQ5EEQAEUITCFSg0dG5Eo/46pyLREichoXGTlfxi
LyDb7CTTTfIyYO89xsg5O+eEEIQQCCG4FIQQpVRrHUJora21DgdOe+8pJWst5/yM
bnlvzgellPe+1jrn/JIxRmMMY+w6iTGWUh6ylPJT8nmePyM/OIlqMP/lGCwAAAAA
SUVORK5CYII=">
<img style="position:absolute;transform:matrix(.32007797,0,-0,.2813348,672.81668,45.18806)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAABEAAAAGCAIAAACq3OKOAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAA/UlEQVR4nGPIygaCnIKCgvKKivr6hq7u7ukzZixbvnzbtu1Hjh27
ePHSzVu37z14+PDR40ePnzwEoccM6uoaQKCtrW1gYGBubuHo6Ojr5xcXF1dYVNzR
2blgwcKt27efOHnq6vXrd+8/ePDoMUgPKysrGxsbOzs7BwcHNzc3Hx+/qIiIrKys
lpaWtY1NUHBwXn5+T1/f6jVrjxw9euXa9bv37jMwwgATExMzMzPQCHawZhERYXl5
eQNDQ09Pz/T0jK6u7lWr1xw5dvza9RsMWAHECKB+Li4uERERNTU1B0fH1NTUvgkT
tm7bjl0Pmmags4UEBdXU1X18/ZqaWwDQkmGQhqVZ6QAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,49.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAAPCAYAAADZCo4zAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAABIklEQVR4nH2OTUsCURiF37/idVLHzGEMnAgkIqhFNEVIQhDiulX0
A1oFbdu0qJ1/oMLxI9CoCMo+MNqIUK2KIAgqCFd1mnOLcFq0eLjnPOdyuYLdHP5D
usVZvGxM4XF1IsDbpovP7TlIZzGD1ryDppsKQMdN6k4cVSsKz+z7pZKIoGbHwE1K
UQPE66HUg3gxA2Wfyh/ouEnVDKPmsxcPQsdNWOr9YTQSQei4yb5fDgYUDpMKRz8w
03ETimNL4cRWOLVDGmY6XhKW88EQWsMGrjIRDXsz9X1RzvxwPWaik7VxVxjCzUJa
ZzpucplWuM07eFoZx/PapD4flke14yZ8kuV1fRofO3l0izmd6bhJ203ifmkE71tZ
oFzQJ3t7xsKF/5cv6okUP5rk6/oAAAAASUVORK5CYII=">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,52.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAFElEQVR4nGOYpiD3H4SnI+FpSBgA7EUOnDmtauYAAAAASUVORK5CYII=">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,52.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAACCAYAAABllJ3tAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAIklEQVR4nGPYqCD3H4Q3IeGNSJhhs6LcfxDegoZBYpuAGAD2mh7/
rAWZaQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,52.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAFElEQVR4nGOYIiP1H4SnIuEpSBgA5wUOTKZlFIcAAAAASUVORK5CYII=">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,52.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAFElEQVR4nGOYpiD3H4SnI+FpSBgA7EUOnDmtauYAAAAASUVORK5CYII=">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,52.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAFElEQVR4nGPYqCD3H4Q3IeGNSBgA+3UPdMB+IvYAAAAASUVORK5CYII=">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,52.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAFElEQVR4nGOYIiP1H4SnIuEpSBgA5wUOTKZlFIcAAAAASUVORK5CYII=">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,52.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAFElEQVR4nGOYpiD3H4SnI+FpSBgA7EUOnDmtauYAAAAASUVORK5CYII=">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,52.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAFElEQVR4nGPYqCD3H4Q3IeGNSBgA+3UPdMB+IvYAAAAASUVORK5CYII=">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,52.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAFElEQVR4nGOYIiP1H4SnIuEpSBgA5wUOTKZlFIcAAAAASUVORK5CYII=">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,51)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAACCAYAAABllJ3tAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAALElEQVR4nGOYq6f8f6a6wv/pSvJwPENV4f8sTcX/IDmGaQpy/0F4
OhKehoQBzY0dmWFUtZ0AAAAASUVORK5CYII=">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,52.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAFElEQVR4nGPYqCD3H4Q3IeGNSBgA+3UPdMB+IvYAAAAASUVORK5CYII=">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,52.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAFElEQVR4nGOYIiP1H4SnIuEpSBgA5wUOTKZlFIcAAAAASUVORK5CYII=">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,51.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAIElEQVR4nGOYq6f8f6a6wv/pSvJwPENV4f8sTcX/IDkA8n4O/jm4
VbcAAAAASUVORK5CYII=">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,51.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAIElEQVR4nGPYpav8f6u6wv9NSvJwvEVV4f92TcX/IDkAAhsP3AEA
394AAAAASUVORK5CYII=">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,51.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAIElEQVR4nGOYrS73f7qizP+pctJwPE1e+v9MZdn/IDkA7FwOoENx
ut8AAAAASUVORK5CYII=">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,51.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAIElEQVR4nGOYq6f8f6a6wv/pSvJwPENV4f8sTcX/IDkA8n4O/jm4
VbcAAAAASUVORK5CYII=">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,51.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAIElEQVR4nGPYpav8f6u6wv9NSvJwvEVV4f92TcX/IDkAAhsP3AEA
394AAAAASUVORK5CYII=">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,51.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAIElEQVR4nGOYrS73f7qizP+pctJwPE1e+v9MZdn/IDkA7FwOoENx
ut8AAAAASUVORK5CYII=">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,51.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAIElEQVR4nGOYq6f8f6a6wv/pSvJwPENV4f8sTcX/IDkA8n4O/jm4
VbcAAAAASUVORK5CYII=">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,51.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAIElEQVR4nGPYpav8f6u6wv9NSvJwvEVV4f92TcX/IDkAAhsP3AEA
394AAAAASUVORK5CYII=">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,51.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAIElEQVR4nGOYrS73f7qizP+pctJwPE1e+v9MZdn/IDkA7FwOoENx
ut8AAAAASUVORK5CYII=">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,50)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAGklEQVR4nGPYGmX8f52P3v/ljlooGCQGkgMAFowRFaWPoagAAAAA
SUVORK5CYII=">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,50)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAGklEQVR4nGO4Fmn8/6y33v+jjlooGCQGkgMAJ7gSCUSvAw4AAAAA
SUVORK5CYII=">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,50)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAGklEQVR4nGPY7KPzf7Wj+v+lFiooGCQGkgMADFIQecPWCiwAAAAA
SUVORK5CYII=">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,50)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAGklEQVR4nGPYGmX8f52P3v/ljlooGCQGkgMAFowRFaWPoagAAAAA
SUVORK5CYII=">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,50)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAGklEQVR4nGO4Fmn8/6y33v+jjlooGCQGkgMAJ7gSCUSvAw4AAAAA
SUVORK5CYII=">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,50)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAGklEQVR4nGPY7KPzf7Wj+v+lFiooGCQGkgMADFIQecPWCiwAAAAA
SUVORK5CYII=">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,50)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAGklEQVR4nGPYGmX8f52P3v/ljlooGCQGkgMAFowRFaWPoagAAAAA
SUVORK5CYII=">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,50)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAGklEQVR4nGO4Fmn8/6y33v+jjlooGCQGkgMAJ7gSCUSvAw4AAAAA
SUVORK5CYII=">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,50)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAGklEQVR4nGPY7KPzf7Wj+v+lFiooGCQGkgMADFIQecPWCiwAAAAA
SUVORK5CYII=">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,48.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAH0lEQVR4nGM41+Hy/0Stw/+DBTYo+FSD0/8rkzz+AwBHcRQGUDUA
0gAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,48.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAACCAYAAABllJ3tAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAMUlEQVR4nGP43O7y/02tw/8n+TYo+F2D0/9fkzz+M1yLNP5/1lvv
/1FHLRQMEgPJAQA8EicoGoYxGAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,48.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAHklEQVR4nGM4U2L1/1i2+f/9CcYo+ESu5f9Ltbb/AThZEx3dlzBh
AAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(.31992594,0,-0,.28798429,672.73599,48.768037)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAIAAAABCAIAAAB7QOjdAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAD0lEQVR4nGNoa2/Pzc0DAAp5At2lO+4NAAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,48.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAH0lEQVR4nGM41+Hy/0Stw/+DBTYo+FSD0/8rkzz+AwBHcRQGUDUA
0gAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,48.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAH0lEQVR4nGP43O7y/02tw/8n+TYo+F2D0/9fkzz+AwBbLhUgSUiK
4gAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(.3199463,0,-0,.24796549,673.576,48.868043)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAIAAACQd1PeAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADElEQVR4nGMoTUsHAAKWAUP0xgb7AAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,48.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAHklEQVR4nGM4U2L1/1i2+f/9CcYo+ESu5f9Ltbb/AThZEx3dlzBh
AAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(.32006837,0,-0,.28796388,673.3761,48.368066)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAIAAAABCAIAAAB7QOjdAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAD0lEQVR4nGOoqKxMTk4GAAlqApQ21l1SAAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,675,48.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAcAAAABCAYAAAASC7TOAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAGklEQVR4nGM41+Hy/0Stw/+DBTYo+FSD038A+2kRWQL+PLMAAAAA
SUVORK5CYII=">
<img style="position:absolute;transform:matrix(.31988529,0,-0,.16399127,673.1759,47.50805)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAIAAAD91JpzAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAFklEQVR4nGOYUFldm5nFUJWemRoWDgAm6wUxNWyXbgAAAABJRU5E
rkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,48.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAH0lEQVR4nGP43O7y/02tw/8n+TYo+F2D0/9fkzz+AwBbLhUgSUiK
4gAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(.3199463,0,-0,.24796549,674.17599,48.46806)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAIAAACQd1PeAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADElEQVR4nGPIjIoGAAJOAR84jf50AAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,675,48.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAcAAAABCAYAAAASC7TOAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAGklEQVR4nGM4U2L1/1i2+f/9CcYo+ESu5X8A78oQksdaHSkAAAAA
SUVORK5CYII=">
<img style="position:absolute;transform:matrix(.32006837,0,-0,.16399127,674.21609,46.98803)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAIAAAD91JpzAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAFklEQVR4nGOorqnJzslhSM/ICAsLAwAk4QTwJm5amQAAAABJRU5E
rkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,675.6667,47)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAACCAYAAAB7Xa1eAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAHUlEQVR4nGO4OsXzPzbMcKLW4f/BAhsUfKrB6T8AE/Qe5iFd70sA
AAAASUVORK5CYII=">
<img style="position:absolute;transform:matrix(.31999714,0,-0,.28796388,673.896,48.128076)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAIAAAABCAIAAAB7QOjdAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAD0lEQVR4nGPoLa8oSkwCAAoCArLkg/WaAAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,675.6667,48.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAYAAAD9yd/wAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAFklEQVR4nGN4U+vw/0m+DQp+1+D0HwDCGg+QRwi6qgAAAABJRU5E
rkJggg==">
<img style="position:absolute;transform:matrix(.3199463,0,-0,.20800787,675.05599,48.088056)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAIAAACQd1PeAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADElEQVR4nGOI8Q8AAAIGAPyDrAGBAAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,675.6667,48.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAYAAAD9yd/wAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAFklEQVR4nGM4lm3+f3+CMQo+kWv5HwCubw4ZpFSWgwAAAABJRU5E
rkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,676.6667,47.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAQAAAABCAYAAAD5PA/NAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAD0lEQVR4nGO4OsXzPzIGAFstCsWKzESaAAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(.3199056,0,-0,.24796549,680.576,47.70805)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAIAAACQd1PeAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADElEQVR4nGMoSEgEAAJ1ATKH/E//AAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,676,47.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAUAAAABCAYAAAAW/mTzAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAD0lEQVR4nGP4PdnzPzoGAJWTDi/gCE2lAAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(.3199056,0,-0,.24796549,680.576,47.70805)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAIAAACQd1PeAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADElEQVR4nGOIDQgCAAINAQACQv+WAAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,676.6667,47.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAQAAAABCAYAAAD5PA/NAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAD0lEQVR4nGO4XGf3HxkDAFZlCjmeBbcQAAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,54)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAE0lEQVR4nGOYrij3H4RnoGGYOADtaQ6tLz315AAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,54)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAFklEQVR4nGPYrCj3H4S3oGGQ2CYgBgD9JQ+M6ohiYwAAAABJRU5E
rkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,54)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAE0lEQVR4nGOYKiv1H4SnoWGYOADoKQ5dYsZloAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,54)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAE0lEQVR4nGOYrij3H4RnoGGYOADtaQ6tLz315AAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,54)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAFklEQVR4nGPYrCj3H4S3oGGQ2CYgBgD9JQ+M6ohiYwAAAABJRU5E
rkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,54)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAE0lEQVR4nGOYKiv1H4SnoWGYOADoKQ5dYsZloAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,54)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAE0lEQVR4nGOYrij3H4RnoGGYOADtaQ6tLz315AAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,54)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAFklEQVR4nGPYrCj3H4S3oGGQ2CYgBgD9JQ+M6ohiYwAAAABJRU5E
rkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,54)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAE0lEQVR4nGOYKiv1H4SnoWGYOADoKQ5dYsZloAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,55.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAGUlEQVR4nGOYqST3f6aS7P9ZyqgYJAaSAwDu9Q7DmlpgLwAAAABJ
RU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,55.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAF0lEQVR4nGPYqiT3fxsQb1dGxSAxkBwA/4EPr0CfpH4AAAAASUVO
RK5CYII=">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,55.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAGElEQVR4nGOYLif1f4ac5P+ZaBgkBpIDAOndDnU8VrEiAAAAAElF
TkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,55.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAGUlEQVR4nGOYqST3f6aS7P9ZyqgYJAaSAwDu9Q7DmlpgLwAAAABJ
RU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,55.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAF0lEQVR4nGPYqiT3fxsQb1dGxSAxkBwA/4EPr0CfpH4AAAAASUVO
RK5CYII=">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,55.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAGElEQVR4nGOYLif1f4ac5P+ZaBgkBpIDAOndDnU8VrEiAAAAAElF
TkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,55.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAGUlEQVR4nGOYqST3f6aS7P9ZyqgYJAaSAwDu9Q7DmlpgLwAAAABJ
RU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,55.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAF0lEQVR4nGPYqiT3fxsQb1dGxSAxkBwA/4EPr0CfpH4AAAAASUVO
RK5CYII=">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,55.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAGElEQVR4nGOYLif1f4ac5P+ZaBgkBpIDAOndDnU8VrEiAAAAAElF
TkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,55)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAACCAYAAABllJ3tAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAALElEQVR4nGOYqST3f6aS7P9ZyqgYJAaSYwBx5qrI/p+nKvt/PhSD
2CAxkBwAx98drUuqtkAAAAAASUVORK5CYII=">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,56.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAHklEQVR4nGPYriz3f5eK3P/dqnL/90AxiA0SA8kBAAKaD9s68eyu
AAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,56.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAHElEQVR4nGOYKSf5fzYQz5GX/D8XikFskBhIDgDrsQ6Ps7niUwAA
AABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,56.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAHklEQVR4nGOYpSz7f66K7P95qrL/50MxiA0SA8kBAPG7Dusy/hIa
AAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,56.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAHklEQVR4nGPYriz3f5eK3P/dqnL/90AxiA0SA8kBAAKaD9s68eyu
AAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,56.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAHElEQVR4nGOYKSf5fzYQz5GX/D8XikFskBhIDgDrsQ6Ps7niUwAA
AABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,56.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAHklEQVR4nGOYpSz7f66K7P95qrL/50MxiA0SA8kBAPG7Dusy/hIa
AAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,56.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAHklEQVR4nGPYriz3f5eK3P/dqnL/90AxiA0SA8kBAAKaD9s68eyu
AAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,56.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAHElEQVR4nGOYKSf5fzYQz5GX/D8XikFskBhIDgDrsQ6Ps7niUwAA
AABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,56.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAHklEQVR4nGOYpSz7f66K7P95qrL/50MxiA0SA8kBAPG7Dusy/hIa
AAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,56.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAACCAYAAABllJ3tAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAMUlEQVR4nGPYriz3f5eK3P/dqnL/90AxiA0SA8kxgAT2qsr+36cm
+38/FIPYIDGQHAASrh/VFt6fjAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,56.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAHElEQVR4nGOYKSf5fzYQz5GX/D8XikFskBhIDgDrsQ6Ps7niUwAA
AABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,58)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAHElEQVR4nGOYryr7f4Ga7P+FQLwIikFskBhIDgD0fw8TUK/Y/wAA
AABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,58)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAHklEQVR4nGPYoyr3f6+q7P99arL/90MxiA0SA8kBAATcD/uN77SC
AAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,58)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAHklEQVR4nGOYKy/5f56CxP/5ihL/F0AxiA0SA8kBAO4TDrEu1IZh
AAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,58)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAHElEQVR4nGOYryr7f4Ga7P+FQLwIikFskBhIDgD0fw8TUK/Y/wAA
AABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,58)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAHklEQVR4nGPYoyr3f6+q7P99arL/90MxiA0SA8kBAATcD/uN77SC
AAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,58)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAHklEQVR4nGOYKy/5f56CxP/5ihL/F0AxiA0SA8kBAO4TDrEu1IZh
AAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,58)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAHElEQVR4nGOYryr7f4Ga7P+FQLwIikFskBhIDgD0fw8TUK/Y/wAA
AABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,58)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAHklEQVR4nGPYoyr3f6+q7P99arL/90MxiA0SA8kBAATcD/uN77SC
AAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,58)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAHklEQVR4nGOYKy/5f56CxP/5ihL/F0AxiA0SA8kBAO4TDrEu1IZh
AAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,59.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAIUlEQVR4nGNYpCb7f4m67P9lmrL/l2vKgDGIDRJbAJQDAPfLD0HM
+fRMAAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,59.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAIklEQVR4nGPYryb7/6C67P8jmrL/j2rKgDGIDRLbqyr7HwAIbxAs
y6VpmAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,59.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAHklEQVR4nGNYoCjxfxEQL1GW+L8UikFskNg8BYn/APE6Dtzxiz5C
AAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,59.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAIUlEQVR4nGNYpCb7f4m67P9lmrL/l2vKgDGIDRJbAJQDAPfLD0HM
+fRMAAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,59.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAIklEQVR4nGPYryb7/6C67P8jmrL/j2rKgDGIDRLbqyr7HwAIbxAs
y6VpmAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,59.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAHklEQVR4nGNYoCjxfxEQL1GW+L8UikFskNg8BYn/APE6Dtzxiz5C
AAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,59.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAIUlEQVR4nGNYpCb7f4m67P9lmrL/l2vKgDGIDRJbAJQDAPfLD0HM
+fRMAAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,59.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAIklEQVR4nGPYryb7/6C67P8jmrL/j2rKgDGIDRLbqyr7HwAIbxAs
y6VpmAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,59.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAHklEQVR4nGNYoCjxfxEQL1GW+L8UikFskNg8BYn/APE6Dtzxiz5C
AAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,59)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAACCAYAAABllJ3tAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAANUlEQVR4nGNYpCb7f4m67P9lmrL/l2vKgDGIDRJbAJRjAHFWasv8
X6sv93+diQIYg/groAoB7XEe3Ip9TP8AAAAASUVORK5CYII=">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,60.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAIklEQVR4nGM4oin7/4S2zP8z+nL/zxorgDGIf0xT5j9IDgAPahCP
eAz60wAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,60.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAIUlEQVR4nGNYoizxf4WqxP9VGlL/V+tIgzGIvwwoDpIDAPc6DzJ9
rrrNAAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,60.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAIklEQVR4nGNYpin7f6W2zP+1+nL/15kogDGIv0JT5j9IDgD+OQ+c
qMOEpQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,60.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAIklEQVR4nGM4oin7/4S2zP8z+nL/zxorgDGIf0xT5j9IDgAPahCP
eAz60wAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,60.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAIUlEQVR4nGNYoizxf4WqxP9VGlL/V+tIgzGIvwwoDpIDAPc6DzJ9
rrrNAAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,60.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAIklEQVR4nGNYpin7f6W2zP+1+nL/15kogDGIv0JT5j9IDgD+OQ+c
qMOEpQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,60.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAIklEQVR4nGM4oin7/4S2zP8z+nL/zxorgDGIf0xT5j9IDgAPahCP
eAz60wAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,60.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAIUlEQVR4nGNYoizxf4WqxP9VGlL/V+tIgzGIvwwoDpIDAPc6DzJ9
rrrNAAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,60.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAIklEQVR4nGNYpin7f6W2zP+1+nL/15kogDGIv0JT5j9IDgD+OQ+c
qMOEpQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,60.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAACCAYAAABllJ3tAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAPUlEQVR4nGM4oin7/4S2zP8z+nL/zxorgDGIf0xT5j9IjuGYlsz/
8xZK/6+5af6/HaD3/6avLpgNEgPJAQBSmyInuN4sNwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,60.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAIUlEQVR4nGNYoizxf4WqxP9VGlL/V+tIgzGIvwwoDpIDAPc6DzJ9
rrrNAAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,62)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGNYoSXzHwAEWgHu/Z+wkwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,62)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAIklEQVR4nGNYoSXzf72F0v+tbpr/dwbq/d/hqwNmg8RAcgAOthCY
ZayBYAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,62)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM4piXzHwAE0gIMwhZDhQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,62)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAIklEQVR4nGM4piXz/7yF0v9rbpr/bwfo/b/pqwtmg8RAcgAgxRGZ
e8xsaQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,62)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGNYpiLxHwAEOAHiRkGWDwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,62)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAIklEQVR4nGNYpiLxf62B3P/NNsr/t7uq/9/mpAZmg8RAcgAGSxAY
9zokPgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,62)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAIklEQVR4nGNYoSXzf72F0v+tbpr/dwbq/d/hqwNmg8RAcgAOthCY
ZayBYAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,62)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAIklEQVR4nGM4piXz/7yF0v9rbpr/bwfo/b/pqwtmg8RAcgAgxRGZ
e8xsaQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,62)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAIklEQVR4nGNYpiLxf62B3P/NNsr/t7uq/9/mpAZmg8RAcgAGSxAY
9zokPgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,62)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAIklEQVR4nGNYoSXzf72F0v+tbpr/dwbq/d/hqwNmg8RAcgAOthCY
ZayBYAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,62)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM4piXzHwAE0gIMwhZDhQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,62)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAIklEQVR4nGM4piXz/7yF0v9rbpr/bwfo/b/pqwtmg8RAcgAgxRGZ
e8xsaQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,62)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGNYpiLxHwAEOAHiRkGWDwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,62)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAIklEQVR4nGNYpiLxf62B3P/NNsr/t7uq/9/mpAZmg8RAcgAGSxAY
9zokPgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,63.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAIUlEQVR4nGNYrSv7f4e/7v/DWdb/jxfZgen9CWZgMZAcACVqEed0
M3xTAAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,63.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAIUlEQVR4nGM4pSv7/5a/7v9nmdb/XxXag+lHCWZgMZAcADg/EvOF
Jv3VAAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,63.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAIUlEQVR4nGNYqSbxf5uz2v8DUUb/jyaagum9QXpgMZAcABmpETUL
lZ9cAAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,63.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAIUlEQVR4nGNYrSv7f4e/7v/DWdb/jxfZgen9CWZgMZAcACVqEed0
M3xTAAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,63.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAIUlEQVR4nGM4pSv7/5a/7v9nmdb/XxXag+lHCWZgMZAcADg/EvOF
Jv3VAAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,63.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAIUlEQVR4nGNYqSbxf5uz2v8DUUb/jyaagum9QXpgMZAcABmpETUL
lZ9cAAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,63.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGNYrSv7HwAEcQH1g7N/PwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,63.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAIUlEQVR4nGNYrSv7f4e/7v/DWdb/jxfZgen9CWZgMZAcACVqEed0
M3xTAAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,63.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM4pSv7HwAE7QIU4aUZ7gAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,63.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAIUlEQVR4nGM4pSv7/5a/7v9nmdb/XxXag+lHCWZgMZAcADg/EvOF
Jv3VAAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,63.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGNYqSbxHwAESgHnOq0flQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,63.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAIUlEQVR4nGNYqSbxf5uz2v8DUUb/jyaagum9QXpgMZAcABmpETUL
lZ9cAAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,63)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAACCAYAAABllJ3tAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAOElEQVR4nGNYrSv7f4e/7v/DWdb/jxfZgen9CWZgMZAcwzoTBTDn
ZKXT/ytT/P+fa/cEs0FiIDkAp7skqEOoMdgAAAAASUVORK5CYII=">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,64.66667)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAIklEQVR4nGM4a6zw/5a/7v+3FU7/f072//+5zRPMBomB5ABGjxPQ
U4c+HgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,64.66667)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAIklEQVR4nGNYrSP9f5uz2v/j6Zb/L9a5/D9TbAdmg8RAcgAmWxH5
zcnh4AAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,64.66667)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAIklEQVR4nGNYZ6Lwf4e/7v+TlU7/r0zx/3+u3RPMBomB5AAzjRLC
ePdoXQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,64.66667)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM4a6zwHwAFEQIg748AaQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,64.66667)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAIklEQVR4nGM4a6zw/5a/7v+3FU7/f072//+5zRPMBomB5ABGjxPQ
U4c+HgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,64.66667)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGNYrSP9HwAEagHyvZGIggAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,64.66667)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAIklEQVR4nGNYrSP9f5uz2v/j6Zb/L9a5/D9TbAdmg8RAcgAmWxH5
zcnh4AAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,64.66667)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAIklEQVR4nGNYZ6Lwf4e/7v+TlU7/r0zx/3+u3RPMBomB5AAzjRLC
ePdoXQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,64.66667)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAIklEQVR4nGM4a6zw/5a/7v+3FU7/f072//+5zRPMBomB5ABGjxPQ
U4c+HgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,64.66667)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAIklEQVR4nGNYrSP9f5uz2v/j6Zb/L9a5/D9TbAdmg8RAcgAmWxH5
zcnh4AAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,64.66667)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAIklEQVR4nGNYZ6Lwf4e/7v+TlU7/r0zx/3+u3RPMBomB5AAzjRLC
ePdoXQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,64.333339)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAACCAYAAACZgbYnAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAEklEQVR4nGM4a6zwn+GEtsx/ABSJBC73N44OAAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,64.333339)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAACCAYAAACZgbYnAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAEklEQVR4nGM4a6zwn+GKo/p/ABURBFurzvElAAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674.6667,64.66667)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAgAAAABCAYAAADjAO9DAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAIklEQVR4nGNYrSP9f5uz2v/j6Zb/L9a5/D9TbAdmg8RAcgAmWxH5
zcnh4AAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,64.66667)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGO4FW32HwAF6QJrvu7ZzAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,64.66667)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM4GWr8HwAFjQJRmbjPwAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,64.66667)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGO4EWr8HwAFyQJg4ihB/wAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,64.66667)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM4EWT4HwAFfAJLisG7ZAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,64.66667)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM4GWr8HwAFjQJRmbjPwAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,63.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGO4EWr8HwAFyQJg4ihB/wAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,63.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGO4Hmj4HwAFtQJZiRW0fAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,63.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM4Hmj4HwAFdQJJ4wg7WQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,63.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGO4Hmj4HwAFtQJZiRW0fAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,63.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM45qv/HwAFYQJCc1X2pQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,61.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAACCAYAAACZgbYnAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAEklEQVR4nGO4GmT8n+FGqPF/ABc6BLkBTCPTAAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,62)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM46mfwHwAFYgJDO2Gp7wAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,62)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGO44mfwHwAFngJSsNKosAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,62)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM44q33HwAFUQI9P+hpdAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,63.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM4Hmj4HwAFdQJJ4wg7WQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,62)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGO4GmT8HwAFtAJa79LvoQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,62)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGO44mfwHwAFngJSsNKosAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,62)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM46mfwHwAFYgJDO2Gp7wAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,62)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGO44mfwHwAFngJSsNKosAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,62)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM44q33HwAFUQI9P+hpdAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,60.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGO4HGT8HwAFrAJYYPMFzwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,60.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM47Gf4HwAFXAJCImZmDgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,60.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGO45Gf4HwAFmAJRbaOyVQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,60.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM45K3/HwAFSwI8GatIqQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,60.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM47Gf4HwAFXAJCImZmDgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,59.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGO4EGD8HwAFmgJTtbm4iwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,59.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM472P4HwAFhgJM+AfJ0AAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,59.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM44GP4HwAFSgI9mAkojwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,59.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM472P4HwAFhgJM+AfJ0AAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,59.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM44Kn/HwAFPQI4lxzHpAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,57.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAACCAYAAACZgbYnAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAEklEQVR4nGM462fyn+FCgPF/ABaqBKHOn75FAAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,58)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPY5234HwAFPwI6El5lHQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,58)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM44234HwAFdwJIuNL1CAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,58)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPY66H/HwAFLgI05pgevwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,59.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM44GP4HwAFSgI9mAkojwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,58)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM462fyHwAFigJPFcJhtgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,58)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM44234HwAFdwJIuNL1CAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,58)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPY5234HwAFPwI6El5lHQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,58)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM44234HwAFdwJIuNL1CAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,58)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPY66H/HwAFLgI05pgevwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,56.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM45WvyHwAFewJLOcRylQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,56.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPY7Wn4HwAFLQI1jCeL9gAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,56.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM46Wn4HwAFZQJDIcbf+gAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,56.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPY5a7/HwAFHwIw1b6cPwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,56.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPY7Wn4HwAFLQI1jCeL9gAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,55.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM44WP6HwAFcgJJZf0s6AAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,55.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM47mn0HwAFXwJC3PyIlwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,55.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPY6Wn0HwAFJwI0bPsFzgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,55.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM47mn0HwAFXwJC3PyIlwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,55.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPY6WbwHwAFGgIv50KMXgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,53.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAACCAYAAACZgbYnAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAEklEQVR4nGM47m36n+GEj+l/ABY7BI8QpKU/AAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,54)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPY4WH0HwAFIAIy6OoP0wAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,54)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM45mH0HwAFWAJAX4BGkwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,54)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPY7mbwHwAFEgItYz7RAwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,55.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPY6Wn0HwAFJwI0bPsFzgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,54)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM47m36HwAFawJHW4FE8wAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,52.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAACCAYAAACZgbYnAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAEklEQVR4nGM44m70n+GYh9F/ABXRBHz+Q5MZAAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,54)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPY4WH0HwAFIAIy6OoP0wAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,54)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM45mH0HwAFWAJAX4BGkwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,54)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPY7mbwHwAFEgItYz7RAwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,52.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM46m36HwAFYwJF5nAlawAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,52.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPY7m70HwAFGQIwK8dtnQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,52.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPY7m70HwAFGQIwK8dtnQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,52.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM44m70HwAFTQI97xVpKQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,52.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPY5mrwHwAFCwIrdd1bngAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,51.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM4E2b5HwAFqAJb11ISowAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,51.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPYG2j6HwAFVQJD0XrNsAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,51.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM4HWj2HwAFjwJSuIxDKwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,51.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPY7Wf8HwAFQAI8VDFdAAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,51.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM4HWj2HwAFjwJSuIxDKwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,49.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAACCAYAAACZgbYnAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAEklEQVR4nGN4UOX2n+FMmOV/ABlBBPpVqRAaAAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,51.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPYG2j6HwAFVQJD0XrNsAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,50)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM4V+T4HwAGFAKBW7Ja6wAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,50)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGO4V+j4HwAGUQKQ9vkpfAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,50)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM4m233HwAF9QJ2JjE2aQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,50)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGN4UOX2HwAGfgKgNNUV6QAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,50)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM4V+T4HwAGFAKBW7Ja6wAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,50)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGO4V+j4HwAGUQKQ9vkpfAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,50)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM4m233HwAF9QJ2JjE2aQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,48.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAACCAYAAACZgbYnAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAEklEQVR4nGP4PNnvP8O9Qsf/ABuVBWPrItofAAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,48.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGP4vijkPwAHbgLtmp1lngAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,48.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGN4OMXvPwAG4ALD/MQtMAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(.3199056,0,-0,.24796549,673.97598,48.588098)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAIAAACQd1PeAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADElEQVR4nGOYW5MJAAM8AYNTZ6/7AAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,48.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGP4PNnvPwAHJQLUwDLnUAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,63.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGO4FW3+HwAF6wJsEOHWZgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,63.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGO4GWH6HwAF2gJmkElylwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,63.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM4E2H6HwAFpgJZCO9NAQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,63.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGO4GWH6HwAF2gJmkElylwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,63.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM4E2r8HwAFmQJUZ9O6fQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,61.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAACCAYAAACZgbYnAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAEklEQVR4nGO4EWH2n+FWtPl/ABe8BNGrhuVmAAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,62)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM4FWryHwAFkwJT1wWo3wAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,62)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGO4FmryHwAFwwJfbYf/gAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,62)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM4FWz0HwAFiQJPdwruiwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,63.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM4E2H6HwAFpgJZCO9NAQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,62)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGO4EWH2HwAF2AJm77VulQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,62)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGO4FmryHwAFwwJfbYf/gAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,62)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM4FWryHwAFkwJT1wWo3wAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,62)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGO4FmryHwAFwwJfbYf/gAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,62)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM4FWz0HwAFiQJPdwruiwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,60.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGO4FmH2HwAF0AJka8kzyAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,60.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM4GWr6HwAFkQJTAVrBwgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,60.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGO4Gmr6HwAFwQJfu9iWnQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,60.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM4EWz8HwAFgwJOY5lEoAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,60.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM4GWr6HwAFkQJTAVrBwgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,59.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGO4GGb+HwAFuAJeGunsDgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,59.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGO4EGz6HwAFpwJYOqc3tQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,59.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM4Gmz6HwAFewJNoMKclQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,59.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGO4EGz6HwAFpwJYOqc3tQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,59.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM4EmD8HwAFagJH0lQ+oQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,57.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAACCAYAAACZgbYnAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAEklEQVR4nGO4EGr+n+FimPl/ABcwBLmhDiAEAAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,58)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM4EmT6HwAFdAJLKsDHMAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,58)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM4H2T2HwAFogJXgSpf3gAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,58)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM4HGD8HwAFZgJGZIsswQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,59.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM4Gmz6HwAFewJNoMKclQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,58)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGO4EGr+HwAFsQJcF0EB+gAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,58)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM4H2T2HwAFogJXgSpf3gAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,58)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM4EmT6HwAFdAJLKsDHMAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,58)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM4H2T2HwAFogJXgSpf3gAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,58)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM4HGD8HwAFZgJGZIsswQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,56.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM4G2LxHwAFpAJZPDtobgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,56.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM4GGj6HwAFZQJH/BPdjQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,56.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM4E2j2HwAFkwJTEnXyOwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,56.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM44G/8HwAFVwJC761FXQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,56.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM4GGj6HwAFZQJH/BPdjQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,55.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM4HWzxHwAFmQJW5qdohAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,55.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM4HWD2HwAFjAJR8Ca3fQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,55.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM4EGj2HwAFYwJHhOZpUwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,55.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM4HWD2HwAFjAJR8Ca3fQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,55.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPY72/yHwAFVQJCVE0ozgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,53.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAACCAYAAACZgbYnAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAEklEQVR4nGM4FWTxn+F0sMV/ABbKBKlkiiEqAAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,54)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPYF2D2HwAFWAJEtbdJlQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,54)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM4GWD2HwAFhAJPWdaKqgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,54)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPY52fyHwAFTgJAwg283gAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,55.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM4EGj2HwAFYwJHhOZpUwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,54)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM4FWTxHwAFkgJUbMFf5AAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,52.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAACCAYAAACZgbYnAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAEklEQVR4nGM46W/2n+FkgNl/ABaGBJwScu29AAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,54)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPYF2D2HwAFWAJEtbdJlQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,54)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM4GWD2HwAFhAJPWdaKqgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,54)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPY52fyHwAFTgJAwg283gAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,52.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM4GWTxHwAFjgJTAa1jRwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,52.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPY52/2HwAFVQJDbN2eUwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,52.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPY52/2HwAFVQJDbN2eUwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,52.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM46W/2HwAFgQJOZ8yp4QAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,52.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPY62vyHwAFRwI+y/o9MQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,51.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM4H2PzHwAFzAJnvUev5gAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,51.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM4HGn5HwAFjQJVCPVm0gAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,51.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM4F2H1HwAFuAJg6vZqlgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,51.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM4FGb+HwAFfAJP5s4IdQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,51.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM4F2H1HwAFuAJg6vZqlgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,49.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAACCAYAAACZgbYnAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAEklEQVR4nGN4WOfxn+F8jM1/ABmcBQ3nNSqNAAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,51.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM4HGn5HwAFjQJVCPVm0gAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,50)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGO4XObyHwAGOgKN4tKyxQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,50)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGN4UObyHwAGbgKalD9M2wAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,50)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGO4VOj4HwAGIQKEgV+plAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,50)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGN4WOfxHwAGkgKnNhMyZQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,50)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGO4XObyHwAGOgKN4tKyxQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,50)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGN4UObyHwAGbgKalD9M2wAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,50)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGO4VOj4HwAGIQKEgV+plAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,48.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAACCAYAAACZgbYnAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAEklEQVR4nGP4PjfoP8ODMpf/ABxCBX9CzSDgAAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,48.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGP4uTLiPwAHkwL6Tph1ygAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,48.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGN4MTfoPwAHHwLXNHAxJwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,64.66667)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGO4k2D5HwAGBgJ1jOjAIQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,64.66667)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM4F2P+HwAFvgJh2V51NQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,64.66667)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGO4HWP+HwAF8gJuQ0qfnwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,64.66667)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM4G2n6HwAFrQJbgol6YQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,64.66667)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGM4F2P+HwAFvgJh2V51NQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,64.66667)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYqyzyHwAECQHUAcBtaAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,64.66667)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYpij8HwAD5QHK49rThgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,64.66667)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYoyj8HwAD/QHQRhqdewAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,64.66667)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYKi/0HwAD2QHGflY3fAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,64.66667)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYpij8HwAD5QHK49rThgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,64.66667)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYryH+HwAEJgHe002rAgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,64.66667)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYrS72HwAEEQHY3zOJbwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,64.66667)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYpy72HwAEHQHb2g6rLwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,64.66667)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYrS72HwAEEQHY3zOJbwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,64.66667)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYrS72HwAEEQHY3zOJbwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,63.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYIy/0HwAD9QHNdHDnKwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,63.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYLSv4HwAD6QHJ7QnGOgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,63.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYKiv4HwAD0QHDQ8X2xQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,63.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYLSv4HwAD6QHJ7QnGOgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,63.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYIiPwHwADyAHAkunISgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,63.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYqyr6HwAEEQHXf3yJ+gAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,63.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYqyr6HwAEEQHXf3yJ+gAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,63.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYpSr6HwAEBQHUNZgIfgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,63.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYqyr6HwAEEQHXf3yJ+gAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,63.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYqSzyHwAD+QHQAEjKngAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,61.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAACCAYAAACZgbYnAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAEklEQVR4nGOYJSv4n2GOvNB/ABC9A5TqIshIAAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,62)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYJC3wHwADvQG9iPcEyAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,62)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYIS3wHwAD1QHDMxmHJAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,62)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYJCXwHwADugG8KVo5bgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,63.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYKiv4HwAD0QHDQ8X2xQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,61.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAACCAYAAACZgbYnAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAEklEQVR4nGOYrSz6n2Guquh/ABEuA6l3aN28AAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,62)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYoSTyHwAD8gHOni+hsQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,62)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYrSTyHwAD/gHR/AmmNAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,62)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYoSTyHwAD8gHOni+hsQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,63.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYpSr6HwAEBQHUNZgIfgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,62)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYJSv4HwAD5QHIKMyt0AAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,62)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYIS3wHwAD1QHDMxmHJAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,62)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYJC3wHwADvQG9iPcEyAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,62)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYIS3wHwAD1QHDMxmHJAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,62)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYJCXwHwADugG8KVo5bgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,62)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYrSz6HwAEAwHT0sZK8AAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,62)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYrSTyHwAD/gHR/AmmNAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,62)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYoSTyHwAD8gHOni+hsQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,62)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYrSTyHwAD/gHR/AmmNAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,62)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYoSTyHwAD8gHOni+hsQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,60.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYISP0HwAD3AHGrWd+BQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,60.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYJC34HwADvwG+IZXPewAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,60.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYIS34HwAD1wHEnRaIjgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,60.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYKCXwHwADtgG7WBCmvQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,60.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYJC34HwADvwG+IZXPewAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,60.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYpSz6HwAD/wHSPxBqcwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,60.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYriT6HwAD8AHOcf30aQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,60.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYpST6HwAD/AHRd7qeJQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,60.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYrijyHwAD6wHM68CC/AAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,60.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYriT6HwAD8AHOcf30aQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,59.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYJi30HwAD0QHDpD5mIgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,59.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYKin4HwADxQG/Q3zHAwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,59.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPolxT8DwADrQG5Sug62AAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,59.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYKin4HwADxQG/Q3zHAwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,59.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPokxD4DwADpAG2+G9nIwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,59.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYoSj6HwAD8QHO+ClEwAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,59.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYoSj6HwAD8QHO+ClEwAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,59.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYqij6HwAD5QHLETklPgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,59.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYoSj6HwAD8QHO+ClEwAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,59.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYqiDyHwAD4AHJGfbTKwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,57.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAACCAYAAACZgbYnAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAEklEQVR4nGOYIiX0n2GatNB/ABBSA4IEoAm9AAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,58)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPolRD8DwADogG2e7dGCAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,58)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYLCH4HwADugG8JSfb6wAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,58)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPoFRf4DwADnQG0IlGozAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,59.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPolxT8DwADrQG5Sug62AAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,57.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAACCAYAAACZgbYnAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAEklEQVR4nGOYpiD6n2GGouh/ABDJA5gN6cXeAAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,58)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYrCD6HwAD2gHIB/i0FgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,58)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYpiD6HwAD5gHLJq5zxgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,58)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYLC/6HwAD1wHHIOooNwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,59.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYqij6HwAD5QHLETklPgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,58)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYIiX0HwADxgHAqlfI1AAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,56.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAACCAYAAACZgbYnAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAEklEQVR4nGOYIC74n2GyhOB/AA/4A3MFpbRTAAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,58)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPolRD8DwADogG2e7dGCAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,58)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYLCH4HwADugG8JSfb6wAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,58)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPoFRf4DwADnQG0IlGozAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,58)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYpiD6HwAD5gHLJq5zxgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,58)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYpiD6HwAD5gHLJq5zxgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,58)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYrCD6HwAD2gHIB/i0FgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,58)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYpiD6HwAD5gHLJq5zxgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,58)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYLC/6HwAD1wHHIOooNwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,56.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYKCH8HwADtgG8hZ5XkAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,56.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPoFhf8DwADlwGzfGCgbwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,56.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYIC74HwADqwG4ALo3DQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,56.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPoEhP4DwADjgGw23cSzwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,56.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPoFhf8DwADlwGzfGCgbwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,56.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYoiD6HwAD3gHJvzT3zgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,56.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYKC/6HwADzwHFgT3q3wAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,56.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYIi/6HwAD2wHIcY0XUAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,56.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYKC/6HwADzwHFgT3q3wAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,56.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYKC/6HwADzwHFgT3q3wAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,55.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYICH8HwADsgG7pyvI9wAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,55.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPoFxf8DwADpwG3SB2VpQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,55.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPoFBf8DwADjwGxrq0bDQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,55.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPoFxf8DwADpwG3SB2VpQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,55.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPoFBP8DwADjAGwX6abOAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,55.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYLC/2HwAD2QHIfWty2AAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,55.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYLC/2HwAD2QHIfWty2AAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,55.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYIC/2HwADzQHF/sH23QAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,55.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYLC/2HwAD2QHIfWty2AAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,55.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYICf6HwADyAHDBSzgwgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,53.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAACCAYAAACZgbYnAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAEklEQVR4nGPoFxf+zzBBQvg/AA/1A3PMWAiHAAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,54)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPoFBf8DwADjwGxrq0bDQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,54)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPoExf8DwADowG2Zf9c4wAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,54)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPoEBX8DwADhQGuMfvFXwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,53.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAACCAYAAACZgbYnAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAEUlEQVR4nGOYJC/2n2EykAAAEIwDjtmkWVsAAAAASUVORK5CYII=">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,54)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPolxP7DwADxgHDcdixrAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,54)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYJCf2HwAD0gHG/rsJkwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,54)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPolxP9DwADxAHCZotgbgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,54)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPoFxf+DwADqwG5MSBQ7wAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,52.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAACCAYAAACZgbYnAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAEklEQVR4nGPoFRP8z9AnLvgfAA++A2kYaublAAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,54)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPoFBf8DwADjwGxrq0bDQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,54)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPoExf8DwADowG2Zf9c4wAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,54)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPoEBX8DwADhQGuMfvFXwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,54)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYJC/2HwAD1QHHXxY0NQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,52.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAACCAYAAACZgbYnAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAEklEQVR4nGOYKCv2n2GSnNh/ABBsA4nbycWHAAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,54)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPolxP7DwADxgHDcdixrAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,54)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYJCf2HwAD0gHG/rsJkwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,54)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPolxP9DwADxAHCZotgbgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,52.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPoExf+DwADpwG4EtHIEQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,52.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPoEBP8DwADiAGviEtvHQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,52.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPoFRP8DwADnAG0U5boEgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,52.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGNoFxX8DwADgQGtLZ9Y8QAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,52.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYKCf2HwADzgHFlLrxKQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,52.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPokxX7DwADvwHBX3Xb1AAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,52.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYKCv2HwADywHEstkWGwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,52.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPokxX9DwADvQHASCYKFgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,51.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYLC/2HwAD2QHIfWty2AAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,51.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPokRP5DwADtgG+7xi83gAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,51.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYJCfyHwADzgHE8cYWuAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,51.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPolhX+DwADrQG76KheAAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,51.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYJCfyHwADzgHE8cYWuAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,51.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPolhX+DwADrQG76KheAAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,51.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYpirxHwAD+wHTsvuTgQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,51.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYrCrxHwAD7wHQpfNDCQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,51.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYqirxHwAD9wHSKtKpZwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,51.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYpCL+HwAD5gHNV1HdGwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,51.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYqirxHwAD9wHSKtKpZwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,49.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAACCAYAAACZgbYnAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAEklEQVR4nGNYaK3wn2GyvNh/ABI5A8PcTooxAAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,50)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYZS73HwAETQHvp0BRUAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,50)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGNYYC73HwAEZQH1XlT0nAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,50)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYaSLzHwAEPAHpXsQ0SgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,49.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAACCAYAAACZgbYnAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAEklEQVR4nGNYZKv4n2GaqsR/ABJ7A9JqfyXOAAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,50)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYb6P4HwAEdgH8oJhwgwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,50)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGNYZK34HwAEfwH+rieobgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,50)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYZ6XwHwAEagH4/JELdgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,50)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGNYaK3wHwAEeQH8kX8IgwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,50)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYZS73HwAETQHvp0BRUAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,50)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGNYYC73HwAEZQH1XlT0nAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,50)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYaSLzHwAEPAHpXsQ0SgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,48.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGNYEaTxHwAE6gIiwVTHKwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,48.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAACCAYAAACZgbYnAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAEklEQVR4nGPYEKjxn2GBudx/ABQ0BB1l/1t+AAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,48.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGNY4af2HwAE2gIc+YDF5wAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,50)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGNYZKv4HwAEhQIAoTPbNwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,50)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYb6P4HwAEdgH8oJhwgwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,50)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGNYZK34HwAEfwH+rieobgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,50)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYZ6XwHwAEagH4/JELdgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,48.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAACCAYAAACZgbYnAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAEklEQVR4nGPYEKL5n2GRteJ/ABRtBCqBT3KnAAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(.3199463,0,-0,.24796549,673.85598,48.66801)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAIAAACQd1PeAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADElEQVR4nGMocXMGAAIvAP4QMEO2AAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,48.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPYGK71HwAFIQIy1oxOCgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(.3199056,0,-0,.24796549,673.896,48.588098)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAIAAACQd1PeAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADElEQVR4nGOo8XIFAAJRAQwRelgSAAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,48.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPYEK79HwAFHwIycE5q7wAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(.3199056,0,-0,.24796549,673.97598,48.588098)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAIAAACQd1PeAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADElEQVR4nGOocLYFAAIvAPk8GhRGAAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,674,48.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPYEKL5HwAFEgItVn7FFQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,64.66667)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYqyzyHwAECQHUAcBtaAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,64.66667)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYpij8HwAD5QHK49rThgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,64.66667)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYoyj8HwAD/QHQRhqdewAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,64.66667)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYKi/0HwAD2QHGflY3fAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,64.66667)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYpij8HwAD5QHK49rThgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,64.66667)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYryX+HwAELAHgm/E9hQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,64.66667)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYoyn+HwAEHQHcIKwo/gAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,64.66667)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYryn+HwAEKQHffPPHHAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,64.66667)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYoyH+HwAEGgHbaGKwbQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,64.66667)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYoyn+HwAEHQHcIKwo/gAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,63.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYIy/0HwAD9QHNdHDnKwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,63.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYLSv4HwAD6QHJ7QnGOgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,63.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYKiv4HwAD0QHDQ8X2xQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,63.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYLSv4HwAD6QHJ7QnGOgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,63.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYIiPwHwADyAHAkunISgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,63.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYpyb2HwAEGgHae6OWiQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,63.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYpyb6HwAEGAHZJo55KQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,63.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYrSb6HwAEDAHWODDligAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,63.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYpyb6HwAEGAHZJo55KQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,63.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYrSr6HwAECQHV8F1jlAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,61.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAACCAYAAACZgbYnAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAEklEQVR4nGOYJSv4n2GOvNB/ABC9A5TqIshIAAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,62)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYJC3wHwADvQG9iPcEyAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,62)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYIS3wHwAD1QHDMxmHJAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,62)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYJCXwHwADugG8KVo5bgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,63.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYKiv4HwAD0QHDQ8X2xQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,61.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAACCAYAAACZgbYnAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAEklEQVR4nGOYoyL6n2Gemth/ABFIA66XtJBAAAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,62)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYqSL6HwAD/gHSzWzhYgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,62)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYrSL6HwAEBgHUX+MPigAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,62)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYqSLyHwAD/AHRZA4q0QAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,63.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYrSb6HwAEDAHWODDligAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,62)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYJSv4HwAD5QHIKMyt0AAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,62)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYIS3wHwAD1QHDMxmHJAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,62)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYJC3wHwADvQG9iPcEyAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,62)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYIS3wHwAD1QHDMxmHJAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,62)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYJCXwHwADugG8KVo5bgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,62)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYoyL6HwAECgHV6Twd6gAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,62)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYrSL6HwAEBgHUX+MPigAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,62)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYqSL6HwAD/gHSzWzhYgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,62)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYrSL6HwAEBgHUX+MPigAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,62)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYqSLyHwAD/AHRZA4q0QAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,60.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYISP0HwAD3AHGrWd+BQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,60.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYJC34HwADvwG+IZXPewAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,60.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYIS34HwAD1wHEnRaIjgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,60.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYKCXwHwADtgG7WBCmvQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,60.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYJC34HwADvwG+IZXPewAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,60.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYrSL6HwAEBgHUX+MPigAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,60.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYoSL6HwAD+gHR6LS6HAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,60.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYrSL6HwAEBgHUX+MPigAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,60.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYoSz6HwAD9wHQguEL6wAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,60.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYoSL6HwAD+gHR6LS6HAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,59.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYKiX0HwADygHBb5KjPgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,59.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYIin4HwADwQG+iKr9UQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,59.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPokxT8DwADqQG4ZwrzngAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,59.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYIin4HwADwQG+iKr9UQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,59.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPokxD4DwADpAG2+G9nIwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,59.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYoST2HwAD9gHQl2YQHQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,59.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYoST6HwAD9AHP3kqj8gAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,59.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYqiT6HwAD6AHM0Co2gQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,59.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYoST6HwAD9AHP3kqj8gAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,59.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYqiT6HwAD6AHM0Co2gQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,57.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAACCAYAAACZgbYnAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAEUlEQVR4nGOYIiX0n2EqkAAAEEsDgBccUHoAAAAASUVORK5CYII=">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,58)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPolRD8DwADogG2e7dGCAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,58)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYLCH4HwADugG8JSfb6wAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,58)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPoFRf4DwADnQG0IlGozAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,59.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPokxT8DwADqQG4ZwrzngAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,57.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAACCAYAAACZgbYnAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAEUlEQVR4nGOYriT2n2EGkAAAEO4DnmVg7MkAAAAASUVORK5CYII=">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,58)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYqij2HwAD5wHMS3kOhwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,58)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYrij2HwAD7wHO9ohvHwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,58)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYqij6HwAD5QHLETklPgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,59.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYqiT6HwAD6AHM0Co2gQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,58)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYIiX0HwADxgHAqlfI1AAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,56.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAACCAYAAACZgbYnAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAEklEQVR4nGOYIC74n2GyhOB/AA/4A3MFpbRTAAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,58)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPolRD8DwADogG2e7dGCAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,58)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYLCH4HwADugG8JSfb6wAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,58)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPoFRf4DwADnQG0IlGozAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,58)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYriT2HwAD8gHPwt565QAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,58)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYrij2HwAD7wHO9ohvHwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,58)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYqij2HwAD5wHMS3kOhwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,58)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYrij2HwAD7wHO9ohvHwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,58)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYqij6HwAD5QHLETklPgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,56.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYKCH8HwADtgG8hZ5XkAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,56.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPoFhf8DwADlwGzfGCgbwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,56.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYIC74HwADqwG4ALo3DQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,56.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPoEhP4DwADjgGw23cSzwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,56.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPoFhf8DwADlwGzfGCgbwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,56.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYqij2HwAD5wHMS3kOhwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,56.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYpCD2HwAD2AHIeASoFAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,56.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYoiD2HwAD4AHKz2gEmgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,56.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYpCD6HwAD1gHHJYXy+wAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,56.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYpCD2HwAD2AHIeASoFAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,55.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYICH8HwADsgG7pyvI9wAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,55.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPoFxf8DwADpwG3SB2VpQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,55.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPoFBf8DwADjwGxrq0bDQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,55.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPoFxf8DwADpwG3SB2VpQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,55.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPoFBP8DwADjAGwX6abOAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,55.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYoiD+HwAD4gHLiASuBQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,55.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYoiD2HwAD4AHKz2gEmgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,55.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYqCD2HwAD1AHHB5W/9QAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,55.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYoiD2HwAD4AHKz2gEmgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,55.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYqCD2HwAD1AHHB5W/9QAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,53.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAACCAYAAACZgbYnAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAEklEQVR4nGPoFxf+zzBBQvg/AA/1A3PMWAiHAAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,54)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPoEBf8DwADiwGwg0/SSwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,54)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPoExf8DwADowG2Zf9c4wAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,54)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPoEBX8DwADhQGuMfvFXwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,53.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAACCAYAAACZgbYnAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAEklEQVR4nGOYLC/+n2GKgvh/ABClA5PWWPitAAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,54)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYoCD2HwAD0AHGzEOFpwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,54)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYpCD2HwAD2AHIeASoFAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,54)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYIC/2HwADzQHF/sH23QAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,54)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPoFxf+DwADqwG5MSBQ7wAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,52.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAACCAYAAACZgbYnAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAEklEQVR4nGPoFRP8z9AnLvgfAA++A2kYaublAAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,54)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPoEBf8DwADiwGwg0/SSwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,54)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPoExf8DwADowG2Zf9c4wAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,54)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPoEBX8DwADhQGuMfvFXwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,54)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYLC/+HwAD2wHJOgfYRwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,52.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAACCAYAAACZgbYnAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAEklEQVR4nGOYJC/2n2GSgth/ABCLA45qfU6jAAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,54)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYoCD2HwAD0AHGzEOFpwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,54)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYpCD2HwAD2AHIeASoFAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,54)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYIC/2HwADzQHF/sH23QAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,52.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPoExf+DwADpwG4EtHIEQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,52.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPoEBP8DwADiAGviEtvHQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,52.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPoFRP8DwADnAG0U5boEgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,52.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGNoFxX8DwADgQGtLZ9Y8QAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,52.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYJC/+HwAD1wHI/8KzrQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,52.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYIC/2HwADzQHF/sH23QAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,52.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYJC/2HwAD1QHHXxY0NQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,52.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYIC/2HwADzQHF/sH23QAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,51.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYLC/2HwAD2QHIfWty2AAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,51.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPokRP5DwADtgG+7xi83gAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,51.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYJCfyHwADzgHE8cYWuAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,51.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPolhX+DwADrQG76KheAAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,51.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYJCfyHwADzgHE8cYWuAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,51.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPolhX+DwADrQG76KheAAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,51.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYpib1HwAEAgHWRrMmtAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,51.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYoib5HwAD+AHTiREn/AAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,51.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYpib5HwAEAAHVG57JFAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,51.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYrCb5HwAD9AHSP841nAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,51.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYpib5HwAEAAHVG57JFAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,49.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAACCAYAAACZgbYnAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAEklEQVR4nGNYaK3wn2GyvNh/ABI5A8PcTooxAAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,50)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYZS73HwAETQHvp0BRUAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,50)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGNYYC73HwAEZQH1XlT0nAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,50)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYaSLzHwAEPAHpXsQ0SgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,49.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAACCAYAAACZgbYnAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAEklEQVR4nGNYbKf0n2GamtR/ABKaA9hscFO4AAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,50)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGNYYKv4HwAEfQH+NiAkiwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,50)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGNYbKv4HwAEiQIBZPaw3QAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,50)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGNYYK34HwAEdwH8E9bJ9gAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,50)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGNYaK3wHwAEeQH8kX8IgwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,50)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYZS73HwAETQHvp0BRUAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,50)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGNYYC73HwAEZQH1XlT0nAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,50)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGOYaSLzHwAEPAHpXsQ0SgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,48.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGNYE6H1HwAFEAIuWlQYkgAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,48.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAACCAYAAACZgbYnAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAEklEQVR4nGPYEqH1n2GBudx/ABSeBCpsUNP9AAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,48.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGNYHaLxHwAE/AInic4W9QAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,50)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGNYbKf0HwAEjgIDH7i4TwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,50)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGNYYKv4HwAEfQH+NiAkiwAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,50)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGNYbKv4HwAEiQIBZPaw3QAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,50)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGNYYK34HwAEdwH8E9bJ9gAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,48.333337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAACCAYAAACZgbYnAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAEklEQVR4nGPYHKXzn2GxreJ/ABTXBDldJp+WAAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,48.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPYGqf7HwAFTAJASQ5OmQAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,683.3334,48.666669)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADUlEQVR4nGPYEqv3HwAFRwI/rjYQ9gAAAABJRU5ErkJggg==">


<p style="top:58.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">been reported to enhance osteoblastic activity and favour im-</span></p>
<p style="top:70.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">plant integration [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96">9</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">,</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96"> 10</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">].</span></p>
<p style="top:83.2pt;left:62.4pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">Platelet-rich plasma (PRP) is emerging as a powerful tool for</span></p>
<p style="top:95.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">tissue healing, thanks to the many GFs contained in</span></p>
<p style="top:108.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">platelet alpha-granules. PRP is defined as a blood derivative,</span></p>
<p style="top:120.6pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">where the platelets concentration is above the baseline levels,</span></p>
<p style="top:133.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">thus providing a large number of bioactive molecules in physio-</span></p>
<p style="top:145.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">logic proportions [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96">11</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">]. Activated platelets can release more than</span></p>
<p style="top:158.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">300 molecules that are responsible for the coordination of nu-</span></p>
<p style="top:170.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">merous cell-cell and cell-extracellular matrix (ECM) interactions</span></p>
<p style="top:182.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">[</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96">12</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">]. The evidence for PRP osteogenic potential has been sug-</span></p>
<p style="top:195.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">gested by several in vitro studies, i.e. PRP addition in culture</span></p>
<p style="top:207.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">medium promoted the proliferation and differentiation of human</span></p>
<p style="top:220.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">mesenchymal stem cells (MSCs) [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96">13</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">,</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96"> 14</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">], and the effect of PRP</span></p>
<p style="top:232.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">on osteogenic differentiation was also seen on human adipose</span></p>
<p style="top:245.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">derived stem cells (ADSCs) [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96">15</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">]. Furthermore, PRP can improve</span></p>
<p style="top:257.6pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">cell chemokinesis and chemotaxis through cytoskeleton reorga-</span></p>
<p style="top:270.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">nization and accelerate cell migration, thus influencing osteoblast</span></p>
<p style="top:282.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">like cells mobility [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96">16</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">]. Finally, anti-microbial effects have been</span></p>
<p style="top:294.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">suggested [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96">17</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">,</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96"> 18</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">], which are highly desirable in relation to a</span></p>
<p style="top:307.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">surgical bone application. However, besides the beneficial role in</span></p>
<p style="top:319.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">terms of proliferation and differentiation, as well as cell migration</span></p>
<p style="top:332.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">and protection towards microbial contamination, in-vitro studies</span></p>
<p style="top:344.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">have also shown controversial results on PRP potential to favour</span></p>
<p style="top:357.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">bone healing [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96">19</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:10.0pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96">21</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">].</span></p>
<p style="top:369.7pt;left:62.4pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">Thus, the aim of this study was to systematically review the</span></p>
<p style="top:382.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">available literature to identify both preclinical in-vivo results</span></p>
<p style="top:394.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">supporting the rational of PRP use for bone healing, and the</span></p>
<p style="top:407.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">evidence from the orthopaedics practice on the actual clinical</span></p>
<p style="top:419.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">benefit of PRP for the treatment of bone disorders.</span></p>
<p style="top:456.1pt;left:51.0pt;line-height:11.0pt"><span style="font-family:XssngvAdvTTb8864ccf.B,serif;font-size:11.0pt;color:#131313">Materials and methods</span></p>
<p style="top:481.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">A systematic review of the literature was performed on the use</span></p>
<p style="top:494.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">of PRP in both pre-clinical in-vivo setting and clinical setting</span></p>
<p style="top:506.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">for the treatment of fractures and delayed unions/non-unions.</span></p>
<p style="top:519.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">The search was conducted on the PubMed database on August</span></p>
<p style="top:531.6pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">1st, 2016 using the following string: (PRP OR platelet-rich</span></p>
<p style="top:544.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">plasma OR plasma rich in growth factors OR platelet derived</span></p>
<p style="top:556.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">growth factor OR platelet derived OR platelet gel OR platelet</span></p>
<p style="top:568.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">concentrate OR PRF OR platelet rich fibrin OR platelet rich</span></p>
<p style="top:581.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">membrane OR ACP OR autologous conditioned plasma OR</span></p>
<p style="top:593.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">PRGF OR platelet lysate) AND (fracture OR trauma OR trau-</span></p>
<p style="top:606.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">matic OR non union OR mal union OR post-traumatic OR</span></p>
<p style="top:618.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">pseudoarthrosis OR delayed union OR bone defect).</span></p>
<p style="top:631.2pt;left:62.4pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">The screening process and analysis were conducted separately</span></p>
<p style="top:643.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">by two independent observers (BDM and GS). First, the articles</span></p>
<p style="top:656.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">were screened by title and abstract, using the following inclusion</span></p>
<p style="top:668.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">criteria: pre-clinical and clinical reports of any level of evidence,</span></p>
<p style="top:681.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">written in English language, published in the last 20 years (1996</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:10.0pt;color:#131313">&#x2013;</span></p>
<p style="top:693.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">2016), on the use of PRP to stimulate long-bone defect treatment,</span></p>
<p style="top:705.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">with focus on fracture and delayed/non-unions healing.</span></p>
<p style="top:58.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">Exclusion criteria were articles written in other languages, re-</span></p>
<p style="top:70.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">views, case reports or case series with less than ten patients</span></p>
<p style="top:83.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">included, or studies analysing other applications of PRP in bone</span></p>
<p style="top:95.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">pathology. In the second step, the full texts of the selected articles</span></p>
<p style="top:108.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">were screened, with further exclusions according to the previous-</span></p>
<p style="top:120.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">ly described criteria. Reference lists from the selected papers</span></p>
<p style="top:133.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">were also screened. A flowchart of the systematic review process</span></p>
<p style="top:145.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">is provided in Fig.</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96"> 1</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">. Relevant data were then extracted and</span></p>
<p style="top:158.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">collected, with the consensus of the two observers, in a database</span></p>
<p style="top:170.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">including pertinent information (type of study, number of cases,</span></p>
<p style="top:182.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">follow-up, PRP preparation, cytology and application modality,</span></p>
<p style="top:195.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">type of surgical treatment or animal model used, type of bone or</span></p>
<p style="top:207.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">other materials applied, type of evaluation and results) to be</span></p>
<p style="top:220.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">analysed for the purposes of the present manuscript.</span></p>
<p style="top:256.8pt;left:306.1pt;line-height:11.0pt"><span style="font-family:XssngvAdvTTb8864ccf.B,serif;font-size:11.0pt;color:#131313">Results</span></p>
<p style="top:282.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">In total 3160 articles were screened and 64 articles were found</span></p>
<p style="top:294.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">to be eligible for inclusion in the present review. Among these,</span></p>
<p style="top:307.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">45 were pre-clinical in-vivo studies [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96">1</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">,</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96"> 2</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">,</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96"> 4</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">,</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96"> 22</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:10.0pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96">63</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">] and 19</span></p>
<p style="top:319.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">were clinical studies [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96">64</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:10.0pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96">83</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">] (Fig.</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96"> 1</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">). The trend of publication</span></p>
<p style="top:332.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">of pre-clinical and clinical trials over years has been reported</span></p>
<p style="top:344.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">in Fig.</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96"> 2</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">. Results will be discussed separately for pre-clinical</span></p>
<p style="top:357.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">and clinical studies.</span></p>
<p style="top:382.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:XssngvAdvTTb8864ccf.B,serif;font-size:10.0pt;color:#131313">Pre-clinical studies</span></p>
<p style="top:407.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:10.0pt;color:#131313">Animal models</span></p>
<p style="top:432.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">Of the 45 identified studies (Table</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96"> 1</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">), 20 (44.4 %) used a</span></p>
<p style="top:444.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">rabbit model, while other animals were used in a smaller num-</span></p>
<p style="top:456.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">ber of studies, i.e. rat in eight studies (17.8 %), sheep in seven</span></p>
<p style="top:469.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">studies (15.6 %), dog in four studies (8.9 %), pig in four</span></p>
<p style="top:481.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">studies (8.9 %) and goat in two studies (4.4 %). With regard</span></p>
<p style="top:494.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">to defect type, bone sites were tibia in 16 studies (35.6 %)</span></p>
<p style="top:506.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">(four segmental, 14 cylindrical defects), femur in 14 studies</span></p>
<p style="top:519.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">(31.1 %) (two segmental, eight cylindrical defects, four frac-</span></p>
<p style="top:531.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">tures), radius in ten studies (22.2 %) (nine segmental, one</span></p>
<p style="top:544.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">fracture), fibula in 1 study (2.2 %) (one fracture), ulna in three</span></p>
<p style="top:556.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">studies (6.7 %) (three segmental defects) and metatarsus in</span></p>
<p style="top:568.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">one study (2.2 %) (one segmental defects).</span></p>
<p style="top:581.4pt;left:317.4pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">With regard to the delivery mode, 3/45 studies delivered</span></p>
<p style="top:593.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">PRP through percutaneous injection while the remaining stud-</span></p>
<p style="top:606.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">ies used the surgical approach to apply PRP either alone or in</span></p>
<p style="top:618.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">combination with other materials. Only one paper described</span></p>
<p style="top:631.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">the combination of percutaneous PRP injection and surgical</span></p>
<p style="top:643.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">PRP delivery with biomaterial. Besides seven articles (16 %)</span></p>
<p style="top:656.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">documenting the effect of PRP alone, most of the studies (38</span></p>
<p style="top:668.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">papers, 84 %) analysed the effect of PRP with other materials:</span></p>
<p style="top:681.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">20 studies (53 %) reported the use of three dimensional scaf-</span></p>
<p style="top:693.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">folds, nine (23.5 %) with auto (</span><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:10.0pt;color:#131313">n</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313"> = 5) / allo (</span><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:10.0pt;color:#131313">n</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313"> = 3) / xenografts</span></p>
<p style="top:705.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">(</span><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:10.0pt;color:#131313">n</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313"> = 1) and nine (23.5 %) with powders/granules/pastes.</span></p>
<p style="top:33.1pt;left:51.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">222</span></p>
<p style="top:33.1pt;left:359.8pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">International Orthopaedics (SICOT) (2017) 41:221</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">237</span></p>


<p style="top:435.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">Finally, with regard to other biological augmentations, 11 pa-</span></p>
<p style="top:447.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">pers (24.4 %) reported the use of MSCs as a co-adjuvant</span></p>
<p style="top:460.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">osteogenic factor in their studies. BMSCs was the favourite</span></p>
<p style="top:472.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">cell source, used in eight papers, followed by bone marrow</span></p>
<p style="top:485.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">concentrate (BMC) in two articles, and BMSCs vs. ADSCs</span></p>
<p style="top:497.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">were reported in one article.</span></p>
<p style="top:435.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:10.0pt;color:#131313">PRP preparation</span></p>
<p style="top:460.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">Platelet count was reported in studies 32/45 (71 %) with het-</span></p>
<p style="top:472.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">erogeneous platelet concentration. However, all showed sig-</span></p>
<p style="top:485.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">nificantly higher levels of platelets than in whole peripheral</span></p>
<p style="top:497.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">blood, ranging from 1.1 x to 10.1 x. Sixteen out of 45 papers</span></p>
<p style="top:56.0pt;left:51.0pt;line-height:8.5pt"><span style="font-family:XssngvAdvTTb8864ccf.B,serif;font-size:8.5pt;color:#131313">Fig. 1</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> PRISMA flowchart of the</span></p>
<p style="top:66.0pt;left:51.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">papers</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2019;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> selection process</span></p>
<img style="position:absolute;transform:matrix(.31992526,0,-0,.3195507,-133.41266,465.7401)" src="data:image/jpeg;base64,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">
<p style="top:536.7pt;left:51.0pt;line-height:8.5pt"><span style="font-family:XssngvAdvTTb8864ccf.B,serif;font-size:8.5pt;color:#131313">Fig. 2</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> Pre-clinical and clinical</span></p>
<p style="top:546.7pt;left:51.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">studies published over time</span></p>
<p style="top:33.1pt;left:51.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">International Orthopaedics (SICOT) (2017) 41:221</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">237</span></p>
<p style="top:33.1pt;left:531.7pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">223</span></p>


<p style="top:707.1pt;left:53.4pt;line-height:8.5pt"><span style="font-family:XssngvAdvTTb8864ccf.B,serif;font-size:8.5pt;color:#131313">Table 1</span></p>
<p style="top:670.6pt;left:53.5pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Complete details of 45 pre-clinical papers identified in this systematic review</span></p>
<p style="top:652.7pt;left:72.4pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Publication</span></p>
<p style="top:575.0pt;left:72.4pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Treatment groups</span></p>
<p style="top:445.2pt;left:72.4pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">PRP characteristics</span></p>
<p style="top:301.0pt;left:72.4pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Animal model</span></p>
<p style="top:195.5pt;left:72.4pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Protocol</span></p>
<p style="top:69.9pt;left:72.4pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Effects</span></p>
<p style="top:707.9pt;left:92.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Scaffold</span></p>
<p style="top:653.5pt;left:92.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">1. Hokugo et al.</span></p>
<p style="top:653.5pt;left:100.7pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2005 [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#392a96">22</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">]</span></p>
<p style="top:575.7pt;left:92.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">1) Gelatin</span></p>
<p style="top:575.7pt;left:100.7pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2) Gelatin + PRP</span></p>
<p style="top:575.7pt;left:109.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">3) Fibrin-glue + PRP</span></p>
<p style="top:575.7pt;left:117.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">4) PRP</span></p>
<p style="top:575.7pt;left:126.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">5) Control (untreated)</span></p>
<p style="top:446.0pt;left:92.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Platelet concentration: NA</span></p>
<p style="top:446.0pt;left:100.7pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Activation: NA</span></p>
<p style="top:446.0pt;left:109.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Leukocytes: NA</span></p>
<p style="top:446.0pt;left:117.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Allogenic</span></p>
<p style="top:446.0pt;left:126.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Fresh/frozen: NA</span></p>
<p style="top:446.0pt;left:134.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">GFs: TGF-</span><span style="font-family:TmgcryAdvTT3713a231+03,serif;font-size:7.5pt;color:#131313">&#x3b2;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">1 and PDGF-BB</span></p>
<p style="top:301.8pt;left:92.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Rabbit ulna segmental defect</span></p>
<p style="top:301.8pt;left:100.7pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">(10 mm)</span></p>
<p style="top:196.3pt;left:92.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Hist: +</span></p>
<p style="top:196.3pt;left:100.7pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">X-Ray: +</span></p>
<p style="top:196.3pt;left:109.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">DEXA: +</span></p>
<p style="top:196.3pt;left:117.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Positive results for PRP in combination</span></p>
<p style="top:187.8pt;left:126.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">with gelatin</span></p>
<p style="top:70.7pt;left:92.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">+</span></p>
<p style="top:653.5pt;left:143.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2. Sugimori et al.</span></p>
<p style="top:653.5pt;left:151.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2006 [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#392a96">23</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">]</span></p>
<p style="top:575.7pt;left:143.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">1) AF</span></p>
<p style="top:575.7pt;left:151.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2) PRP</span></p>
<p style="top:575.7pt;left:160.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">3) AF + PRP</span></p>
<p style="top:575.7pt;left:168.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">4) Control (untreated)</span></p>
<p style="top:446.0pt;left:143.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Platelet concentration: 2.5 x</span></p>
<p style="top:446.0pt;left:151.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Activation: NA</span></p>
<p style="top:446.0pt;left:160.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Leukocytes: NA</span></p>
<p style="top:446.0pt;left:168.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Allogenic</span></p>
<p style="top:446.0pt;left:176.9pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Fresh/frozen: NA</span></p>
<p style="top:446.0pt;left:185.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">GFs: NA</span></p>
<p style="top:301.8pt;left:143.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Rat tibial cylindrical defect</span></p>
<p style="top:301.8pt;left:151.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">(3.5 mm x 4.5 mm)</span></p>
<p style="top:196.3pt;left:143.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Hist: +</span></p>
<p style="top:196.3pt;left:151.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Positive results for PRP in combination</span></p>
<p style="top:187.8pt;left:160.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">with AF</span></p>
<p style="top:70.7pt;left:143.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">+</span></p>
<p style="top:653.5pt;left:193.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">3. Sarkar et al.</span></p>
<p style="top:653.5pt;left:202.3pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2006 [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#392a96">4</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">]</span></p>
<p style="top:575.7pt;left:193.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">1) Collagen + PRP</span></p>
<p style="top:575.7pt;left:202.3pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2) Collagen</span></p>
<p style="top:446.0pt;left:193.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Platelet concentration: 3.5 x</span></p>
<p style="top:446.0pt;left:202.3pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Activation: NA</span></p>
<p style="top:446.0pt;left:210.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Leukocytes: yes</span></p>
<p style="top:446.0pt;left:219.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Autologous</span></p>
<p style="top:446.0pt;left:227.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Fresh</span></p>
<p style="top:446.0pt;left:236.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">GFs: NA</span></p>
<p style="top:301.8pt;left:193.9pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Sheep tibial segmental defect</span></p>
<p style="top:301.8pt;left:202.3pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">(25 mm)</span></p>
<p style="top:196.3pt;left:193.9pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Hist: =</span></p>
<p style="top:196.3pt;left:202.3pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">X-Ray: =</span></p>
<p style="top:196.3pt;left:210.7pt;line-height:7.5pt"><span style="font-family:TmgcryAdvTT3713a231+03,serif;font-size:7.5pt;color:#131313">&#x3bc;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">CT: =</span></p>
<p style="top:196.3pt;left:219.3pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Mech: =</span></p>
<p style="top:70.7pt;left:193.9pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">=</span></p>
<p style="top:653.5pt;left:244.7pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">4. Rai et al.</span></p>
<p style="top:653.5pt;left:253.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2007 [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#392a96">24</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">]</span></p>
<p style="top:575.7pt;left:244.7pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">1) PCL/TCP</span></p>
<p style="top:575.7pt;left:253.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2) PCL/TCP + PRP</span></p>
<p style="top:446.0pt;left:244.7pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Platelet concentration: NA</span></p>
<p style="top:446.0pt;left:253.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Activation: calcium chloride\thrombin</span></p>
<p style="top:446.0pt;left:261.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Leukocytes: NA</span></p>
<p style="top:446.0pt;left:270.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Allogenic</span></p>
<p style="top:446.0pt;left:278.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Fresh</span></p>
<p style="top:446.0pt;left:287.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">GFs: NA</span></p>
<p style="top:301.8pt;left:244.7pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Rat femoral segmental defect</span></p>
<p style="top:301.8pt;left:253.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">(8 mm)</span></p>
<p style="top:196.3pt;left:244.7pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Hist: =</span></p>
<p style="top:196.3pt;left:253.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">X-Ray: +</span></p>
<p style="top:196.3pt;left:261.5pt;line-height:7.5pt"><span style="font-family:TmgcryAdvTT3713a231+03,serif;font-size:7.5pt;color:#131313">&#x3bc;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">CT: +</span></p>
<p style="top:196.3pt;left:270.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Mech: +</span></p>
<p style="top:70.7pt;left:244.7pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">+</span></p>
<p style="top:653.5pt;left:295.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">5. Kasten et al.</span></p>
<p style="top:653.5pt;left:304.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2008 [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#392a96">25</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">]</span></p>
<p style="top:575.7pt;left:295.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">1) CDHA + BMSCs</span></p>
<p style="top:575.7pt;left:304.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2) CDHA + PRP</span></p>
<p style="top:575.7pt;left:312.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">3) CDHA + PRP + BMSCs</span></p>
<p style="top:575.7pt;left:320.9pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">4) CDHA</span></p>
<p style="top:575.7pt;left:329.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">5) ABG</span></p>
<p style="top:575.7pt;left:337.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">6) Control (untreated)</span></p>
<p style="top:446.0pt;left:295.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Platelet concentration: 5.3 x</span></p>
<p style="top:446.0pt;left:304.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Activation: calcium chloride\thrombin</span></p>
<p style="top:446.0pt;left:312.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Leukocytes: NA</span></p>
<p style="top:446.0pt;left:320.9pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Allogenic</span></p>
<p style="top:446.0pt;left:329.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Frozen</span></p>
<p style="top:446.0pt;left:337.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">GFs: NA</span></p>
<p style="top:301.8pt;left:295.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Rabbit radius segmental defect</span></p>
<p style="top:301.8pt;left:304.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">(15 mm)</span></p>
<p style="top:196.3pt;left:295.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Hist: +</span></p>
<p style="top:196.3pt;left:304.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">X-Ray: +</span></p>
<p style="top:196.3pt;left:312.4pt;line-height:7.5pt"><span style="font-family:TmgcryAdvTT3713a231+03,serif;font-size:7.5pt;color:#131313">&#x3bc;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">CT: +</span></p>
<p style="top:196.3pt;left:321.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Mech: +</span></p>
<p style="top:70.7pt;left:295.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">+</span></p>
<p style="top:653.5pt;left:346.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">6. Lysiak-Drwal et al.</span></p>
<p style="top:653.5pt;left:354.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2008 [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#392a96">26</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">]</span></p>
<p style="top:575.8pt;left:346.3pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">1) BOC + BG</span></p>
<p style="top:575.8pt;left:354.7pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2) BOC + BG + PRP</span></p>
<p style="top:575.8pt;left:363.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">3) Control (untreated)</span></p>
<p style="top:446.0pt;left:346.3pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Platelet concentration: NA</span></p>
<p style="top:446.0pt;left:354.7pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Activation: NA</span></p>
<p style="top:446.0pt;left:363.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Leukocytes: yes</span></p>
<p style="top:446.0pt;left:371.7pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Allogenic/autologous: NA</span></p>
<p style="top:446.0pt;left:380.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Fresh/frozen: NA</span></p>
<p style="top:446.0pt;left:388.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">GFs: NA</span></p>
<p style="top:301.8pt;left:346.3pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Rabbit femoral cylindrical</span></p>
<p style="top:301.8pt;left:354.7pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">defect</span></p>
<p style="top:301.8pt;left:363.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">(5 mm)</span></p>
<p style="top:196.3pt;left:346.3pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Hist: +</span></p>
<p style="top:70.7pt;left:346.3pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">+</span></p>
<p style="top:653.5pt;left:397.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">7. Nair et al.</span></p>
<p style="top:653.5pt;left:405.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2009 [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#392a96">1</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">]</span></p>
<p style="top:575.8pt;left:397.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">1) HASi</span></p>
<p style="top:575.8pt;left:405.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2) HASi + BMSCs</span></p>
<p style="top:575.8pt;left:414.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">3) HASi + BMSCs + PRP</span></p>
<p style="top:446.0pt;left:397.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Platelet concentration: 1.5 x</span></p>
<p style="top:446.0pt;left:405.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Activation: NA</span></p>
<p style="top:446.0pt;left:414.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Leukocytes: NA</span></p>
<p style="top:446.0pt;left:422.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Autologous</span></p>
<p style="top:446.0pt;left:430.9pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Fresh</span></p>
<p style="top:446.0pt;left:439.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">GFs: NA</span></p>
<p style="top:301.8pt;left:397.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Goat femoral segmental defect</span></p>
<p style="top:301.8pt;left:405.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">(20 mm)</span></p>
<p style="top:196.3pt;left:397.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Hist: +</span></p>
<p style="top:196.3pt;left:405.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">X-Ray: +</span></p>
<p style="top:70.7pt;left:397.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">+</span></p>
<p style="top:653.5pt;left:447.9pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">8. Niemeyer et al.</span></p>
<p style="top:653.5pt;left:456.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2010 [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#392a96">27</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">]</span></p>
<p style="top:575.8pt;left:447.9pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">1) HA/collagen + BMSCs</span></p>
<p style="top:575.8pt;left:456.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2) HA/collagen + ASCs</span></p>
<p style="top:575.8pt;left:464.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">3) HA/collagen + ASCs + PRP</span></p>
<p style="top:575.8pt;left:473.3pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">4) Control (untreated)</span></p>
<p style="top:446.0pt;left:447.9pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Platelet concentration: 4.5 x</span></p>
<p style="top:446.0pt;left:456.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Activation: calcium chloride/thrombin</span></p>
<p style="top:446.0pt;left:464.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Leukocytes: No</span></p>
<p style="top:446.0pt;left:473.3pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Xenogenic</span></p>
<p style="top:446.0pt;left:481.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Frozen</span></p>
<p style="top:446.0pt;left:490.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">GFs: PDGF-AB and TGF-</span><span style="font-family:TmgcryAdvTT3713a231+03,serif;font-size:7.5pt;color:#131313">&#x3b2;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">1</span></p>
<p style="top:301.8pt;left:447.9pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Sheep tibial segmental defect</span></p>
<p style="top:301.8pt;left:456.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">(30 mm)</span></p>
<p style="top:196.3pt;left:447.9pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Hist: +</span></p>
<p style="top:196.3pt;left:456.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">X-Ray: +</span></p>
<p style="top:70.7pt;left:447.9pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">+</span></p>
<p style="top:653.5pt;left:498.7pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">9. Bi et al.</span></p>
<p style="top:653.5pt;left:507.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2010 [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#392a96">28</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">]</span></p>
<p style="top:575.8pt;left:498.7pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">1) TCP/chitosan</span></p>
<p style="top:575.8pt;left:507.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2) TCP/chitosan + PRP</span></p>
<p style="top:575.8pt;left:515.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">3) Control (untreated)</span></p>
<p style="top:446.0pt;left:498.7pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Platelet concentration: 5.3 x</span></p>
<p style="top:446.0pt;left:507.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Activation: calcium chloride\thrombin</span></p>
<p style="top:446.0pt;left:515.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Leukocytes: NA</span></p>
<p style="top:446.0pt;left:524.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Allogenic/autologous: NA</span></p>
<p style="top:446.0pt;left:532.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Fresh/frozen: NA</span></p>
<p style="top:301.8pt;left:498.7pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Goat tibia cylindrical defect</span></p>
<p style="top:301.8pt;left:507.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">(12 mm)</span></p>
<p style="top:196.3pt;left:498.7pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Hist: +</span></p>
<p style="top:196.3pt;left:507.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">X-Ray: +</span></p>
<p style="top:70.7pt;left:498.7pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">+</span></p>
<p style="top:33.1pt;left:51.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">224</span></p>
<p style="top:33.1pt;left:359.8pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">International Orthopaedics (SICOT) (2017) 41:221</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">237</span></p>


<p style="top:707.1pt;left:53.4pt;line-height:8.5pt"><span style="font-family:XssngvAdvTTb8864ccf.B,serif;font-size:8.5pt;color:#131313">Table 1</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> (continued)</span></p>
<p style="top:652.7pt;left:72.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Publication</span></p>
<p style="top:575.0pt;left:72.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Treatment groups</span></p>
<p style="top:445.2pt;left:72.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">PRP characteristics</span></p>
<p style="top:301.0pt;left:72.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Animal model</span></p>
<p style="top:195.5pt;left:72.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Protocol</span></p>
<p style="top:69.9pt;left:72.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Effects</span></p>
<p style="top:446.0pt;left:92.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">GFs: TGF-</span><span style="font-family:TmgcryAdvTT3713a231+03,serif;font-size:7.5pt;color:#131313">&#x3b2;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">1, PDGF-BB, bFGF and VEGF</span></p>
<p style="top:653.5pt;left:100.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">10. Kon et al.</span></p>
<p style="top:653.5pt;left:109.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2010 [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#392a96">29</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">]</span></p>
<p style="top:575.7pt;left:100.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">1) COL/HA</span></p>
<p style="top:575.7pt;left:109.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2) COL/HA + PRP</span></p>
<p style="top:575.7pt;left:117.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">3) Control (untreated)</span></p>
<p style="top:446.0pt;left:100.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Platelet concentration: 3.2 x</span></p>
<p style="top:446.0pt;left:109.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Activation: calcium chloride</span></p>
<p style="top:446.0pt;left:117.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Leukocytes: yes</span></p>
<p style="top:446.0pt;left:126.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Autologous</span></p>
<p style="top:446.0pt;left:134.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Fresh</span></p>
<p style="top:446.0pt;left:142.9pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">GFs: TGF-</span><span style="font-family:TmgcryAdvTT3713a231+03,serif;font-size:7.5pt;color:#131313">&#x3b2;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">1, PDGF-AB and IL1</span></p>
<p style="top:301.8pt;left:100.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Sheep femoral condyle</span></p>
<p style="top:301.8pt;left:109.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">cylindrical defect</span></p>
<p style="top:301.8pt;left:117.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">(7 mm x 9 mm)</span></p>
<p style="top:196.3pt;left:99.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Hist:</span><span style="font-family:YcxdxmAdvTT3713a231+22,serif;font-size:7.5pt;color:#131313"> &#x2212;</span></p>
<p style="top:196.3pt;left:108.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">X-Ray:</span><span style="font-family:YcxdxmAdvTT3713a231+22,serif;font-size:7.5pt;color:#131313"> &#x2212;</span></p>
<p style="top:70.7pt;left:100.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">-</span></p>
<p style="top:653.5pt;left:151.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">11. Kanthan et al.</span></p>
<p style="top:653.5pt;left:159.9pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2011 [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#392a96">30</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">]</span></p>
<p style="top:575.8pt;left:151.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">1) PRP</span></p>
<p style="top:575.8pt;left:159.9pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2) Coral</span></p>
<p style="top:575.8pt;left:168.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">3) Coral + PRP</span></p>
<p style="top:575.8pt;left:176.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">4) Control (untreated)</span></p>
<p style="top:446.0pt;left:151.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Platelet concentration: 2.6 - 4.6 x</span></p>
<p style="top:446.0pt;left:159.9pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Activation: calcium chloride/thrombin</span></p>
<p style="top:446.0pt;left:168.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Leukocytes: NA</span></p>
<p style="top:446.0pt;left:176.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Autologous</span></p>
<p style="top:446.0pt;left:185.3pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Fresh</span></p>
<p style="top:446.0pt;left:193.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">GFs: NA</span></p>
<p style="top:301.8pt;left:151.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Rabbit tibial segmental defect</span></p>
<p style="top:301.8pt;left:159.9pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">(20 mm)</span></p>
<p style="top:196.3pt;left:151.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Hist: +</span></p>
<p style="top:196.3pt;left:159.9pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">X-Ray: +</span></p>
<p style="top:70.7pt;left:151.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">+</span></p>
<p style="top:653.5pt;left:202.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">12. Zhang et al.</span></p>
<p style="top:653.5pt;left:210.7pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2011 [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#392a96">31</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">]</span></p>
<p style="top:575.8pt;left:202.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">1) Bioactive glass</span></p>
<p style="top:575.8pt;left:210.7pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2) Bioactive glass + PRP</span></p>
<p style="top:575.8pt;left:219.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">3) Control (untreated)</span></p>
<p style="top:446.0pt;left:202.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Platelet concentration: NA</span></p>
<p style="top:446.0pt;left:210.7pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Activation: calcium chloride/thrombin</span></p>
<p style="top:446.0pt;left:219.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Leukocytes: NA</span></p>
<p style="top:446.0pt;left:227.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Allogenic/autologous: NA</span></p>
<p style="top:446.0pt;left:236.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Fresh/frozen: NA</span></p>
<p style="top:446.0pt;left:244.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">GFs: NA</span></p>
<p style="top:301.8pt;left:202.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Rabbit radius segmental defect</span></p>
<p style="top:301.8pt;left:210.7pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">(15 mm)</span></p>
<p style="top:196.3pt;left:202.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Hist: +</span></p>
<p style="top:196.3pt;left:210.7pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">X-Ray: +</span></p>
<p style="top:196.3pt;left:219.1pt;line-height:7.5pt"><span style="font-family:TmgcryAdvTT3713a231+03,serif;font-size:7.5pt;color:#131313">&#x3bc;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">CT: +</span></p>
<p style="top:70.8pt;left:202.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">+</span></p>
<p style="top:653.6pt;left:253.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">13. Parizi et al.</span></p>
<p style="top:653.6pt;left:261.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2012 [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#392a96">32</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">]</span></p>
<p style="top:575.8pt;left:253.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">1) Coral</span></p>
<p style="top:575.8pt;left:261.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2) Coral + PRP +1 injection 4 days post op</span></p>
<p style="top:575.8pt;left:270.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">3) Control (untreated)</span></p>
<p style="top:446.0pt;left:253.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Platelet concentration: 10.1 x</span></p>
<p style="top:446.0pt;left:261.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Activation: NA</span></p>
<p style="top:446.0pt;left:270.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Leukocytes: no</span></p>
<p style="top:446.0pt;left:278.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Xenogenic</span></p>
<p style="top:446.0pt;left:286.9pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Frozen</span></p>
<p style="top:446.0pt;left:295.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">GFs: NA</span></p>
<p style="top:301.8pt;left:253.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Rabbit radius segmental defect</span></p>
<p style="top:301.8pt;left:261.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">(10 mm)</span></p>
<p style="top:196.3pt;left:253.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Hist: +</span></p>
<p style="top:196.3pt;left:261.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">X-Ray: +</span></p>
<p style="top:196.3pt;left:270.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Mech: +</span></p>
<p style="top:70.8pt;left:253.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">+</span></p>
<p style="top:653.6pt;left:303.9pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">14. Oryan et al.</span></p>
<p style="top:653.6pt;left:312.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2012 [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#392a96">33</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">]</span></p>
<p style="top:575.8pt;left:303.9pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">1) HA</span></p>
<p style="top:575.8pt;left:312.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2) HA + hPRP</span></p>
<p style="top:575.8pt;left:320.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">3) Control (untreated)</span></p>
<p style="top:446.0pt;left:303.9pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Platelet concentration: 10.1 x</span></p>
<p style="top:446.0pt;left:312.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Activation: NA</span></p>
<p style="top:446.0pt;left:320.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Leukocytes: No</span></p>
<p style="top:446.0pt;left:329.3pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Xenogenic</span></p>
<p style="top:446.0pt;left:337.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Frozen</span></p>
<p style="top:446.0pt;left:346.3pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">GFs: NA</span></p>
<p style="top:301.8pt;left:303.9pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Rabbit radius segmental defect</span></p>
<p style="top:301.8pt;left:312.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">(10 mm)</span></p>
<p style="top:196.3pt;left:303.9pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Hist: +</span></p>
<p style="top:196.3pt;left:312.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">X-Ray: +</span></p>
<p style="top:196.3pt;left:320.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Mech: =</span></p>
<p style="top:70.8pt;left:303.9pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">+</span></p>
<p style="top:653.6pt;left:354.7pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">15. Kasten et al.</span></p>
<p style="top:653.6pt;left:363.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2012 [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#392a96">34</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">]</span></p>
<p style="top:575.8pt;left:354.7pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">1) CDHA</span></p>
<p style="top:575.8pt;left:363.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2) CDHA + PRP</span></p>
<p style="top:575.8pt;left:371.7pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">3) CDHA + PRP + BMSCs</span></p>
<p style="top:575.8pt;left:380.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">4) CDHA + BMSCs</span></p>
<p style="top:575.8pt;left:388.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">5) CDHA + BMSCs +</span></p>
<p style="top:575.7pt;left:397.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">VEGF (transfected)</span></p>
<p style="top:446.0pt;left:354.7pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Platelet concentration: 5.3 x</span></p>
<p style="top:446.0pt;left:363.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Activation: calcium chloride/ thrombin</span></p>
<p style="top:446.0pt;left:371.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Leukocytes: NA</span></p>
<p style="top:446.0pt;left:380.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Allogenic</span></p>
<p style="top:446.0pt;left:388.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Frozen</span></p>
<p style="top:446.0pt;left:397.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">GFs: NA</span></p>
<p style="top:301.8pt;left:354.7pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Rabbit radius segmental defect</span></p>
<p style="top:301.8pt;left:363.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">(15 mm)</span></p>
<p style="top:196.3pt;left:354.7pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Hist: +</span></p>
<p style="top:196.3pt;left:363.0pt;line-height:7.5pt"><span style="font-family:TmgcryAdvTT3713a231+03,serif;font-size:7.5pt;color:#131313">&#x3bc;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">CT: +</span></p>
<p style="top:70.7pt;left:354.7pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">+</span></p>
<p style="top:653.5pt;left:405.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">16. Kim et al.</span></p>
<p style="top:653.5pt;left:414.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2014 [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#392a96">35</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">]</span></p>
<p style="top:575.7pt;left:405.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">1) Gelatin + PRP</span></p>
<p style="top:575.7pt;left:414.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2) Gelatin + SEW2871 micelles</span></p>
<p style="top:575.7pt;left:422.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">3) Gelatin + SEW2871 micelles + PRP</span></p>
<p style="top:575.7pt;left:430.9pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">4) Control (untreated)</span></p>
<p style="top:446.0pt;left:405.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Platelet concentration: 8</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:7.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">10 x</span></p>
<p style="top:446.0pt;left:414.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Activation: calcium chloride</span></p>
<p style="top:446.0pt;left:422.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Leukocytes: NA</span></p>
<p style="top:446.0pt;left:430.9pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Allogenic</span></p>
<p style="top:446.0pt;left:439.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Fresh/frozen: NA</span></p>
<p style="top:446.0pt;left:447.7pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">GFs: TGF-</span><span style="font-family:TmgcryAdvTT3713a231+03,serif;font-size:7.5pt;color:#131313">&#x3b2;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">1 and SDF-1</span></p>
<p style="top:301.8pt;left:405.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Rat ulnar segmental defect</span></p>
<p style="top:301.8pt;left:414.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">(6 mm)</span></p>
<p style="top:196.3pt;left:405.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Hist: +</span></p>
<p style="top:196.3pt;left:414.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">X-Ray: +</span></p>
<p style="top:196.3pt;left:422.3pt;line-height:7.5pt"><span style="font-family:TmgcryAdvTT3713a231+03,serif;font-size:7.5pt;color:#131313">&#x3bc;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">CT: +</span></p>
<p style="top:70.7pt;left:405.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">+</span></p>
<p style="top:653.5pt;left:456.3pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">17. Filardo et al.</span></p>
<p style="top:653.5pt;left:464.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2014 [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#392a96">36</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">]</span></p>
<p style="top:575.7pt;left:456.3pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">1) BioSiC(HaCol)</span></p>
<p style="top:575.7pt;left:464.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2) BioSiC (HaCol) + PRP</span></p>
<p style="top:575.7pt;left:473.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">3) BioSiC (HaCol) + BMSCs</span></p>
<p style="top:446.0pt;left:456.3pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Platelet concentration: 2.8 x</span></p>
<p style="top:446.0pt;left:464.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Activation: calcium chloride</span></p>
<p style="top:446.0pt;left:473.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Leukocytes: yes</span></p>
<p style="top:446.0pt;left:481.7pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Autologous</span></p>
<p style="top:446.0pt;left:490.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Fresh</span></p>
<p style="top:446.0pt;left:498.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">GFs: NA</span></p>
<p style="top:301.8pt;left:456.3pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Sheep metatarsus segmental defect</span></p>
<p style="top:301.8pt;left:464.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">(20 mm)</span></p>
<p style="top:196.3pt;left:456.3pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Hist: +</span></p>
<p style="top:196.3pt;left:464.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">X-Ray: =</span></p>
<p style="top:70.7pt;left:456.3pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">+</span></p>
<p style="top:653.5pt;left:507.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">18. Zhong et al.</span></p>
<p style="top:653.5pt;left:515.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2014 [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#392a96">37</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">]</span></p>
<p style="top:575.7pt;left:507.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">1)</span><span style="font-family:TmgcryAdvTT3713a231+03,serif;font-size:7.5pt;color:#131313"> &#x3b2;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">-TCP + BMSCs</span></p>
<p style="top:575.7pt;left:515.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2)</span><span style="font-family:TmgcryAdvTT3713a231+03,serif;font-size:7.5pt;color:#131313"> &#x3b2;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">-TCP + BMSCs</span></p>
<p style="top:575.7pt;left:524.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">+ PRP</span></p>
<p style="top:575.7pt;left:532.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">3) Autogenic ilium (control)</span></p>
<p style="top:446.0pt;left:507.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Platelet concentration: NA</span></p>
<p style="top:446.0pt;left:515.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Activation: calcium chloride/thrombin</span></p>
<p style="top:446.0pt;left:524.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Leukocytes: NA</span></p>
<p style="top:446.0pt;left:532.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Autologous</span></p>
<p style="top:301.8pt;left:507.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Dog tibia cylindrical defect</span></p>
<p style="top:301.8pt;left:515.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">(10 mm)</span></p>
<p style="top:196.3pt;left:507.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Hist: +</span></p>
<p style="top:196.3pt;left:515.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">X-Ray: +</span></p>
<p style="top:196.3pt;left:524.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Mech: +</span></p>
<p style="top:70.7pt;left:507.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">+</span></p>
<p style="top:33.1pt;left:51.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">International Orthopaedics (SICOT) (2017) 41:221</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">237</span></p>
<p style="top:33.1pt;left:531.7pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">225</span></p>


<p style="top:707.1pt;left:53.4pt;line-height:8.5pt"><span style="font-family:XssngvAdvTTb8864ccf.B,serif;font-size:8.5pt;color:#131313">Table 1</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> (continued)</span></p>
<p style="top:652.7pt;left:72.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Publication</span></p>
<p style="top:575.0pt;left:72.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Treatment groups</span></p>
<p style="top:445.2pt;left:72.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">PRP characteristics</span></p>
<p style="top:301.0pt;left:72.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Animal model</span></p>
<p style="top:195.5pt;left:72.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Protocol</span></p>
<p style="top:69.9pt;left:72.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Effects</span></p>
<p style="top:446.0pt;left:92.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Frozen</span></p>
<p style="top:446.0pt;left:100.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">GFs: NA</span></p>
<p style="top:653.5pt;left:109.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">19. He et al.</span></p>
<p style="top:653.5pt;left:117.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2015 [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#392a96">2</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">]</span></p>
<p style="top:575.7pt;left:109.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">1) PLGA/CPC</span></p>
<p style="top:575.7pt;left:117.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2) PLGA/CPC + PRP</span></p>
<p style="top:446.0pt;left:109.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Platelet concentration: 3.3 x</span></p>
<p style="top:446.0pt;left:117.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Activation: calcium chloride/ thrombin</span></p>
<p style="top:446.0pt;left:126.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Leukocytes: yes</span></p>
<p style="top:446.0pt;left:134.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Allogenic</span></p>
<p style="top:446.0pt;left:143.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Fresh/frozen: NA</span></p>
<p style="top:446.0pt;left:151.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">GFs: NA</span></p>
<p style="top:301.8pt;left:109.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Rabbit femoral cylindrical defect</span></p>
<p style="top:301.8pt;left:117.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">(6 mm x 10 mm)</span></p>
<p style="top:301.8pt;left:126.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Rabbit radius segmental defect</span></p>
<p style="top:301.8pt;left:134.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">(15 mm)</span></p>
<p style="top:196.3pt;left:109.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">In femoral defect:</span></p>
<p style="top:196.3pt;left:117.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Hist: +</span></p>
<p style="top:196.3pt;left:126.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">X-Ray: +</span></p>
<p style="top:196.3pt;left:134.4pt;line-height:7.5pt"><span style="font-family:TmgcryAdvTT3713a231+03,serif;font-size:7.5pt;color:#131313">&#x3bc;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">CT: +</span></p>
<p style="top:196.3pt;left:143.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">In radial defect:</span></p>
<p style="top:196.3pt;left:151.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Hist: +</span></p>
<p style="top:196.3pt;left:159.9pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">X-Ray: +</span></p>
<p style="top:196.3pt;left:168.3pt;line-height:7.5pt"><span style="font-family:TmgcryAdvTT3713a231+03,serif;font-size:7.5pt;color:#131313">&#x3bc;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">CT: +</span></p>
<p style="top:70.7pt;left:109.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">+</span></p>
<p style="top:653.5pt;left:176.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">20. Chen et al.</span></p>
<p style="top:653.5pt;left:185.3pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2016 [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#392a96">38</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">]</span></p>
<p style="top:575.7pt;left:176.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">1) CS + PRP</span></p>
<p style="top:575.7pt;left:185.3pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2) CS</span></p>
<p style="top:575.7pt;left:193.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">3) PRP</span></p>
<p style="top:575.7pt;left:202.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">4) BMP-2 (positive control)</span></p>
<p style="top:446.0pt;left:176.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Platelet concentration: 8</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:7.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">10 x</span></p>
<p style="top:446.0pt;left:185.3pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Activation: calcium chloride/thrombin</span></p>
<p style="top:446.0pt;left:193.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Leukocytes: NA</span></p>
<p style="top:446.0pt;left:202.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Autologous</span></p>
<p style="top:446.0pt;left:210.7pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Fresh</span></p>
<p style="top:446.0pt;left:219.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">GFs: NA</span></p>
<p style="top:301.8pt;left:176.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Rabbit radius segmental defect</span></p>
<p style="top:301.8pt;left:185.3pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">(12 mm)</span></p>
<p style="top:196.3pt;left:176.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Hist: +</span></p>
<p style="top:196.3pt;left:185.3pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">X-Ray: +</span></p>
<p style="top:196.3pt;left:193.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">: +</span></p>
<p style="top:196.3pt;left:202.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Superior results for CS + PRP with</span></p>
<p style="top:187.8pt;left:210.7pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">respect to CS and PRP alone, but</span></p>
<p style="top:187.8pt;left:219.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">similar results with BMP-2</span></p>
<p style="top:70.7pt;left:176.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">+</span></p>
<p style="top:707.9pt;left:227.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Autograft/</span></p>
<p style="top:699.4pt;left:236.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">allograft/</span></p>
<p style="top:699.4pt;left:244.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">xenograft</span></p>
<p style="top:653.5pt;left:227.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">21. Dallari et al.</span></p>
<p style="top:653.5pt;left:236.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2006 [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#392a96">39</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">]</span></p>
<p style="top:575.7pt;left:227.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">1) BMSCs + PRP</span></p>
<p style="top:575.7pt;left:236.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2) FDBA + BMSCs</span></p>
<p style="top:575.7pt;left:244.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">3) FDBA + PRP</span></p>
<p style="top:575.7pt;left:253.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">4) FDBA + PRP + BMSCs</span></p>
<p style="top:446.0pt;left:227.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Platelet concentration: 2.8 x</span></p>
<p style="top:446.0pt;left:236.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Activation: calcium chloride/thrombin</span></p>
<p style="top:446.0pt;left:244.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Leukocytes: yes</span></p>
<p style="top:446.0pt;left:253.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Autologous</span></p>
<p style="top:446.0pt;left:261.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Fresh</span></p>
<p style="top:446.0pt;left:270.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">GFs: NA</span></p>
<p style="top:301.8pt;left:227.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Rabbit femoral cylindrical defect</span></p>
<p style="top:301.8pt;left:236.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">(diameter: 6 mm; depth: 10 mm)</span></p>
<p style="top:196.3pt;left:226.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Hist:</span><span style="font-family:YcxdxmAdvTT3713a231+22,serif;font-size:7.5pt;color:#131313"> &#x2212;</span></p>
<p style="top:196.3pt;left:236.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Superior results for FDBA + PRP +</span></p>
<p style="top:187.8pt;left:244.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">BMSCs</span></p>
<p style="top:70.7pt;left:227.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">+</span></p>
<p style="top:653.5pt;left:278.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">22. Kroese-Deutman</span></p>
<p style="top:653.5pt;left:286.9pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">et al.</span></p>
<p style="top:653.5pt;left:295.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2008 [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#392a96">40</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">]</span></p>
<p style="top:575.7pt;left:278.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">1) Ti</span></p>
<p style="top:575.7pt;left:286.9pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2) Ti-Bone chips</span></p>
<p style="top:575.7pt;left:295.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">3) Ti-Bone chips + PRP</span></p>
<p style="top:446.0pt;left:275.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Platelet concentration: 1000</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:7.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">1500 x 10</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:5.3pt;color:#131313">9</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313"> / L</span></p>
<p style="top:446.0pt;left:286.9pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Activation: bovine thrombin</span></p>
<p style="top:446.0pt;left:295.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Leukocytes: NA</span></p>
<p style="top:446.0pt;left:303.9pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Autologous</span></p>
<p style="top:446.0pt;left:312.3pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Fresh</span></p>
<p style="top:446.0pt;left:320.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">GFs: NA</span></p>
<p style="top:301.8pt;left:278.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Rabbit radial segmental defect</span></p>
<p style="top:301.8pt;left:286.9pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">(15 mm)</span></p>
<p style="top:196.3pt;left:278.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Hist: +</span></p>
<p style="top:196.3pt;left:286.9pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">X-Ray: =</span></p>
<p style="top:70.7pt;left:278.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">+</span></p>
<p style="top:653.5pt;left:329.3pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">23. Molina-Minano</span></p>
<p style="top:645.0pt;left:337.7pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">et al.</span></p>
<p style="top:653.5pt;left:346.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2009 [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#392a96">41</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">]</span></p>
<p style="top:575.7pt;left:329.3pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">1) Autograft</span></p>
<p style="top:575.7pt;left:337.7pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2) PRP</span></p>
<p style="top:575.7pt;left:346.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">3) Autograft + PRP</span></p>
<p style="top:575.7pt;left:354.7pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">4) Control (untreated)</span></p>
<p style="top:446.0pt;left:329.3pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Platelet concentration: NA</span></p>
<p style="top:446.0pt;left:337.7pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Activation: calcium chloride</span></p>
<p style="top:446.0pt;left:346.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Leukocytes: NA</span></p>
<p style="top:446.0pt;left:354.7pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Allogenic</span></p>
<p style="top:446.0pt;left:363.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Fresh</span></p>
<p style="top:446.0pt;left:371.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">GFs: NA</span></p>
<p style="top:301.8pt;left:329.3pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Rabbit tibial cylindrical defect</span></p>
<p style="top:301.8pt;left:337.7pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">(4 mm)</span></p>
<p style="top:196.3pt;left:329.3pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Hist: =</span></p>
<p style="top:196.3pt;left:337.7pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">X-Ray:</span></p>
<p style="top:196.3pt;left:346.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">+ at 1 m</span></p>
<p style="top:196.3pt;left:354.7pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">= at 2 m</span></p>
<p style="top:70.7pt;left:329.3pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">+</span></p>
<p style="top:653.5pt;left:380.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">24. Hakimi et al.</span></p>
<p style="top:653.5pt;left:388.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2010 [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#392a96">42</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">]</span></p>
<p style="top:575.7pt;left:380.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">1) Autograft</span></p>
<p style="top:575.7pt;left:388.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2) Autograft + PRP</span></p>
<p style="top:446.0pt;left:380.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Platelet concentration: 4.9 x</span></p>
<p style="top:446.0pt;left:388.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Activation: calcium chloride/thrombin</span></p>
<p style="top:446.0pt;left:397.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Leukocytes: yes</span></p>
<p style="top:446.0pt;left:405.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Autologous</span></p>
<p style="top:446.0pt;left:414.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Fresh</span></p>
<p style="top:446.0pt;left:422.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">GFs: TGF-</span><span style="font-family:TmgcryAdvTT3713a231+03,serif;font-size:7.5pt;color:#131313">&#x3b2;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">1 and PDGF-BB</span></p>
<p style="top:301.8pt;left:380.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Pig tibial cylindrical defect</span></p>
<p style="top:301.8pt;left:388.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">(11 x 25 mm)</span></p>
<p style="top:196.3pt;left:380.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Hist: +</span></p>
<p style="top:196.3pt;left:388.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">X-Ray: =</span></p>
<p style="top:70.7pt;left:380.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">+</span></p>
<p style="top:653.5pt;left:430.9pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">25. Nather et al.</span></p>
<p style="top:653.5pt;left:439.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2012 [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#392a96">43</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">]</span></p>
<p style="top:575.7pt;left:430.9pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">1) Autograft</span></p>
<p style="top:575.7pt;left:439.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2) Allograft</span></p>
<p style="top:575.7pt;left:447.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">3) Allograft + PRP</span></p>
<p style="top:446.0pt;left:430.9pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Platelet concentration: NA</span></p>
<p style="top:446.0pt;left:439.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Activation: thrombin</span></p>
<p style="top:446.0pt;left:447.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Leukocytes: NA</span></p>
<p style="top:446.0pt;left:456.3pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Autologous</span></p>
<p style="top:446.0pt;left:464.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Fresh</span></p>
<p style="top:446.0pt;left:473.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">GFs: NA</span></p>
<p style="top:301.8pt;left:430.9pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Rabbit tibial segmental defect</span></p>
<p style="top:301.8pt;left:439.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">(15 mm)</span></p>
<p style="top:196.3pt;left:430.9pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Hist:</span></p>
<p style="top:196.3pt;left:439.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">+ at 12 w</span></p>
<p style="top:196.3pt;left:447.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">= at 24 w</span></p>
<p style="top:196.3pt;left:456.3pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">X-Ray:</span></p>
<p style="top:196.3pt;left:464.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">= for all the aspects related to</span></p>
<p style="top:187.8pt;left:473.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">mineralization and bone volume</span></p>
<p style="top:196.3pt;left:481.7pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">+ for resorption index</span></p>
<p style="top:70.7pt;left:430.9pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">+</span></p>
<p style="top:653.5pt;left:490.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">26. Kurikchy et al.</span></p>
<p style="top:653.5pt;left:498.7pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2013 [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#392a96">44</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">]</span></p>
<p style="top:575.7pt;left:490.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">1) Xenograft</span></p>
<p style="top:575.7pt;left:498.7pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2) Xenograft + PRP</span></p>
<p style="top:575.7pt;left:507.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">3) Control (untreated)</span></p>
<p style="top:446.0pt;left:490.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Platelet concentration: 2</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:7.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">3 x</span></p>
<p style="top:446.0pt;left:498.7pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Activation: calcium chloride</span></p>
<p style="top:446.0pt;left:507.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Leukocytes: NA</span></p>
<p style="top:446.0pt;left:515.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Autologous</span></p>
<p style="top:446.0pt;left:524.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Fresh</span></p>
<p style="top:446.0pt;left:532.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">GFs: NA</span></p>
<p style="top:301.8pt;left:490.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Rabbit femoral cylindrical defect</span></p>
<p style="top:301.8pt;left:498.7pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">(3 mm)</span></p>
<p style="top:196.3pt;left:490.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Hist: +</span></p>
<p style="top:70.7pt;left:490.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">+</span></p>
<p style="top:33.1pt;left:51.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">226</span></p>
<p style="top:33.1pt;left:359.8pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">International Orthopaedics (SICOT) (2017) 41:221</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">237</span></p>


<p style="top:707.1pt;left:53.4pt;line-height:8.5pt"><span style="font-family:XssngvAdvTTb8864ccf.B,serif;font-size:8.5pt;color:#131313">Table 1</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> (continued)</span></p>
<p style="top:652.7pt;left:72.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Publication</span></p>
<p style="top:575.0pt;left:72.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Treatment groups</span></p>
<p style="top:445.2pt;left:72.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">PRP characteristics</span></p>
<p style="top:301.0pt;left:72.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Animal model</span></p>
<p style="top:195.5pt;left:72.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Protocol</span></p>
<p style="top:69.9pt;left:72.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Effects</span></p>
<p style="top:653.5pt;left:92.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">27. Zhang et al.</span></p>
<p style="top:653.5pt;left:100.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2013 [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#392a96">45</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">]</span></p>
<p style="top:575.7pt;left:92.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">1) DPB + PRP + BMSCs</span></p>
<p style="top:575.7pt;left:100.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2) DPB + BMSCs</span></p>
<p style="top:575.7pt;left:109.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">3) DPB + PRP</span></p>
<p style="top:575.7pt;left:117.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">4) DPB</span></p>
<p style="top:446.0pt;left:92.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Platelet concentration: 4 x</span></p>
<p style="top:446.0pt;left:100.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Activation: calcium chloride\thrombin</span></p>
<p style="top:446.0pt;left:109.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Leukocytes: NA</span></p>
<p style="top:446.0pt;left:117.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Allogenic</span></p>
<p style="top:446.0pt;left:126.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Fresh/frozen: NA</span></p>
<p style="top:446.0pt;left:134.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">GFs: TGF-</span><span style="font-family:TmgcryAdvTT3713a231+03,serif;font-size:7.5pt;color:#131313">&#x3b2;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">1, PDGF, EGF and VEGF</span></p>
<p style="top:301.8pt;left:92.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Rabbit radial segmental defect</span></p>
<p style="top:301.8pt;left:100.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">(15 mm)</span></p>
<p style="top:196.3pt;left:92.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Hist: +</span></p>
<p style="top:196.3pt;left:100.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">X-Ray: +</span></p>
<p style="top:196.3pt;left:109.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">DEXA:</span></p>
<p style="top:196.3pt;left:117.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">+ for new bone tissue quality</span></p>
<p style="top:70.7pt;left:92.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">+</span></p>
<p style="top:653.5pt;left:143.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">28. Schneppendahl et al.</span></p>
<p style="top:653.5pt;left:151.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2015 [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#392a96">46</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">]</span></p>
<p style="top:575.7pt;left:143.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">1) Autograft + PRP</span></p>
<p style="top:575.7pt;left:151.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2) Autograft</span></p>
<p style="top:446.0pt;left:143.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Platelet concentration: 5.4 x</span></p>
<p style="top:446.0pt;left:151.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Activation: calcium chloride/thrombin</span></p>
<p style="top:446.0pt;left:159.9pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Leukocytes: NA</span></p>
<p style="top:446.0pt;left:168.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Autologous</span></p>
<p style="top:446.0pt;left:176.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Fresh</span></p>
<p style="top:446.0pt;left:185.3pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">GFs: TGF-</span><span style="font-family:TmgcryAdvTT3713a231+03,serif;font-size:7.5pt;color:#131313">&#x3b2;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">1; PDGF-BB; VEGF</span></p>
<p style="top:301.8pt;left:143.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Rabbit radial segmental defect</span></p>
<p style="top:301.8pt;left:151.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">(15x4x3 mm)</span></p>
<p style="top:196.3pt;left:143.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Hist: +</span></p>
<p style="top:196.3pt;left:151.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">X-Ray: +</span></p>
<p style="top:70.7pt;left:143.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">+</span></p>
<p style="top:653.5pt;left:193.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">29. Park et al.</span></p>
<p style="top:653.5pt;left:202.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2016 [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#392a96">47</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">]</span></p>
<p style="top:575.7pt;left:193.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">1) Synthetic bone</span></p>
<p style="top:575.7pt;left:202.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2) CGF</span></p>
<p style="top:575.7pt;left:210.7pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">3) PRF</span></p>
<p style="top:575.7pt;left:219.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">4) Control (untreated)</span></p>
<p style="top:446.0pt;left:193.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Platelet concentration: NA</span></p>
<p style="top:446.0pt;left:202.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Activation: NA</span></p>
<p style="top:446.0pt;left:210.7pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Leukocytes: NA</span></p>
<p style="top:446.0pt;left:219.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Autologous</span></p>
<p style="top:446.0pt;left:227.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Fresh</span></p>
<p style="top:446.0pt;left:236.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">GFs: TGF-</span><span style="font-family:TmgcryAdvTT3713a231+03,serif;font-size:7.5pt;color:#131313">&#x3b2;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313"> and VEGF</span></p>
<p style="top:301.8pt;left:193.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Dog femur cylindrical defect</span></p>
<p style="top:301.8pt;left:202.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">(8 mm)</span></p>
<p style="top:196.3pt;left:193.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Hist: +</span></p>
<p style="top:70.7pt;left:193.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">+</span></p>
<p style="top:707.9pt;left:244.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Powder/granules 30. Rabillard et al.</span></p>
<p style="top:653.5pt;left:253.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2009 [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#392a96">48</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">]</span></p>
<p style="top:575.7pt;left:244.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">1) CaP</span></p>
<p style="top:575.7pt;left:253.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2) CaP + PRP</span></p>
<p style="top:446.0pt;left:244.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Platelet concentration: 3-6x</span></p>
<p style="top:446.0pt;left:253.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Activation: calcium Borogluconate +</span></p>
<p style="top:437.5pt;left:261.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">batroxobin</span></p>
<p style="top:446.0pt;left:270.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Leukocytes: NA</span></p>
<p style="top:446.0pt;left:278.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Autologous</span></p>
<p style="top:446.0pt;left:286.9pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Fresh</span></p>
<p style="top:446.0pt;left:295.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">GFs: NA</span></p>
<p style="top:301.8pt;left:244.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Dog ulnar segmental defect</span></p>
<p style="top:301.8pt;left:253.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">(20 mm)</span></p>
<p style="top:196.3pt;left:244.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Hist: =</span></p>
<p style="top:196.3pt;left:253.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">X-Ray: =</span></p>
<p style="top:196.3pt;left:261.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">SEM: =</span></p>
<p style="top:70.7pt;left:244.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">=</span></p>
<p style="top:653.5pt;left:303.9pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">31. Jungbluth et al.</span></p>
<p style="top:653.5pt;left:312.3pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2010 [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#392a96">49</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">]</span></p>
<p style="top:575.7pt;left:303.9pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">1) CaP</span></p>
<p style="top:575.7pt;left:312.3pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2) CaP + PRP</span></p>
<p style="top:446.0pt;left:303.9pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Platelet concentration: 4.4 x</span></p>
<p style="top:446.0pt;left:312.3pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Activation: calcium chloride/ thrombin</span></p>
<p style="top:446.0pt;left:320.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Leukocytes: NA</span></p>
<p style="top:446.0pt;left:329.3pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Autogenous</span></p>
<p style="top:446.0pt;left:337.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Fresh</span></p>
<p style="top:446.0pt;left:346.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">GFs: TGF-</span><span style="font-family:TmgcryAdvTT3713a231+03,serif;font-size:7.5pt;color:#131313">&#x3b2;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">1 and PDGF-BB</span></p>
<p style="top:301.8pt;left:303.9pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Pig tibial defect cylindrical defect</span></p>
<p style="top:301.8pt;left:312.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">(11x25 mm)</span></p>
<p style="top:196.3pt;left:303.9pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Hist: +</span></p>
<p style="top:196.3pt;left:312.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">X-Ray: +</span></p>
<p style="top:70.7pt;left:303.9pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">+</span></p>
<p style="top:653.5pt;left:354.7pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">32. Batista et al.</span></p>
<p style="top:653.5pt;left:363.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2011 [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#392a96">50</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">]</span></p>
<p style="top:575.7pt;left:354.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">1)</span><span style="font-family:TmgcryAdvTT3713a231+03,serif;font-size:7.5pt;color:#131313"> &#x3b2;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313"> - TCP + PRP</span></p>
<p style="top:575.7pt;left:363.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2)</span><span style="font-family:TmgcryAdvTT3713a231+03,serif;font-size:7.5pt;color:#131313"> &#x3b2;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313"> - TCP + BMCs</span></p>
<p style="top:446.0pt;left:354.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Platelet concentration: 6.2 x</span></p>
<p style="top:446.0pt;left:363.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Activation: calcium gluonate</span></p>
<p style="top:446.0pt;left:371.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Leukocytes: NA</span></p>
<p style="top:446.0pt;left:380.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Allogenic</span></p>
<p style="top:446.0pt;left:388.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Fresh</span></p>
<p style="top:446.0pt;left:397.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">GFs: NA</span></p>
<p style="top:301.8pt;left:354.7pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Rabbit tibial cylindrical defect</span></p>
<p style="top:301.8pt;left:363.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">(3.3 mm)</span></p>
<p style="top:196.3pt;left:354.7pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Hist: +</span></p>
<p style="top:196.3pt;left:363.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">X-Ray: =</span></p>
<p style="top:196.3pt;left:371.5pt;line-height:7.5pt"><span style="font-family:TmgcryAdvTT3713a231+03,serif;font-size:7.5pt;color:#131313">&#x3bc;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">CT: +</span></p>
<p style="top:70.7pt;left:354.7pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">+</span></p>
<p style="top:653.5pt;left:405.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">33. Bolukbasi et al.</span></p>
<p style="top:653.5pt;left:414.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2013 [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#392a96">51</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">]</span></p>
<p style="top:575.7pt;left:405.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">1) BCP</span></p>
<p style="top:575.7pt;left:414.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2) BCP + PRF</span></p>
<p style="top:575.7pt;left:422.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">3) PRF</span></p>
<p style="top:575.7pt;left:430.9pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">4) Control (untreated)</span></p>
<p style="top:446.0pt;left:405.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Platelet concentration: NA</span></p>
<p style="top:446.0pt;left:414.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Activation: no</span></p>
<p style="top:446.0pt;left:422.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Leukocytes: NA</span></p>
<p style="top:446.0pt;left:430.9pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Autologous</span></p>
<p style="top:446.0pt;left:439.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Fresh</span></p>
<p style="top:446.0pt;left:447.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">GFs: NA</span></p>
<p style="top:301.8pt;left:405.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Sheep tibial cylindrical defect</span></p>
<p style="top:301.8pt;left:414.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">(5 mm)</span></p>
<p style="top:196.3pt;left:405.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Hist: +</span></p>
<p style="top:70.7pt;left:405.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">+</span></p>
<p style="top:653.5pt;left:456.3pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">34. Hakimi et al.</span></p>
<p style="top:653.5pt;left:464.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2014 [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#392a96">52</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">]</span></p>
<p style="top:575.7pt;left:456.3pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">1) CPG</span></p>
<p style="top:575.7pt;left:464.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2) CPG + BMCs</span></p>
<p style="top:575.7pt;left:473.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">3) CPG + BMCs + PRP</span></p>
<p style="top:575.7pt;left:481.7pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">4) Autografts</span></p>
<p style="top:446.0pt;left:456.3pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Platelet concentration: 4.7 x</span></p>
<p style="top:446.0pt;left:464.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Activation: calcium chloride/thrombin</span></p>
<p style="top:446.0pt;left:473.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Leukocytes: yes</span></p>
<p style="top:446.0pt;left:481.7pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Autologous</span></p>
<p style="top:446.0pt;left:490.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Fresh</span></p>
<p style="top:446.0pt;left:498.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">GFs: TGF-</span><span style="font-family:TmgcryAdvTT3713a231+03,serif;font-size:7.5pt;color:#131313">&#x3b2;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">1 and PDGF-BB</span></p>
<p style="top:301.8pt;left:456.3pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Pig tibial cylindrical defect</span></p>
<p style="top:301.8pt;left:464.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">(25 x 11 mm)</span></p>
<p style="top:196.3pt;left:456.3pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Hist: +</span></p>
<p style="top:196.3pt;left:464.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">X-Ray: +</span></p>
<p style="top:196.3pt;left:473.2pt;line-height:7.5pt"><span style="font-family:TmgcryAdvTT3713a231+03,serif;font-size:7.5pt;color:#131313">&#x3bc;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">CT: +</span></p>
<p style="top:196.3pt;left:481.7pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">X-Ray superior for CPG + BMSCs + PRP</span></p>
<p style="top:187.8pt;left:490.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">compared to CPG alone and CPG +</span></p>
<p style="top:187.8pt;left:498.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">BMSCs, but similar results compared</span></p>
<p style="top:187.8pt;left:507.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">to autograft</span></p>
<p style="top:70.7pt;left:456.3pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">+</span></p>
<p style="top:653.5pt;left:515.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">35. Yilmaz et al.</span></p>
<p style="top:653.5pt;left:524.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2014 [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#392a96">53</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">]</span></p>
<p style="top:575.7pt;left:515.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">1) PRF</span></p>
<p style="top:575.7pt;left:524.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2)</span><span style="font-family:TmgcryAdvTT3713a231+03,serif;font-size:7.5pt;color:#131313"> &#x3b2;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">-TCP</span></p>
<p style="top:575.7pt;left:532.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">3)</span><span style="font-family:TmgcryAdvTT3713a231+03,serif;font-size:7.5pt;color:#131313"> &#x3b2;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">-TCP + PRF</span></p>
<p style="top:446.0pt;left:515.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Platelet concentration: NA</span></p>
<p style="top:446.0pt;left:524.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Activation: no</span></p>
<p style="top:446.0pt;left:532.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Leukocytes: NA</span></p>
<p style="top:301.8pt;left:515.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Pig tibia cylindrical defect</span></p>
<p style="top:301.8pt;left:524.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">(5 mm)</span></p>
<p style="top:196.3pt;left:515.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Hist: +</span></p>
<p style="top:196.3pt;left:524.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Superior results for</span><span style="font-family:TmgcryAdvTT3713a231+03,serif;font-size:7.5pt;color:#131313"> &#x3b2;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">-TCP + PRF</span></p>
<p style="top:70.7pt;left:515.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">+</span></p>
<p style="top:33.1pt;left:51.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">International Orthopaedics (SICOT) (2017) 41:221</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">237</span></p>
<p style="top:33.1pt;left:531.7pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">227</span></p>


<p style="top:707.1pt;left:53.4pt;line-height:8.5pt"><span style="font-family:XssngvAdvTTb8864ccf.B,serif;font-size:8.5pt;color:#131313">Table 1</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> (continued)</span></p>
<p style="top:652.7pt;left:72.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Publication</span></p>
<p style="top:575.0pt;left:72.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Treatment groups</span></p>
<p style="top:445.2pt;left:72.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">PRP characteristics</span></p>
<p style="top:301.0pt;left:72.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Animal model</span></p>
<p style="top:195.5pt;left:72.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Protocol</span></p>
<p style="top:69.9pt;left:72.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Effects</span></p>
<p style="top:575.7pt;left:92.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">4) Control (untreated)</span></p>
<p style="top:446.0pt;left:92.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Autologous</span></p>
<p style="top:446.0pt;left:100.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Fresh</span></p>
<p style="top:446.0pt;left:109.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">GFs: NA</span></p>
<p style="top:653.5pt;left:117.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">36. Malhotra et al.</span></p>
<p style="top:653.5pt;left:126.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2014 [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#392a96">54</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">]</span></p>
<p style="top:575.7pt;left:117.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">1) BCP + 33 % PRP</span></p>
<p style="top:575.7pt;left:126.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2) BCP + 66 % PRP</span></p>
<p style="top:575.7pt;left:134.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">3) BCP + 100 % PRP</span></p>
<p style="top:575.7pt;left:143.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">4) Autografts</span></p>
<p style="top:575.7pt;left:151.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">5) BCP</span></p>
<p style="top:575.7pt;left:159.9pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">6) Control (untreated)</span></p>
<p style="top:446.0pt;left:117.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Platelet concentration: 2.9 x</span></p>
<p style="top:446.0pt;left:126.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Activation: calcium chloride/thrombin</span></p>
<p style="top:446.0pt;left:134.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Leukocytes: 0.6 x</span></p>
<p style="top:446.0pt;left:143.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Fibrinogen: 0.6 x</span></p>
<p style="top:446.0pt;left:151.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Autologous</span></p>
<p style="top:446.0pt;left:159.9pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Fresh</span></p>
<p style="top:446.0pt;left:168.3pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">GFs: TGF-</span><span style="font-family:TmgcryAdvTT3713a231+03,serif;font-size:7.5pt;color:#131313">&#x3b2;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">1</span></p>
<p style="top:301.8pt;left:117.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Sheep femoral cylindrical defect</span></p>
<p style="top:301.8pt;left:126.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">(11x20 mm)</span></p>
<p style="top:196.3pt;left:117.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Hist: +</span></p>
<p style="top:196.3pt;left:126.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">X-Ray: +</span></p>
<p style="top:196.3pt;left:134.4pt;line-height:7.5pt"><span style="font-family:TmgcryAdvTT3713a231+03,serif;font-size:7.5pt;color:#131313">&#x3bc;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">CT: +</span></p>
<p style="top:196.3pt;left:143.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Highest dose of PRP: greater micro-CT</span></p>
<p style="top:187.8pt;left:151.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">bone volume compared with BCP</span></p>
<p style="top:187.8pt;left:159.9pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">alone</span></p>
<p style="top:196.3pt;left:168.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">All PRP doses: better histomorphometric</span></p>
<p style="top:187.8pt;left:176.9pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">parameters vs BCP alone</span></p>
<p style="top:70.7pt;left:117.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">+</span></p>
<p style="top:653.5pt;left:185.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">37. Qi et al.</span></p>
<p style="top:653.5pt;left:193.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2015 [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#392a96">55</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">]</span></p>
<p style="top:575.7pt;left:185.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">1) BMSCs + PRP gel</span></p>
<p style="top:575.7pt;left:193.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2) CaP</span></p>
<p style="top:575.7pt;left:202.3pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">3) CaP + PRP gel</span></p>
<p style="top:575.7pt;left:210.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">4) CaP + BMSCs</span></p>
<p style="top:575.7pt;left:219.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">5) CaP + BMSCs + PRP gel</span></p>
<p style="top:575.7pt;left:227.7pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">6) Control (untreated)</span></p>
<p style="top:446.0pt;left:185.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Platelet concentration: 6 x</span></p>
<p style="top:446.0pt;left:193.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Activation: calcium chloride/ thrombin</span></p>
<p style="top:446.0pt;left:202.3pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Leukocytes:NA</span></p>
<p style="top:446.0pt;left:210.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Allogenic</span></p>
<p style="top:446.0pt;left:219.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Fresh/frozen: NA</span></p>
<p style="top:446.0pt;left:227.7pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">GFs: NA</span></p>
<p style="top:301.8pt;left:185.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Rat femur cylindrical defect</span></p>
<p style="top:301.8pt;left:193.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">(2.5 x 5 mm)</span></p>
<p style="top:196.3pt;left:185.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Hist: +</span></p>
<p style="top:196.3pt;left:193.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">X-Ray: +</span></p>
<p style="top:196.3pt;left:202.3pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">SEM:+</span></p>
<p style="top:196.3pt;left:210.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Superior results for CaP + BMSCs + PRP</span></p>
<p style="top:187.8pt;left:219.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">gel</span></p>
<p style="top:70.7pt;left:185.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">+</span></p>
<p style="top:653.5pt;left:236.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">38. Velev et al.</span></p>
<p style="top:653.5pt;left:244.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2015 [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#392a96">56</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">]</span></p>
<p style="top:575.7pt;left:236.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">1) TCP cement</span></p>
<p style="top:575.7pt;left:244.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2) TCP cement + PRP</span></p>
<p style="top:575.7pt;left:253.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">3) TCP cement + GH</span></p>
<p style="top:446.0pt;left:236.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Platelet concentration: NA</span></p>
<p style="top:446.0pt;left:244.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Activation: No</span></p>
<p style="top:446.0pt;left:253.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Leukocytes: No</span></p>
<p style="top:446.0pt;left:261.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Autologous</span></p>
<p style="top:446.0pt;left:270.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Fresh</span></p>
<p style="top:446.0pt;left:278.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">GFs: NA</span></p>
<p style="top:301.8pt;left:236.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Rabbit tibia cylindrical defect</span></p>
<p style="top:301.8pt;left:244.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">(6 mm)</span></p>
<p style="top:196.3pt;left:236.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Hist: + for qualitative analysis</span></p>
<p style="top:196.3pt;left:244.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">= for quantitative analysis</span></p>
<p style="top:70.7pt;left:236.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">+</span></p>
<p style="top:707.9pt;left:287.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">PRP alone</span></p>
<p style="top:653.5pt;left:287.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">39. Simman et al.</span></p>
<p style="top:653.5pt;left:295.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2008 [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#392a96">57</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">]</span></p>
<p style="top:575.7pt;left:287.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">1) PRP</span></p>
<p style="top:575.7pt;left:295.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2) Control (untreated)</span></p>
<p style="top:446.0pt;left:287.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Platelet concentration: 2.7 x</span></p>
<p style="top:446.0pt;left:295.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Activation: calcium chloride/thrombin</span></p>
<p style="top:446.0pt;left:303.9pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Leukocytes: NA</span></p>
<p style="top:446.0pt;left:312.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Allogenic</span></p>
<p style="top:446.0pt;left:320.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Fresh/frozen: NA</span></p>
<p style="top:446.0pt;left:329.3pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">GFs: TGF-</span><span style="font-family:TmgcryAdvTT3713a231+03,serif;font-size:7.5pt;color:#131313">&#x3b2;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">1, P-selectin and BMP-2</span></p>
<p style="top:301.8pt;left:287.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Rat femoral fracture</span></p>
<p style="top:196.3pt;left:287.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Hist: +</span></p>
<p style="top:196.3pt;left:295.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">X-Ray: +</span></p>
<p style="top:196.3pt;left:303.9pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Mech: =</span></p>
<p style="top:70.7pt;left:287.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">+</span></p>
<p style="top:653.5pt;left:337.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">40. Gumieiro et al.</span></p>
<p style="top:653.5pt;left:346.3pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2010 [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#392a96">58</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">]</span></p>
<p style="top:575.7pt;left:337.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">1) PRP</span></p>
<p style="top:575.7pt;left:346.3pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2) Control (untreated)</span></p>
<p style="top:446.0pt;left:337.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Platelet concentration: 4x</span></p>
<p style="top:446.0pt;left:346.3pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Activation: calcium chloride</span></p>
<p style="top:446.0pt;left:354.7pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Leukocytes: NA</span></p>
<p style="top:446.0pt;left:363.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Allogenic</span></p>
<p style="top:446.0pt;left:371.7pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Fresh</span></p>
<p style="top:446.0pt;left:380.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">GFs: NA</span></p>
<p style="top:301.8pt;left:337.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Rat tibial cylindrical defect</span></p>
<p style="top:301.8pt;left:346.3pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">(3 mm)</span></p>
<p style="top:196.3pt;left:337.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Hist: +</span></p>
<p style="top:196.3pt;left:346.3pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">The effect of PRP is present more in the</span></p>
<p style="top:187.8pt;left:354.7pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">first 14 days</span></p>
<p style="top:70.7pt;left:337.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">+</span></p>
<p style="top:653.5pt;left:388.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">41. Souza et al.</span></p>
<p style="top:653.5pt;left:397.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2012 [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#392a96">59</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">]</span></p>
<p style="top:575.7pt;left:388.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">1) PRP</span></p>
<p style="top:575.7pt;left:397.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2) Control (untreated)</span></p>
<p style="top:446.0pt;left:388.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Platelet concentration: 338 %</span></p>
<p style="top:446.0pt;left:397.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Activation: calcium chloride</span></p>
<p style="top:446.0pt;left:405.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Leukocytes: NA</span></p>
<p style="top:446.0pt;left:414.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Autologous</span></p>
<p style="top:446.0pt;left:422.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Fresh</span></p>
<p style="top:446.0pt;left:430.9pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">GFs: NA</span></p>
<p style="top:301.8pt;left:388.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Dog radial fracture with 2 mm gap Hist: +</span></p>
<p style="top:196.3pt;left:397.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">X-Ray: +</span></p>
<p style="top:196.3pt;left:405.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">DEXA: +</span></p>
<p style="top:196.3pt;left:414.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Mech: +</span></p>
<p style="top:70.7pt;left:388.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">+</span></p>
<p style="top:653.5pt;left:439.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">42. Chen et al.</span></p>
<p style="top:653.5pt;left:447.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2013 [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#392a96">60</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">]</span></p>
<p style="top:575.7pt;left:439.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">1) High conc PRP</span></p>
<p style="top:575.7pt;left:447.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2) Medium conc PRP</span></p>
<p style="top:575.7pt;left:456.3pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">3) Low conc PRP</span></p>
<p style="top:575.7pt;left:464.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">4) PPP</span></p>
<p style="top:575.7pt;left:473.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">5) Control (untreated)</span></p>
<p style="top:446.0pt;left:439.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Platelet concentration (high/medium/low)</span></p>
<p style="top:446.0pt;left:447.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Activation: calcium chloride/thrombin</span></p>
<p style="top:446.0pt;left:456.3pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Leukocytes: NA</span></p>
<p style="top:446.0pt;left:464.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Allogenic</span></p>
<p style="top:446.0pt;left:473.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Fresh/frozen: NA</span></p>
<p style="top:446.0pt;left:481.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">GFs: TGF-</span><span style="font-family:TmgcryAdvTT3713a231+03,serif;font-size:7.5pt;color:#131313">&#x3b2;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">1 and PDGF-BB</span></p>
<p style="top:301.8pt;left:439.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Rat femoral fracture</span></p>
<p style="top:196.3pt;left:439.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Hist: +</span></p>
<p style="top:196.3pt;left:447.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">X-Ray: +</span></p>
<p style="top:196.3pt;left:456.3pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Mech: +</span></p>
<p style="top:196.3pt;left:464.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Superior results for medium conc. of PRP</span></p>
<p style="top:70.7pt;left:439.4pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">+</span></p>
<p style="top:653.5pt;left:490.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">43. Neves et al.</span></p>
<p style="top:653.5pt;left:498.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2013 [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#392a96">61</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">]</span></p>
<p style="top:575.7pt;left:490.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">1) PRP</span></p>
<p style="top:575.7pt;left:498.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2) HBO</span></p>
<p style="top:575.7pt;left:507.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">3) PRP+ HBO</span></p>
<p style="top:575.7pt;left:515.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">4) Control (untreated)</span></p>
<p style="top:446.0pt;left:490.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Platelet concentration: 2x</span></p>
<p style="top:446.0pt;left:498.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Activation: No</span></p>
<p style="top:446.0pt;left:507.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Leukocytes: No</span></p>
<p style="top:446.0pt;left:515.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Autologous</span></p>
<p style="top:446.0pt;left:524.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Fresh</span></p>
<p style="top:446.0pt;left:532.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">GFs: NA</span></p>
<p style="top:301.8pt;left:490.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Rabbit fibula segmental fracture</span></p>
<p style="top:196.3pt;left:490.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Hist: +</span></p>
<p style="top:70.7pt;left:490.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">+</span></p>
<p style="top:33.1pt;left:51.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">228</span></p>
<p style="top:33.1pt;left:359.8pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">International Orthopaedics (SICOT) (2017) 41:221</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">237</span></p>


<p style="top:58.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">reported information about leukocytes content in PRP, nine of</span></p>
<p style="top:70.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">which described the use of leukocyte-rich PRP and seven of</span></p>
<p style="top:83.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">leukocyte-poor PRP. Only one paper out of 45 reported fibrin-</span></p>
<p style="top:95.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">ogen content. Fourteen studies analysed PRP for GFs, which</span></p>
<p style="top:108.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">included TGF-</span><span style="font-family:TmgcryAdvTT3713a231+03,serif;font-size:10.0pt;color:#131313">&#x3b2;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">1 (in 14), PDGF (in ten), VEGF (in four),</span></p>
<p style="top:120.6pt;left:306.2pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">bFGF (in one), SDF-1 (in one), p-selectine (in one), BMP-2</span></p>
<p style="top:133.1pt;left:306.2pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">(in one), IL-1 (in one) and EGF (in one).</span></p>
<p style="top:145.5pt;left:317.5pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">Thirty-two out of 45 papers (71 %) reported information</span></p>
<p style="top:158.0pt;left:306.2pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">about the use of fresh or frozen PRP: 26 were fresh and six</span></p>
<p style="top:170.4pt;left:306.2pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">frozen; while 42 (93.3 %) papers reported the type of PRP in</span></p>
<p style="top:182.9pt;left:306.2pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">terms of autologous (in 24), allogeneic (in 15), and xenoge-</span></p>
<p style="top:195.3pt;left:306.2pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">neic (in three) origin. Finally, PRP activation modality was not</span></p>
<p style="top:207.8pt;left:306.2pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">reported in 12 studies; among studies where this was specified</span></p>
<p style="top:220.2pt;left:306.2pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">(33 papers, 73.3 %), 20 (60.6 %) reported a combination of</span></p>
<p style="top:232.7pt;left:306.2pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">CaCl</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">2</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313"> and thrombin, nine (27.3 %) used CaCl</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">2</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313"> alone, two</span></p>
<p style="top:245.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">(6.1 %) thrombin alone, one (3 %) calcium gluconate, one</span></p>
<p style="top:257.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">(3 %) calcium borogluconate and one (3 %) batroxobin.</span></p>
<p style="top:282.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:10.0pt;color:#131313">Pre-clinical findings</span></p>
<p style="top:307.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">Overall positive results were shown in 41 studies (91 %),</span></p>
<p style="top:319.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">while three studies (7 %) showed the same results as control</span></p>
<p style="top:332.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">and one study (2 %) showed negative effects of PRP use. In</span></p>
<p style="top:344.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">particular, among the 20 studies reporting the use of PRP with</span></p>
<p style="top:357.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">scaffolds (hydroxyapatite alone or in combination with colla-</span></p>
<p style="top:369.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">gen was the most frequent material used), 18 showed positive</span></p>
<p style="top:382.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">results; among the nine papers using bone grafts, all reported</span></p>
<p style="top:394.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">good results. Among the nine studies on PRP with powder/</span></p>
<p style="top:407.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">granules, eight showed a good outcome. Finally, among the</span></p>
<p style="top:419.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">seven studies where PRP was used alone, six reported good</span></p>
<p style="top:432.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">results while one study using PRP injections failed to show</span></p>
<p style="top:444.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">significant effects. Finally, the use of MSCs always provided a</span></p>
<p style="top:456.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">benefit, with PRP further increasing the outcome in all 11</span></p>
<p style="top:469.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">studies.</span></p>
<p style="top:481.7pt;left:317.5pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">Further analyses have been performed according to the</span></p>
<p style="top:494.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">results of each specific evaluation performed. The histological</span></p>
<p style="top:506.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">outcome has been reported in 45 papers, with 38 (84.4 %)</span></p>
<p style="top:519.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">showing significant improvement in bone healing. The radio-</span></p>
<p style="top:531.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">graphic outcome was reported in 32/45 papers; among these</span></p>
<p style="top:544.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">studies 24 (75.0 %) showed significant bone consolidation.</span></p>
<p style="top:556.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">The micro-computed tomography (CT) outcome was reported</span></p>
<p style="top:568.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">in 11 papers and significant bone area formation was reported</span></p>
<p style="top:581.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">in nine (81.8 %) studies. DEXA analysis was reported only in</span></p>
<p style="top:593.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">three studies, with good results in favour of PRP in all papers.</span></p>
<p style="top:606.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">Finally, biomechanical tests in regard to torsion, torque and</span></p>
<p style="top:618.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">bone strength, were performed in ten papers and seven (70 %)</span></p>
<p style="top:631.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">of these studies documented significantly better biomechani-</span></p>
<p style="top:643.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">cal properties.</span></p>
<p style="top:668.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:XssngvAdvTTb8864ccf.B,serif;font-size:10.0pt;color:#131313">Clinical studies</span></p>
<p style="top:693.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">A total of 19 clinical trials were found to be eligible for inclu-</span></p>
<p style="top:705.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">sion in the present review: nine dealt with fracture</span></p>
<p style="top:707.1pt;left:53.1pt;line-height:8.5pt"><span style="font-family:XssngvAdvTTb8864ccf.B,serif;font-size:8.5pt;color:#131313">Table 1</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> (continued)</span></p>
<p style="top:652.7pt;left:72.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Publication</span></p>
<p style="top:575.0pt;left:72.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Treatment groups</span></p>
<p style="top:445.2pt;left:72.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">PRP characteristics</span></p>
<p style="top:301.0pt;left:72.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Animal model</span></p>
<p style="top:195.5pt;left:72.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Protocol</span></p>
<p style="top:69.9pt;left:72.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Effects</span></p>
<p style="top:653.5pt;left:91.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">44. Hernandez</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:7.5pt;color:#131313"> &#x2013;</span></p>
<p style="top:653.5pt;left:100.3pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Fernandez et al.</span></p>
<p style="top:653.5pt;left:108.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2013 [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#392a96">62</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">]</span></p>
<p style="top:575.7pt;left:91.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">1) PRP</span></p>
<p style="top:575.7pt;left:100.3pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2) Control (untreated)</span></p>
<p style="top:446.0pt;left:91.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Platelet concentration: 4.6 x</span></p>
<p style="top:446.0pt;left:100.3pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Activation: calcium chloride</span></p>
<p style="top:446.0pt;left:108.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Leukocytes: No</span></p>
<p style="top:446.0pt;left:117.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Autologous</span></p>
<p style="top:446.0pt;left:125.7pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Fresh/frozen: NA</span></p>
<p style="top:446.0pt;left:134.2pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">GFs: NA</span></p>
<p style="top:301.8pt;left:91.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Sheep femur osteotomy model</span></p>
<p style="top:196.3pt;left:91.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Hist: =</span></p>
<p style="top:196.3pt;left:100.2pt;line-height:7.5pt"><span style="font-family:TmgcryAdvTT3713a231+03,serif;font-size:7.5pt;color:#131313">&#x3bc;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">CT: =</span></p>
<p style="top:70.7pt;left:91.8pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">=</span></p>
<p style="top:653.5pt;left:142.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">45. Guzel et al.</span></p>
<p style="top:653.5pt;left:151.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2015 [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#392a96">63</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">]</span></p>
<p style="top:575.7pt;left:142.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">1) PRP</span></p>
<p style="top:575.7pt;left:151.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">2) Control (untreated)</span></p>
<p style="top:446.0pt;left:142.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Platelet concentration: NA</span></p>
<p style="top:446.0pt;left:151.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Activation: calcium chloride</span></p>
<p style="top:446.0pt;left:159.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Leukocytes: No</span></p>
<p style="top:446.0pt;left:168.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Allogenic</span></p>
<p style="top:446.0pt;left:176.5pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Fresh/frozen: NA</span></p>
<p style="top:446.0pt;left:185.0pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">GFs: NA</span></p>
<p style="top:301.8pt;left:142.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Rat femoral fracture</span></p>
<p style="top:196.3pt;left:142.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Hist: +</span></p>
<p style="top:196.3pt;left:151.1pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">Mech: +</span></p>
<p style="top:70.7pt;left:142.6pt;line-height:7.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.5pt;color:#131313">+</span></p>
<p style="top:707.1pt;left:203.8pt;line-height:8.5pt"><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313">PRP</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> Platelet- rich Plasma,</span><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> AF</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> Apatite foam,</span><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> PCL/TCP</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> Polycaprolactone-tricalcium phosphate,</span><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> CDHA</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> Calcium deficient hydroxyapatite,</span><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> BOC + BG</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> Bio-Oss Collagen + BioGide Perio membrane,</span><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> HASi</span></p>
<p style="top:707.1pt;left:213.8pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Triphasic ceramic-coated hydroxypatite,</span><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> HA</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> Hydroxapatite,</span><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> TCP</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> Tri-calcium phospahte,</span><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> COL/HA</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> Collagen + Hydroxapatite,</span><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> hPRP</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> Human platelet rich plasma,</span><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> BioSic</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> Biomorphic silicon carbide,</span><span style="font-family:VpgjdnAdvTT50a2f13e.I+03,serif;font-size:8.5pt;color:#131313"> &#x3b2;</span><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313">-TCP</span></p>
<p style="top:707.1pt;left:223.7pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Beta-tricalcium phospahte,</span><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> PLGA/CPC</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> Poly (lactic-</span><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313">co</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">-glycolic acid) + calcium phosphate cement,</span><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> CS</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> Calcium sulphate,</span><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> FDBA</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> Fried dried bone allograft,</span><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> Ti</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> Titanium,</span><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> DPB</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> Deproteinized bone matrix,</span></p>
<p style="top:707.1pt;left:233.7pt;line-height:8.5pt"><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313">CGF</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> Concentrated growth factor,</span><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> PRF</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> Platelet rich fibrin,</span><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> CaP</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> Calcium phospahte,</span><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> BCP</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> Biphasic calcium phosphate,</span><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> CPG</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> Calcium phosphate granules,</span><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> BMSCs</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> Bone marrow derived mesenchymal stem</span></p>
<p style="top:707.1pt;left:243.6pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">cells,</span><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> ASCs</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> Adipose derived stem cells,</span><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> BMCs</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> Bone marrow concentrate,</span><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> HBO</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> Hyperbaric oxygen,</span><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> TGF-</span><span style="font-family:VpgjdnAdvTT50a2f13e.I+03,serif;font-size:8.5pt;color:#131313">&#x3b2;</span><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313">1</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> Transforming growth factor beta 1,</span><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> PDGF-BB</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> Platelet-derived growth factor,</span><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> bFGF</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> Basic</span></p>
<p style="top:707.1pt;left:253.6pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">fibroblast growth factor,</span><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> VEGF</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> Vascular endothelial growth factor,</span><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> IL-1</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> Interleukin-1,</span><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> SDF-1</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> Stromal cell-derived factor 1,</span><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> EGF</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> Epidermal growth factor,</span><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> BMP-2</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> Bone morphogenetic protein 2,</span><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> Hist</span></p>
<p style="top:707.1pt;left:263.5pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Histology analysis,</span><span style="font-family:VpgjdnAdvTT50a2f13e.I+03,serif;font-size:8.5pt;color:#131313"> &#x3bc;</span><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313">CT</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> Micro-computed tomography,</span><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> DEXA</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> Dual-energy x-ray absorptiometry,</span><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> Mech</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> Mechanical analysis,</span><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> NA</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> Not available</span></p>
<p style="top:33.1pt;left:51.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">International Orthopaedics (SICOT) (2017) 41:221</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">237</span></p>
<p style="top:33.1pt;left:531.7pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">229</span></p>


<p style="top:58.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">management [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96">64</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:10.0pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96">72</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">] whereas ten focused on fracture compli-</span></p>
<p style="top:70.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">cations [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96">73</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:10.0pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96">83</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">] (i.e. delayed unions or non-unions; Table</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96"> 2</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">).</span></p>
<p style="top:102.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:10.0pt;color:#131313">Treatment of fractures</span></p>
<p style="top:126.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">Eight out of nine studies were RCTs and one was a retrospec-</span></p>
<p style="top:139.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">tive comparative trial [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96">64</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">]. Three studies aimed at understand-</span></p>
<p style="top:151.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">ing the role of PRP in stimulating healing after iatrogenic</span></p>
<p style="top:164.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">fractures: two trials in opening-wedge high tibial osteotomy</span></p>
<p style="top:176.6pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">(HTO) [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96">65</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">,</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96"> 66</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">] and one in tibial distraction osteogenesis for</span></p>
<p style="top:189.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">limb lengthening [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96">67</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">]. The other six trials focused on dispa-</span></p>
<p style="top:201.6pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">rate traumatic injuries: two papers on hip fractures [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96">68</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">,</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96"> 69</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">],</span></p>
<p style="top:214.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">one paper on calcaneus fractures [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96">70</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">], one (the retrospective</span></p>
<p style="top:226.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">comparative trial) on complex bimalleolar fractures [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96">64</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">], one</span></p>
<p style="top:238.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">on tibial pilon fractures [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96">71</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">] and one on intra-articular distal</span></p>
<p style="top:251.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">radial fractures [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96">72</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">]. With regard to the application strategies,</span></p>
<p style="top:263.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">PRP was locally applied during surgery in eight studies,</span></p>
<p style="top:276.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">whereas in one case a delayed PRP injection was applied</span></p>
<p style="top:288.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">(3</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:10.0pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">6 weeks after primary surgery) [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96">70</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">]. PRP was leukocyte-</span></p>
<p style="top:301.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">rich in five papers and leukocyte-depleted in two studies,</span></p>
<p style="top:313.6pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">while in two papers authors did not provide specific details</span></p>
<p style="top:326.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">about the PRP formulation adopted. In six trials PRP was</span></p>
<p style="top:338.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">associated to other</span><span style="font-family:WgvqvpAdvP0004,serif;font-size:10.0pt;color:#131313"> B</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">augmentation strategies</span><span style="font-family:WswsfsAdvP0005,serif;font-size:10.0pt;color:#131313">^</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">, such as MSCs</span></p>
<p style="top:351.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">and/or bone graft (Table</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96"> 2</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">).</span></p>
<p style="top:363.4pt;left:62.3pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">Overall, eight out of nine papers reported radiologic out-</span></p>
<p style="top:375.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">comes: six of them revealed better results with PRP, one found</span></p>
<p style="top:388.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">no difference, whereas one paper documented worse radiolog-</span></p>
<p style="top:400.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">ic results with the biologic augmentation. Clinical outcomes</span></p>
<p style="top:413.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">were reported in only five papers, i.e. functional subjective</span></p>
<p style="top:425.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">scores and/or objective measurements and/or complications</span></p>
<p style="top:438.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">after PRP treatment: in three cases PRP did not provide any</span></p>
<p style="top:450.6pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">beneficial contribution, whereas in the remaining two studies</span></p>
<p style="top:463.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">it contributed to a superior clinical outcome. Finally, only one</span></p>
<p style="top:475.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">trial documented histomorphometric results, showing that the</span></p>
<p style="top:488.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">addition of PRP to bone chips, even more if combined with</span></p>
<p style="top:500.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">BMC augmentation, was able to promote a superior healing of</span></p>
<p style="top:512.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">the high tibial osteotomy gap site (Table</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96"> 2</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">).</span></p>
<p style="top:544.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:10.0pt;color:#131313">Treatment of delayed unions/non unions</span></p>
<p style="top:568.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">Out of the ten studies (11 papers in total) on the application of</span></p>
<p style="top:581.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">PRP to manage delayed unions or non-unions [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96">73</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:10.0pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96">83</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">], four</span></p>
<p style="top:593.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">used a minimally invasive approach through percutaneous</span></p>
<p style="top:606.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">PRP injections, six studies used PRP as topical enhancer dur-</span></p>
<p style="top:618.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">ing revision surgery, whereas one study reported results of</span></p>
<p style="top:631.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">both treatment approaches (Table</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96"> 2</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">). Only one trial (which</span></p>
<p style="top:643.6pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">was the object of two different publications, one reporting</span></p>
<p style="top:656.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">the preliminary results and the other reporting the complete</span></p>
<p style="top:668.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">data) was a RCT [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96">73</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">,</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96"> 74</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">], whereas all the others were case</span></p>
<p style="top:681.0pt;left:50.9pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">series. In four studies PRP was used together with other aug-</span></p>
<p style="top:693.4pt;left:50.9pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">mentation strategies (bone graft or synthetic bone). PRP was</span></p>
<p style="top:705.9pt;left:50.9pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">leukocyte-rich in two studies and leukocyte-depleted in three</span></p>
<p style="top:58.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">studies, while in five trials authors did not provide specific</span></p>
<p style="top:70.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">details about the PRP formulation adopted (Table</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96"> 2</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">).</span></p>
<p style="top:83.2pt;left:317.4pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">All but one [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96">75</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">] study considered patients affected by de-</span></p>
<p style="top:95.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">layed union/non-union in different anatomical districts pooled</span></p>
<p style="top:108.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">together (mainly humerus, femur and tibia, which are the most</span></p>
<p style="top:120.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">common sites for this kind of complication), thus reducing the</span></p>
<p style="top:133.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">homogeneity of the cohorts of patients. With regard to the</span></p>
<p style="top:145.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">outcome, two case series (where PRP was injected at the site</span></p>
<p style="top:158.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">of non-union or delayed union) failed to documented a bene-</span></p>
<p style="top:170.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">ficial effect of the biological stimulation [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96">76</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">,</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96"> 77</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">]. The other</span></p>
<p style="top:182.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">reports suggested instead a positive role of PRP, although the</span></p>
<p style="top:195.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">only RCT documented a clear advantage of bone</span></p>
<p style="top:207.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">morphogeneic protein 7 (BMP-7) over PRP in stimulating</span></p>
<p style="top:220.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">bone healing (Table</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96"> 2</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">) [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96">73</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">,</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96"> 74</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">].</span></p>
<p style="top:256.8pt;left:306.1pt;line-height:11.0pt"><span style="font-family:XssngvAdvTTb8864ccf.B,serif;font-size:11.0pt;color:#131313">Discussion</span></p>
<p style="top:282.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">This systematic research of the literature documented a grow-</span></p>
<p style="top:294.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">ing interest on PRP use for bone disorders, with an increasing</span></p>
<p style="top:307.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">number of papers published over time which show a complex</span></p>
<p style="top:319.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">scenery and more controversial results than previously</span></p>
<p style="top:332.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">thought.</span></p>
<p style="top:344.8pt;left:317.5pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">In fact, while basic science suggests several favourable</span></p>
<p style="top:357.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">potential effects of PRP for bone healing, and platelet concen-</span></p>
<p style="top:369.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">trates have also been successfully used in other medical fields</span></p>
<p style="top:382.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">to enhance bone and soft tissue regeneration [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96">5</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">,</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96"> 84</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:10.0pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96">86</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">], the</span></p>
<p style="top:394.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">evidence on its real benefit is questionable. The first phase of</span></p>
<p style="top:407.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">the literature analysis focused on preclinical in-vivo evidence,</span></p>
<p style="top:419.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">which should allow us to understand potential and indications</span></p>
<p style="top:432.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">for PRP use. This systematic review documented 45 papers</span></p>
<p style="top:444.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">reporting heterogeneous models both in terms of animal mod-</span></p>
<p style="top:456.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">el and defect type chosen. This is an important factor to con-</span></p>
<p style="top:469.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">sider in terms of results transferability to the clinical field. In</span></p>
<p style="top:481.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">fact, although several models are appropriate for the evalua-</span></p>
<p style="top:494.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">tion of bone regeneration, not all of them closely reproduce</span></p>
<p style="top:506.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">human tissue characteristics. Chosen models should present</span></p>
<p style="top:519.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">physiological and pathophysiological analogies to favour re-</span></p>
<p style="top:531.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">sults transferability: for this reason larger models more closely</span></p>
<p style="top:544.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">resemble the human condition [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96">87</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">]. For example, pig models</span></p>
<p style="top:556.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">present bone features similar to humans in terms of mineral</span></p>
<p style="top:568.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">density, concentration and healing capacity, with a 1.2 to</span></p>
<p style="top:581.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">1.5 mm per day growth rate, similar to bone regeneration</span></p>
<p style="top:593.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">capacity in humans [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96">88</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">]. Among the studies found in this</span></p>
<p style="top:606.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">systematic review, only four chose the pig model, while the</span></p>
<p style="top:618.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">majority adopted smaller models with rabbits or even rats.</span></p>
<p style="top:631.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">Moreover, these animal models analysed surgically-created</span></p>
<p style="top:643.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">acute lesions which were treated immediately, oppositely to</span></p>
<p style="top:656.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">what happens in the clinical practice. Despite the inherent</span></p>
<p style="top:668.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">limits of these models in terms of transferability to humans,</span></p>
<p style="top:681.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">these studies still showed overall promising findings, with a</span></p>
<p style="top:693.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">positive outcome documented in 91.1 % of the papers.</span></p>
<p style="top:705.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">However, a more in depth analysis shed some doubts on the</span></p>
<p style="top:33.1pt;left:51.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">230</span></p>
<p style="top:33.1pt;left:359.8pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">International Orthopaedics (SICOT) (2017) 41:221</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">237</span></p>


<p style="top:707.6pt;left:52.8pt;line-height:8.5pt"><span style="font-family:XssngvAdvTTb8864ccf.B,serif;font-size:8.5pt;color:#131313">Table 2</span></p>
<p style="top:671.1pt;left:52.9pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Synopsis of clinical trials dealing with PRP application in fractures and non-union/delayed union management</span></p>
<p style="top:707.6pt;left:71.8pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Fractures</span></p>
<p style="top:708.8pt;left:92.4pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Publication</span></p>
<p style="top:633.1pt;left:92.4pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Study design</span></p>
<p style="top:577.9pt;left:92.4pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">N of patients</span></p>
<p style="top:496.2pt;left:92.4pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Pathology</span></p>
<p style="top:420.5pt;left:92.4pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Therapeutic protocol</span></p>
<p style="top:344.8pt;left:92.4pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Platelet count</span></p>
<p style="top:344.7pt;left:100.9pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">and leukocytes</span></p>
<p style="top:264.7pt;left:92.4pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Activation</span></p>
<p style="top:204.1pt;left:92.4pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">F-up</span></p>
<p style="top:148.3pt;left:92.4pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Main findings</span></p>
<p style="top:708.8pt;left:109.4pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Namazi H et al., Orthop</span></p>
<p style="top:700.3pt;left:117.8pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Tramatol Surg</span></p>
<p style="top:700.3pt;left:126.3pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Res.2016 [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#392a96">72</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">]</span></p>
<p style="top:633.1pt;left:109.4pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Randomized</span></p>
<p style="top:624.6pt;left:117.8pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">controlled trial</span></p>
<p style="top:577.9pt;left:109.4pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">30 patients:</span></p>
<p style="top:577.9pt;left:117.3pt;line-height:7.0pt"><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:7.0pt;color:#131313">n</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313"> = 15 percutaneous fixation</span></p>
<p style="top:569.4pt;left:126.3pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">+ PRP</span></p>
<p style="top:577.9pt;left:134.3pt;line-height:7.0pt"><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:7.0pt;color:#131313">n</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313"> = 15 percutaneous fixation</span></p>
<p style="top:496.2pt;left:109.4pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Distal radius fracture</span></p>
<p style="top:420.5pt;left:109.4pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Intra-articular injection of</span></p>
<p style="top:412.0pt;left:117.8pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">PRP immediately after</span></p>
<p style="top:412.0pt;left:126.3pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">percutaneous pinning</span></p>
<p style="top:412.0pt;left:134.8pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">fixation</span></p>
<p style="top:344.7pt;left:109.4pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Platelet count: NA</span></p>
<p style="top:344.7pt;left:117.8pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Leukocytes: no</span></p>
<p style="top:264.7pt;left:109.4pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">no</span></p>
<p style="top:204.1pt;left:109.4pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">6 months</span></p>
<p style="top:148.4pt;left:109.4pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">PRP has significant effect on</span></p>
<p style="top:139.8pt;left:117.8pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">reduction of pain and functional</span></p>
<p style="top:139.8pt;left:126.3pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">recovery</span></p>
<p style="top:708.8pt;left:143.2pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Rodriguez-Collazo ER</span></p>
<p style="top:700.3pt;left:151.7pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">et al., Strategies</span></p>
<p style="top:700.3pt;left:160.2pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Trauma Limb</span></p>
<p style="top:700.3pt;left:168.6pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Reconstr. 2015 [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#392a96">64</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">]</span></p>
<p style="top:633.1pt;left:143.2pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Case series</span></p>
<p style="top:577.9pt;left:143.2pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">20 patient with relevant</span></p>
<p style="top:569.4pt;left:151.7pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">comorbidities</span></p>
<p style="top:577.9pt;left:159.6pt;line-height:7.0pt"><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:7.0pt;color:#131313">n</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313"> = 10 BMC + PRP +</span></p>
<p style="top:569.4pt;left:168.6pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">DBM+ EF</span></p>
<p style="top:577.9pt;left:177.1pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">n =10 DBM+ EF (historical</span></p>
<p style="top:569.4pt;left:185.5pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">controls)</span></p>
<p style="top:496.2pt;left:143.2pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Bimalleolar fractures</span></p>
<p style="top:420.5pt;left:143.2pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">PRP and BMC mixed</span></p>
<p style="top:412.0pt;left:151.7pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">with DBM and</span></p>
<p style="top:412.0pt;left:160.1pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">injected locally at the</span></p>
<p style="top:412.0pt;left:168.6pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">fracture site</span></p>
<p style="top:344.7pt;left:143.2pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Platelet count: NA</span></p>
<p style="top:344.7pt;left:151.7pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Leukocytes: yes</span></p>
<p style="top:264.7pt;left:143.2pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">no</span></p>
<p style="top:204.1pt;left:143.2pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">18 months</span></p>
<p style="top:148.3pt;left:143.2pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">External fixation + DBM, BMA and</span></p>
<p style="top:139.8pt;left:151.7pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">PRP promoted fracture healing of</span></p>
<p style="top:139.8pt;left:160.1pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">the distal tibia and fibula in</span></p>
<p style="top:139.8pt;left:168.6pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">patients with significant</span></p>
<p style="top:139.8pt;left:177.1pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">co-morbidities</span></p>
<p style="top:708.8pt;left:193.1pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Samy AM</span></p>
<p style="top:708.8pt;left:201.6pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Int orthop. 2015 [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#392a96">68</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">]</span></p>
<p style="top:633.1pt;left:193.1pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Randomized</span></p>
<p style="top:624.6pt;left:201.6pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">controlled trial</span></p>
<p style="top:577.9pt;left:193.1pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">60 patients:</span></p>
<p style="top:577.9pt;left:201.6pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">n =30 screw fixation</span></p>
<p style="top:577.9pt;left:210.1pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">n =30 screw fixation + PRP</span></p>
<p style="top:496.2pt;left:193.1pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Femoral neck fracture</span></p>
<p style="top:420.5pt;left:193.1pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">PRP locally applied</span></p>
<p style="top:412.0pt;left:201.6pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">during surgery</span></p>
<p style="top:344.7pt;left:193.1pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Platelet count: NA</span></p>
<p style="top:344.7pt;left:201.6pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Leukocytes: no</span></p>
<p style="top:264.7pt;left:193.1pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">n.a.</span></p>
<p style="top:204.1pt;left:193.1pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">48 months</span></p>
<p style="top:148.4pt;left:193.1pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">PRP was a beneficial adjuvant to the</span></p>
<p style="top:139.8pt;left:201.6pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">classical internal fixation</span></p>
<p style="top:139.8pt;left:210.1pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">technique: both radiologic and</span></p>
<p style="top:139.8pt;left:218.5pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">clinical outcome were better in</span></p>
<p style="top:139.8pt;left:227.0pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">PRP group</span></p>
<p style="top:708.8pt;left:235.4pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Lee Dh et al.,</span></p>
<p style="top:708.8pt;left:243.9pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Clin Orthop Relat</span></p>
<p style="top:700.3pt;left:252.4pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Res.2014 [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#392a96">67</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">]</span></p>
<p style="top:633.1pt;left:235.4pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Randomized</span></p>
<p style="top:624.6pt;left:243.9pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">controlled trial</span></p>
<p style="top:577.9pt;left:235.4pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">20 patients:</span></p>
<p style="top:577.9pt;left:243.4pt;line-height:7.0pt"><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:7.0pt;color:#131313">n</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313"> = 10 external fixation</span></p>
<p style="top:577.9pt;left:252.4pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">n =10 external fixation +</span></p>
<p style="top:569.4pt;left:260.8pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">BMC + PRP</span></p>
<p style="top:496.2pt;left:235.4pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Tibal distraction</span></p>
<p style="top:487.7pt;left:243.9pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">osteogenesis (limb</span></p>
<p style="top:487.7pt;left:252.4pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">lenghtening)</span></p>
<p style="top:420.5pt;left:235.4pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">PRP + BMC locally</span></p>
<p style="top:412.0pt;left:243.9pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">injected at the</span></p>
<p style="top:412.0pt;left:252.4pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">osteotomy gap site</span></p>
<p style="top:344.8pt;left:235.4pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Platelet count: NA</span></p>
<p style="top:344.8pt;left:243.9pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Leukocytes: yes</span></p>
<p style="top:264.7pt;left:235.4pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">no</span></p>
<p style="top:204.2pt;left:235.4pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">24 months</span></p>
<p style="top:148.4pt;left:235.4pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">BMC + PRP significantly improved</span></p>
<p style="top:139.9pt;left:243.9pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">bone healing in distraction</span></p>
<p style="top:139.9pt;left:252.4pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">osteogenesis of the tibia, allowing</span></p>
<p style="top:139.9pt;left:260.8pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">earlier return to weightbearing</span></p>
<p style="top:708.8pt;left:269.3pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Griffin XL et al.,</span></p>
<p style="top:708.8pt;left:277.8pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">BMJ Open. 2013 [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#392a96">69</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">]</span></p>
<p style="top:633.1pt;left:269.3pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Randomized</span></p>
<p style="top:624.6pt;left:277.8pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">controlled trial</span></p>
<p style="top:577.9pt;left:269.3pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">200 patients</span></p>
<p style="top:577.9pt;left:277.3pt;line-height:7.0pt"><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:7.0pt;color:#131313">n</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313"> = 99 screw fixation</span></p>
<p style="top:577.9pt;left:285.7pt;line-height:7.0pt"><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:7.0pt;color:#131313">n</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313"> = 101 screw fixation +</span></p>
<p style="top:569.4pt;left:294.7pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">PRP</span></p>
<p style="top:496.2pt;left:269.3pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Femoral neck fracture</span></p>
<p style="top:420.5pt;left:269.3pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">PRP locally applied</span></p>
<p style="top:412.0pt;left:277.8pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">during surgery</span></p>
<p style="top:344.8pt;left:269.3pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Platelet count: NA</span></p>
<p style="top:344.8pt;left:277.8pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Leukocytes: yes</span></p>
<p style="top:264.7pt;left:269.4pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">no</span></p>
<p style="top:204.1pt;left:269.4pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">12 months</span></p>
<p style="top:148.3pt;left:269.4pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">There was no significant clinical</span></p>
<p style="top:139.8pt;left:277.9pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">difference following to PRP</span></p>
<p style="top:139.8pt;left:286.3pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">therapy.</span></p>
<p style="top:148.3pt;left:294.8pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Only a shorter hospital stay was</span></p>
<p style="top:139.8pt;left:303.3pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">registered for PRP group.</span></p>
<p style="top:708.8pt;left:311.7pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Liebergall M et al., Mol.</span></p>
<p style="top:700.3pt;left:320.2pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Ther.2013 [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#392a96">71</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">]</span></p>
<p style="top:633.1pt;left:311.7pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Randomized</span></p>
<p style="top:624.6pt;left:320.2pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">controlled trial</span></p>
<p style="top:577.9pt;left:311.7pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">24 patients</span></p>
<p style="top:577.9pt;left:319.7pt;line-height:7.0pt"><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:7.0pt;color:#131313">n</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313"> =12 ORIF</span></p>
<p style="top:577.9pt;left:328.2pt;line-height:7.0pt"><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:7.0pt;color:#131313">n</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313"> = 12 ORIF + DBM+</span></p>
<p style="top:569.4pt;left:337.2pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">MSCs + PRP</span></p>
<p style="top:496.2pt;left:311.7pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Disttal tibial fractures</span></p>
<p style="top:420.5pt;left:311.7pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">PRP and MSCs mixed</span></p>
<p style="top:412.0pt;left:320.2pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">with DBM and</span></p>
<p style="top:412.0pt;left:328.6pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">injected at the fracture</span></p>
<p style="top:412.0pt;left:337.1pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">site 3</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:7.0pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">6 weeks after</span></p>
<p style="top:412.0pt;left:345.6pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">primary surgery</span></p>
<p style="top:344.7pt;left:310.7pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Platelet count: 1.10 X 10</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:4.9pt;color:#131313">6</span></p>
<p style="top:336.2pt;left:319.1pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">per mm</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:4.9pt;color:#131313">3</span></p>
<p style="top:344.7pt;left:328.7pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Leukocytes: NA</span></p>
<p style="top:264.7pt;left:311.7pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">n.a.</span></p>
<p style="top:204.1pt;left:311.7pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">12 months</span></p>
<p style="top:148.3pt;left:311.7pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">The combination of</span></p>
<p style="top:139.8pt;left:320.2pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">PRP + MSCs + DBM is a safe</span></p>
<p style="top:139.8pt;left:328.7pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">therapeutic option and contributed</span></p>
<p style="top:139.8pt;left:337.2pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">to reduce the time of bone fusion</span></p>
<p style="top:708.8pt;left:354.1pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Wei LC et al.,</span></p>
<p style="top:708.8pt;left:362.6pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">J Orthop Res.2012 [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#392a96">70</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">]</span></p>
<p style="top:633.1pt;left:354.1pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Randomized</span></p>
<p style="top:624.6pt;left:362.6pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">controlled trial</span></p>
<p style="top:577.9pt;left:354.1pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">254 patients</span></p>
<p style="top:577.9pt;left:362.6pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">n =101 ORIF + autograft</span></p>
<p style="top:577.9pt;left:371.0pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">n =85 ORIF + allograft +</span></p>
<p style="top:569.4pt;left:379.5pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">PRP</span></p>
<p style="top:577.9pt;left:388.0pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">n =90 ORIF + allograft</span></p>
<p style="top:496.2pt;left:354.1pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Calcaneal fractures</span></p>
<p style="top:420.4pt;left:354.1pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">PRP mixed with bone</span></p>
<p style="top:412.0pt;left:362.6pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">allograft and applied</span></p>
<p style="top:412.0pt;left:371.0pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">locally during ORIF</span></p>
<p style="top:344.7pt;left:354.0pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Platelet count: 780000</span></p>
<p style="top:336.2pt;left:362.5pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">platelets/ uL</span></p>
<p style="top:344.7pt;left:371.0pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Leukocytes: NA</span></p>
<p style="top:264.7pt;left:354.0pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Thrombin + CaCl</span></p>
<p style="top:204.1pt;left:354.0pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">72 months</span></p>
<p style="top:148.4pt;left:354.0pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">PRP-augmented allografts showed</span></p>
<p style="top:139.8pt;left:362.5pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">better radiological results</span></p>
<p style="top:139.8pt;left:371.0pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">compared to allograft alone</span></p>
<p style="top:708.8pt;left:395.5pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Perbooms JC et al.,</span></p>
<p style="top:708.8pt;left:404.0pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Int Orthop. 2012 [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#392a96">66</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">]</span></p>
<p style="top:633.1pt;left:395.5pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Randomized</span></p>
<p style="top:624.6pt;left:404.0pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">controlled trial</span></p>
<p style="top:577.9pt;left:395.5pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">41 patients</span></p>
<p style="top:577.9pt;left:404.0pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">n =20 bone chips + PRP</span></p>
<p style="top:577.9pt;left:412.4pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">n =21 bone chips</span></p>
<p style="top:496.2pt;left:395.5pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">High tibial osteotomy</span></p>
<p style="top:420.5pt;left:395.5pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">PRP mixed with the bone</span></p>
<p style="top:412.0pt;left:404.0pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">chips and put in the</span></p>
<p style="top:412.0pt;left:412.4pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">osteotomy gap site</span></p>
<p style="top:344.7pt;left:395.5pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Platelet count: NA</span></p>
<p style="top:344.7pt;left:404.0pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Leukocytes: yes</span></p>
<p style="top:264.7pt;left:395.5pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Thrombin</span></p>
<p style="top:204.2pt;left:395.5pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">12 weeks</span></p>
<p style="top:148.4pt;left:395.5pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">PRP provided detrimental effects</span></p>
<p style="top:139.9pt;left:404.0pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">with significant lower bone</span></p>
<p style="top:139.9pt;left:412.4pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">density around the osteotomy</span></p>
<p style="top:139.9pt;left:420.9pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">wedge at one and 12 weeks after</span></p>
<p style="top:139.9pt;left:429.4pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">surgery</span></p>
<p style="top:708.8pt;left:437.9pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Dallari D et al.,</span></p>
<p style="top:708.8pt;left:446.3pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">J bone Joint surg Am.</span></p>
<p style="top:700.3pt;left:454.7pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">2007 [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#392a96">65</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">]</span></p>
<p style="top:633.1pt;left:437.9pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Randomized</span></p>
<p style="top:624.6pt;left:446.3pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">controlled trial</span></p>
<p style="top:577.9pt;left:437.9pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">33 patients</span></p>
<p style="top:577.9pt;left:446.3pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">n =11 bone chips + PRP</span></p>
<p style="top:577.9pt;left:454.2pt;line-height:7.0pt"><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:7.0pt;color:#131313">n</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313"> = 12 bone chips + PRP+</span></p>
<p style="top:569.4pt;left:463.2pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">BMC</span></p>
<p style="top:577.9pt;left:471.7pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">n =10 bone chips</span></p>
<p style="top:496.2pt;left:437.8pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">High tibial osteotomy</span></p>
<p style="top:420.5pt;left:437.8pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">PRP mixed with the bone</span></p>
<p style="top:412.0pt;left:446.3pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">chips and put in the</span></p>
<p style="top:412.0pt;left:454.7pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">osteotomy gap site</span></p>
<p style="top:344.8pt;left:434.8pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Platelet count: 1 &#xd7; 10</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:4.9pt;color:#131313">6</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313"> per</span></p>
<p style="top:336.2pt;left:445.3pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">mm</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:4.9pt;color:#131313">3</span></p>
<p style="top:344.7pt;left:454.8pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Leukocytes: yes</span></p>
<p style="top:264.7pt;left:437.9pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Thrombin</span></p>
<p style="top:204.1pt;left:437.9pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">12 months</span></p>
<p style="top:148.4pt;left:437.9pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">PRP increased the osteogenic</span></p>
<p style="top:139.8pt;left:446.4pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">potential of the bone chips and</span></p>
<p style="top:139.8pt;left:454.8pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">provided better outcome in terms</span></p>
<p style="top:139.8pt;left:463.3pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">of radiologic healing of the</span></p>
<p style="top:139.8pt;left:471.8pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">osteotomy site. Further beneficial</span></p>
<p style="top:139.8pt;left:480.2pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">effects with the addition of BMC</span></p>
<p style="top:708.8pt;left:497.1pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Non-union/delayed union</span></p>
<p style="top:708.8pt;left:505.7pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Malhotra R et al.,</span></p>
<p style="top:700.3pt;left:514.1pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Musculoskelet Surg.</span></p>
<p style="top:700.3pt;left:522.5pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">2015 [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#392a96">78</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">]</span></p>
<p style="top:633.1pt;left:505.6pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Case series</span></p>
<p style="top:577.9pt;left:505.6pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">94 patients</span></p>
<p style="top:496.2pt;left:505.6pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Long bone non union</span></p>
<p style="top:420.5pt;left:505.6pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">PRP injection at the site of</span></p>
<p style="top:412.0pt;left:514.1pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">non-union</span></p>
<p style="top:344.7pt;left:505.6pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Platelet count: minimum 2</span></p>
<p style="top:336.2pt;left:511.0pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">x 10</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:4.9pt;color:#131313">6</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313"> per mm</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:4.9pt;color:#131313">3</span></p>
<p style="top:344.7pt;left:522.6pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Leukocytes: no</span></p>
<p style="top:264.7pt;left:505.7pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">n.a.</span></p>
<p style="top:204.1pt;left:505.7pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">4 months</span></p>
<p style="top:148.4pt;left:505.7pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">PRP was a safe and effective</span></p>
<p style="top:139.8pt;left:514.1pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">treatment for managing</span></p>
<p style="top:139.8pt;left:522.6pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">non-unions</span></p>
<p style="top:708.8pt;left:531.1pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Say F et al.,</span></p>
<p style="top:633.0pt;left:531.1pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Case series</span></p>
<p style="top:577.9pt;left:531.1pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">20 patients</span></p>
<p style="top:344.8pt;left:531.1pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Platelet count: NA</span></p>
<p style="top:264.7pt;left:531.1pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">CaCl</span></p>
<p style="top:204.1pt;left:531.1pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">12 months</span></p>
<p style="top:33.1pt;left:51.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">International Orthopaedics (SICOT) (2017) 41:221</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">237</span></p>
<p style="top:33.1pt;left:531.7pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">231</span></p>


<p style="top:707.3pt;left:51.1pt;line-height:8.5pt"><span style="font-family:XssngvAdvTTb8864ccf.B,serif;font-size:8.5pt;color:#131313">Table 2</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> (continued)</span></p>
<p style="top:707.3pt;left:70.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Fractures</span></p>
<p style="top:708.5pt;left:90.7pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Acta Chir Orthop</span></p>
<p style="top:700.0pt;left:99.2pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Traumatol Cech. 2014</span></p>
<p style="top:700.0pt;left:107.6pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">[</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#392a96">77</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">]</span></p>
<p style="top:495.9pt;left:90.7pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Long bone non</span></p>
<p style="top:487.4pt;left:99.2pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">union/delayed union</span></p>
<p style="top:420.2pt;left:90.7pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">3 PRP injections at the</span></p>
<p style="top:411.7pt;left:99.2pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">site of non-union at</span></p>
<p style="top:411.7pt;left:107.6pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">one week interval</span></p>
<p style="top:344.4pt;left:90.7pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Leukocytes: no</span></p>
<p style="top:148.0pt;left:90.7pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">PRP had no additional healing</span></p>
<p style="top:139.6pt;left:99.2pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">potential</span></p>
<p style="top:708.5pt;left:116.1pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Golos J et al.,</span></p>
<p style="top:708.5pt;left:124.6pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Ortop Traumatol Rehabil.</span></p>
<p style="top:700.0pt;left:133.0pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">2014 [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#392a96">79</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">]</span></p>
<p style="top:632.7pt;left:116.1pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Case series</span></p>
<p style="top:577.5pt;left:116.1pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">132 patients</span></p>
<p style="top:495.8pt;left:116.1pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Long bone non union</span></p>
<p style="top:420.1pt;left:116.1pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">PRP injection at the site of</span></p>
<p style="top:411.7pt;left:124.6pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">non-union</span></p>
<p style="top:344.4pt;left:116.1pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Platelet count: NA</span></p>
<p style="top:344.4pt;left:124.6pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Leukocytes: n.a.</span></p>
<p style="top:264.3pt;left:116.1pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">n.a.</span></p>
<p style="top:203.8pt;left:116.1pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">4 months</span></p>
<p style="top:148.1pt;left:116.1pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">PRP was effective in treatment of</span></p>
<p style="top:139.6pt;left:124.6pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">delayed union of long bones</span></p>
<p style="top:708.5pt;left:140.6pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Tarallo L et al.,</span></p>
<p style="top:708.5pt;left:149.0pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Eur J Orthop Surg</span></p>
<p style="top:700.0pt;left:157.5pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Traumatol. 2012 [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#392a96">75</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">]</span></p>
<p style="top:632.7pt;left:140.6pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Case series</span></p>
<p style="top:577.5pt;left:140.6pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">10 patients</span></p>
<p style="top:495.9pt;left:140.6pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Isolated non-union of the</span></p>
<p style="top:487.4pt;left:149.0pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">ulna</span></p>
<p style="top:420.2pt;left:140.6pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">PRP + bone autograft</span></p>
<p style="top:411.7pt;left:149.0pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">locally applied during</span></p>
<p style="top:411.7pt;left:157.5pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">revision surgery</span></p>
<p style="top:344.5pt;left:140.6pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Platelet count: NA</span></p>
<p style="top:344.5pt;left:149.0pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Leukocytes: yes</span></p>
<p style="top:264.3pt;left:140.6pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Thrombin +</span></p>
<p style="top:255.8pt;left:149.0pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">calcium</span></p>
<p style="top:255.8pt;left:157.5pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">gluconate</span></p>
<p style="top:203.9pt;left:140.6pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">minimum</span></p>
<p style="top:195.4pt;left:149.0pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">3 months</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:7.0pt;color:#131313"> &#x2013;</span></p>
<p style="top:195.4pt;left:157.5pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">maximum</span></p>
<p style="top:195.4pt;left:166.0pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">36 months</span></p>
<p style="top:148.1pt;left:140.6pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">High rate of clinical and radiologic</span></p>
<p style="top:139.6pt;left:149.0pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">healing with the biologic</span></p>
<p style="top:139.6pt;left:157.5pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">augmentation</span></p>
<p style="top:708.5pt;left:174.4pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Galasso O et al.,</span></p>
<p style="top:708.5pt;left:182.9pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">J Orthop Traumatol. 2008</span></p>
<p style="top:700.0pt;left:191.4pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">[</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#392a96">80</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">]</span></p>
<p style="top:632.7pt;left:174.4pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Case series</span></p>
<p style="top:577.5pt;left:174.4pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">22 patients</span></p>
<p style="top:495.8pt;left:174.4pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Long bone non union</span></p>
<p style="top:420.2pt;left:174.4pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">PRP applied locally</span></p>
<p style="top:411.7pt;left:182.9pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">during revision</span></p>
<p style="top:411.7pt;left:191.4pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">surgery</span></p>
<p style="top:344.5pt;left:174.4pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Platelet count : NA</span></p>
<p style="top:344.5pt;left:182.9pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Leukocytes: NA</span></p>
<p style="top:264.3pt;left:174.4pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Batroxobin and</span></p>
<p style="top:255.8pt;left:182.9pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">CaCl</span></p>
<p style="top:203.9pt;left:174.4pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">13 months</span></p>
<p style="top:148.1pt;left:174.4pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Intramedullary nailing and PRP</span></p>
<p style="top:139.6pt;left:182.9pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">produced comparable results with</span></p>
<p style="top:139.6pt;left:191.3pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">less complications</span></p>
<p style="top:708.5pt;left:199.8pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Sanchez M et al.,</span></p>
<p style="top:708.5pt;left:208.3pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">J Orthop Trauma. 2009</span></p>
<p style="top:700.0pt;left:216.7pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">[</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#392a96">81</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">]</span></p>
<p style="top:632.7pt;left:199.8pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Case series</span></p>
<p style="top:577.5pt;left:199.8pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">15 patients</span></p>
<p style="top:495.8pt;left:199.8pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Non hypertrophic non</span></p>
<p style="top:487.4pt;left:208.3pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">union/delayed unions</span></p>
<p style="top:420.2pt;left:199.8pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">PRP mebrane locally</span></p>
<p style="top:411.7pt;left:208.3pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">applied during</span></p>
<p style="top:411.7pt;left:216.7pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">revision surgery</span></p>
<p style="top:411.7pt;left:225.2pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">(sometimes with bone</span></p>
<p style="top:411.7pt;left:233.7pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">graft)</span></p>
<p style="top:420.2pt;left:242.1pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">PRP injection at the site of</span></p>
<p style="top:411.7pt;left:250.6pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">non-union (without</span></p>
<p style="top:411.7pt;left:259.1pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">surgery)</span></p>
<p style="top:344.5pt;left:199.8pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Platelet count: NA</span></p>
<p style="top:344.5pt;left:208.3pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Leukocytes: no</span></p>
<p style="top:264.3pt;left:199.8pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">CaCl</span></p>
<p style="top:203.8pt;left:199.8pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">8 months</span></p>
<p style="top:148.1pt;left:199.8pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">PRP was clinically safe and</span></p>
<p style="top:139.6pt;left:208.3pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">enhanced the healing of</span></p>
<p style="top:139.6pt;left:216.7pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">non-hypertrophic non unions</span></p>
<p style="top:708.5pt;left:267.6pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Mariconda M et al.,</span></p>
<p style="top:708.5pt;left:276.0pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">J Orthop Trauma. 2008</span></p>
<p style="top:700.0pt;left:284.5pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">[</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#392a96">76</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">]</span></p>
<p style="top:632.7pt;left:267.6pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Case series</span></p>
<p style="top:577.5pt;left:267.6pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">20 patients</span></p>
<p style="top:495.8pt;left:267.6pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Long bone non union</span></p>
<p style="top:420.2pt;left:267.6pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">PRP locally applied</span></p>
<p style="top:411.7pt;left:276.0pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">during revision</span></p>
<p style="top:411.7pt;left:284.5pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">surgery (external</span></p>
<p style="top:411.7pt;left:293.0pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">fixation)</span></p>
<p style="top:344.4pt;left:267.6pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Platelet count: NA</span></p>
<p style="top:344.4pt;left:276.0pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Leukocytes: NA</span></p>
<p style="top:264.3pt;left:267.6pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Thrombin +</span></p>
<p style="top:255.8pt;left:276.0pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">calcium</span></p>
<p style="top:255.8pt;left:284.4pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">gluconate</span></p>
<p style="top:203.9pt;left:267.5pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">9 months</span></p>
<p style="top:148.1pt;left:267.5pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">The study failed to show any clinical</span></p>
<p style="top:139.6pt;left:276.0pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">usefulness of PRP</span></p>
<p style="top:708.5pt;left:301.4pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Bielecki T et al.,</span></p>
<p style="top:708.5pt;left:309.8pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Eur Surg Res. 2008 [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#392a96">82</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">]</span></p>
<p style="top:632.7pt;left:301.4pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Case series</span></p>
<p style="top:577.5pt;left:301.4pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">32 patients</span></p>
<p style="top:495.8pt;left:301.4pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Long bone non union</span></p>
<p style="top:420.1pt;left:301.4pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">PRP injection at the site of</span></p>
<p style="top:411.7pt;left:309.8pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">non-union</span></p>
<p style="top:344.4pt;left:301.4pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Platelet count: 241 &#xb1; 64 X</span></p>
<p style="top:335.9pt;left:306.9pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">10</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:4.9pt;color:#131313">6</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313"> per mm</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:4.9pt;color:#131313">3</span></p>
<p style="top:344.4pt;left:318.5pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Leukocytes : yes</span></p>
<p style="top:264.3pt;left:301.5pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Thrombin + CaCl</span></p>
<p style="top:203.8pt;left:301.5pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">6 months</span></p>
<p style="top:148.1pt;left:301.5pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">PRP injection was a valid strategy to</span></p>
<p style="top:139.6pt;left:310.0pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">obtain union</span></p>
<p style="top:708.5pt;left:326.9pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Calori et al.,</span></p>
<p style="top:708.5pt;left:335.4pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Injury. 2008 [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#392a96">73</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">] +</span></p>
<p style="top:708.5pt;left:343.9pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Calori et al.,</span></p>
<p style="top:708.5pt;left:352.3pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Injury. 2006 [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#392a96">74</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">]</span></p>
<p style="top:632.7pt;left:326.9pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Randomized</span></p>
<p style="top:624.2pt;left:335.4pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">controlled trial</span></p>
<p style="top:577.6pt;left:326.9pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">120 patients</span></p>
<p style="top:577.6pt;left:334.9pt;line-height:7.0pt"><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:7.0pt;color:#131313">n</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313"> = 60 BMP-7</span></p>
<p style="top:577.6pt;left:343.3pt;line-height:7.0pt"><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:7.0pt;color:#131313">n</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313"> = 60 PRP</span></p>
<p style="top:495.9pt;left:326.9pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Long bone non union</span></p>
<p style="top:420.2pt;left:326.9pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">PRP or BMP-7 locally</span></p>
<p style="top:411.7pt;left:335.4pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">applied during revi-</span></p>
<p style="top:411.7pt;left:343.8pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">sion surgery (some-</span></p>
<p style="top:411.7pt;left:352.3pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">times with bone graft)</span></p>
<p style="top:344.4pt;left:325.8pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Platelet count: 1.582 x 10</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:4.9pt;color:#131313">6</span></p>
<p style="top:335.9pt;left:334.3pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">per mm</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:4.9pt;color:#131313">3</span></p>
<p style="top:344.4pt;left:343.9pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Leukocytes: NA</span></p>
<p style="top:264.3pt;left:326.9pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">CaCl</span></p>
<p style="top:203.8pt;left:326.9pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">mean</span></p>
<p style="top:195.3pt;left:335.4pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">12.3 months</span></p>
<p style="top:148.1pt;left:326.9pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">BMP-7 is significantly more</span></p>
<p style="top:139.6pt;left:335.4pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">effective than PRP in promoting</span></p>
<p style="top:139.6pt;left:343.9pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">bone healing, both at radiolofic</span></p>
<p style="top:139.6pt;left:352.3pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">and clinical evaluation</span></p>
<p style="top:708.5pt;left:360.8pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Chiang CC et al.,</span></p>
<p style="top:708.5pt;left:369.2pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">J Trauma. 2007 [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#392a96">83</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">]</span></p>
<p style="top:632.7pt;left:360.8pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Case series</span></p>
<p style="top:577.5pt;left:360.8pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">12 patients</span></p>
<p style="top:495.8pt;left:360.8pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Long bone non union</span></p>
<p style="top:420.2pt;left:360.8pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">PRP + bone graft applied</span></p>
<p style="top:411.7pt;left:369.2pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">locally during revision</span></p>
<p style="top:411.7pt;left:377.7pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">surgery</span></p>
<p style="top:344.4pt;left:360.8pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Platelet count: n.a.</span></p>
<p style="top:344.4pt;left:369.2pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Leukocytes: NA</span></p>
<p style="top:264.3pt;left:360.8pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">Thrombin + CaCl</span></p>
<p style="top:203.8pt;left:360.8pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">mean</span></p>
<p style="top:195.3pt;left:369.2pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">32.4 months</span></p>
<p style="top:148.0pt;left:360.8pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">There was a beneficial potential of</span></p>
<p style="top:139.5pt;left:369.2pt;line-height:7.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">PRP in treating non unions</span></p>
<p style="top:707.3pt;left:395.7pt;line-height:8.5pt"><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313">PRP</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> Platelet-rich Plasma,</span><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> ORIF</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> open reduction and internal fixation,</span><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> EF</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> External Fixation,</span><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> DBM</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> Demineralized Bone Matrix</span><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> BMC</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> Bone Marrow Concentrate,</span><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> BMP-7</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> Bone Morphogeneic Protein-7,</span></p>
<p style="top:707.3pt;left:405.7pt;line-height:8.5pt"><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313">MSC</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> Mesenchymal Stem cells,</span><span style="font-family:VsdqbwAdvTT50a2f13e.I,serif;font-size:8.5pt;color:#131313"> NA</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> Not available</span></p>
<p style="top:33.1pt;left:51.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">232</span></p>
<p style="top:33.1pt;left:359.8pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">International Orthopaedics (SICOT) (2017) 41:221</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">237</span></p>


<p style="top:58.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">real potential of PRP. In fact, looking at the specific evalua-</span></p>
<p style="top:70.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">tions performed, the percentage of success decreased. While</span></p>
<p style="top:83.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">histological analysis showed an improvement in 84.4 % of the</span></p>
<p style="top:95.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">experiments, imaging analysis showed a lower success, with a</span></p>
<p style="top:108.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">75.0 % success rate documented through radiological analy-</span></p>
<p style="top:120.6pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">sis. Moreover, the higher quality of the regenerated tissue</span></p>
<p style="top:133.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">should lead to a stronger tissue, but biomechanical analysis</span></p>
<p style="top:145.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">could prove superior results related to PRP use only in 72.7 %</span></p>
<p style="top:158.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">of the studies. This is an important factor, because it raises</span></p>
<p style="top:170.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">some caution on the interpretation of the positive results of</span></p>
<p style="top:182.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">several studies based on different and more successful out-</span></p>
<p style="top:195.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">comes. An improved regeneration should allow for higher</span></p>
<p style="top:207.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">biomechanical properties to be considered significant, other-</span></p>
<p style="top:220.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">wise the real usefulness of this biological augmentation re-</span></p>
<p style="top:232.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">mains questionable. Besides the lack of biomechanical evalu-</span></p>
<p style="top:245.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">ations, performed only in a minority of preclinical studies,</span></p>
<p style="top:257.6pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">other aspects hinder the understanding of PRP potential.</span></p>
<p style="top:270.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">These lie in the limitations of the current preclinical literature,</span></p>
<p style="top:282.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">in terms of extreme heterogeneity of the published studies as</span></p>
<p style="top:294.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">well as often poor study quality.</span></p>
<p style="top:307.4pt;left:62.4pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">Most of the studies fail to report key aspects that may</span></p>
<p style="top:319.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">influence the final outcome and hinder a correct interpretation</span></p>
<p style="top:332.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">of the results: platelet concentrations, leukocyte components,</span></p>
<p style="top:344.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">activation modality etc. are often overlooked. Even though</span></p>
<p style="top:357.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">several products with a wide range of cell concentration are</span></p>
<p style="top:369.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">included in the PRP family [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96">89</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">], the number and type of cells</span></p>
<p style="top:382.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">applied is not a secondary aspect. A platelet concentration of</span></p>
<p style="top:394.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">approximately (1,000,000/</span><span style="font-family:TmgcryAdvTT3713a231+03,serif;font-size:10.0pt;color:#131313">&#x3bc;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">l) has been linked to positive bio-</span></p>
<p style="top:407.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">logical effects in bone regeneration by Weibrich et al. [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96">90</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">].</span></p>
<p style="top:419.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">Chen et al. [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96">60</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">] showed how a medium concentration of PRP</span></p>
<p style="top:431.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">(2.65 &#xb1; 0.2 &#xd7; 10</span><sup><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">9</span></sup><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">/ml) induced osteogenic differentiation of</span></p>
<p style="top:444.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">BMSCs and improved fracture healing, while a high concen-</span></p>
<p style="top:456.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">tration of PRP (8.21 &#xb1; 0.4 &#xd7; 10</span><sup><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:7.0pt;color:#131313">9</span></sup><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">/ml) inhibited osteogenic dif-</span></p>
<p style="top:469.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">ferentiation of BMSCs and delayed callus remodelling in a rat</span></p>
<p style="top:481.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">femoral osteotomy. Other than the importance of platelet num-</span></p>
<p style="top:494.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">ber, Perut et al. [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96">21</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">] underlined the contribution of other cells</span></p>
<p style="top:506.6pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">to the overall effect: leukocyte-rich PRP induced significantly</span></p>
<p style="top:519.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">higher proliferation of BMSCs compared to leukocyte-</span></p>
<p style="top:531.6pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">depleted PRP. Moreover, other studies emphasized the impor-</span></p>
<p style="top:544.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">tance of further aspects related to PRP, such as storage or</span></p>
<p style="top:556.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">activation modality that, together with the autologous or allo-</span></p>
<p style="top:568.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">geneic nature, the characteristics of the donor and the prepa-</span></p>
<p style="top:581.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">ration method etc., may influence the molecules released and</span></p>
<p style="top:593.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">the biological results of platelet concentrates [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96">88</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">,</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96"> 91</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">,</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96"> 92</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">]. PRP</span></p>
<p style="top:606.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">effects may also depend on the treatment condition, i.e. the</span></p>
<p style="top:618.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">application modality, in particular in terms of injective or sur-</span></p>
<p style="top:631.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">gical delivery (a more solid state with more fibrin may imply a</span></p>
<p style="top:643.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">different release of the GFs from the fibrin net [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96">93</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">]), and even</span></p>
<p style="top:656.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">more with combined augmentation procedures. Preclinical</span></p>
<p style="top:668.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">studies are highly heterogeneous in terms of materials com-</span></p>
<p style="top:681.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">bined with PRP, which has been suggested to influence cell-</span></p>
<p style="top:693.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">signalling molecules that promote osteogenesis [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96">20</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">] and, in</span></p>
<p style="top:705.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">the end, the success rate [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96">5</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">]. Moreover, PRP has also been</span></p>
<p style="top:58.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">combined with MSCs: while overall results of the combined</span></p>
<p style="top:70.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">treatment seemed positive, the independent contribution of</span></p>
<p style="top:83.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">PRP remains questionable.</span></p>
<p style="top:95.7pt;left:317.5pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">All these factors contribute to the complexity of the pre-</span></p>
<p style="top:108.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">clinical findings and leave many open questions on the opti-</span></p>
<p style="top:120.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">mization and transferability of PRP potential for humans use.</span></p>
<p style="top:133.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">Overall clinical findings confirm the preclinical scenery. The</span></p>
<p style="top:145.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">lack of clear indications on the best way to apply platelet</span></p>
<p style="top:158.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">concentrates is reflected by an extreme heterogeneity in terms</span></p>
<p style="top:170.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">of PRP preparations, as well as in targets and delivery</span></p>
<p style="top:182.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">methods. Moreover, the quality of the studies is limited: as</span></p>
<p style="top:195.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">for the preclinical field, many key parameters are omitted,</span></p>
<p style="top:207.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">the study design is poor and even for randomized trial low</span></p>
<p style="top:220.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">patients numbers and the presence of concomitant confound-</span></p>
<p style="top:232.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">ing factors hinder the possibility to have clear results. This is a</span></p>
<p style="top:245.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">key aspect since a tendency to report better results with lower</span></p>
<p style="top:257.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">quality studies compared to more scientific robust ones has</span></p>
<p style="top:270.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">already been reported [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96">5</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">]. Finally, it has to also be emphasized</span></p>
<p style="top:282.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">for clinical studies that not all positive results may be clinical-</span></p>
<p style="top:294.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">ly significant. In fact, the rational of a biological augmentation</span></p>
<p style="top:307.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">is to favour a faster recovery. Earlier weight bearing and mo-</span></p>
<p style="top:319.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">bilization may lead to fewer adhesions, higher postoperative</span></p>
<p style="top:332.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">range of motion and earlier return to physical activity [</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#392a96">88</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">]. To</span></p>
<p style="top:344.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">this aim, positive histological or imaging findings may be</span></p>
<p style="top:357.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">insufficient if not coupled by a significant increase in biome-</span></p>
<p style="top:369.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">chanical quality of bone. The analysis of the clinical studies in</span></p>
<p style="top:382.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">terms of documented clinical benefit shows an even lower</span></p>
<p style="top:394.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">outcome than what is suggested by imaging findings, which</span></p>
<p style="top:407.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">further questions the real benefit provided by PRP use to fa-</span></p>
<p style="top:419.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">vour bone regeneration in the clinical practice.</span></p>
<p style="top:431.9pt;left:317.5pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">Thus, while positive findings have been suggested by the</span></p>
<p style="top:444.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">pre-clinical literature, a more in depth evaluation shed some</span></p>
<p style="top:456.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">doubts on the real role of PRP, which are confirmed by the</span></p>
<p style="top:469.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">limited benefits documented in the human experience.</span></p>
<p style="top:481.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">Currently, there is no evidence to support the routine use of</span></p>
<p style="top:494.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">PRP to enhance bone healing. Therefore, until trials with high</span></p>
<p style="top:506.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">methodological quality will allow the optimization of its bio-</span></p>
<p style="top:519.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">logical potential and clearly prove results and indications,</span></p>
<p style="top:531.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">PRP use should be restricted to controlled studies investigat-</span></p>
<p style="top:544.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">ing its real benefit for the treatment of bone pathologies.</span></p>
<p style="top:580.6pt;left:306.1pt;line-height:11.0pt"><span style="font-family:XssngvAdvTTb8864ccf.B,serif;font-size:11.0pt;color:#131313">Conclusions</span></p>
<p style="top:606.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">This systematic research of the literature documented a grow-</span></p>
<p style="top:618.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">ing interest on PRP use for bone disorders. While the overall</span></p>
<p style="top:631.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">pre-clinical results seem to support the benefit of PRP in</span></p>
<p style="top:643.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">91.1 % of the studies, a more in depth analysis underlines a</span></p>
<p style="top:656.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">lower success rate, with a positive outcome of 84.4 % in terms</span></p>
<p style="top:668.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">of histological analysis, and even lower when considering</span></p>
<p style="top:681.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">radiological and biomechanical analysis, 75.0 % and</span></p>
<p style="top:693.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">72.7 %, respectively. This is reflected by controversial find-</span></p>
<p style="top:705.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">ings also documented in the clinical literature, where the real</span></p>
<p style="top:33.1pt;left:51.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">International Orthopaedics (SICOT) (2017) 41:221</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">237</span></p>
<p style="top:33.1pt;left:531.7pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">233</span></p>


<p style="top:58.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">benefit of PRP use to treat fractures and non-unions is ques-</span></p>
<p style="top:70.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">tionable. Overall, the available literature presents major limi-</span></p>
<p style="top:83.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">tations in terms of low quality and extreme heterogeneity,</span></p>
<p style="top:95.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">which hamper the possibility to optimize PRP treatment and</span></p>
<p style="top:108.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">translate positive preclinical findings on its biological poten-</span></p>
<p style="top:120.6pt;left:51.0pt;line-height:10.0pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:10.0pt;color:#131313">tial to favour bone healing into a real clinical benefit.</span></p>
<p style="top:154.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:XssngvAdvTTb8864ccf.B,serif;font-size:8.5pt;color:#131313">Acknowledgment</span></p>
<p style="top:154.5pt;left:122.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">This work was partially supported by European</span></p>
<p style="top:164.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Union Seventh Framework Programme FP7- PEOPLE-2013-ITN under</span></p>
<p style="top:174.4pt;left:51.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Grant Agreement no. 607051-Bioinspire: Training program on new</span></p>
<p style="top:184.4pt;left:51.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">bioinspired bone regeneration.</span></p>
<p style="top:216.6pt;left:51.0pt;line-height:8.5pt"><span style="font-family:XssngvAdvTTb8864ccf.B,serif;font-size:8.5pt;color:#131313">Compliance with ethical standards</span></p>
<p style="top:239.0pt;left:51.0pt;line-height:8.5pt"><span style="font-family:XssngvAdvTTb8864ccf.B,serif;font-size:8.5pt;color:#131313">Conflict of interest</span></p>
<p style="top:239.0pt;left:124.7pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Elizaveta Kon</span></p>
<p style="top:249.0pt;left:62.4pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Zimmer-Biomet (USA): Paid presenter or speaker</span></p>
<p style="top:258.9pt;left:62.4pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Cartiheal (Israel): Paid consultant; Stock or stock options</span></p>
<p style="top:268.9pt;left:62.4pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Fidia (Italy): Paid presenter or speaker</span></p>
<p style="top:278.8pt;left:62.4pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Finceramica (Italy): Paid presenter or speaker</span></p>
<p style="top:288.8pt;left:62.4pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">International Cartilage Repair Society: Board or committee member</span></p>
<p style="top:298.8pt;left:62.4pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Journal of Experimental Orthopedics: Editorial or governing board</span></p>
<p style="top:308.8pt;left:62.4pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Giuseppe Filardo</span></p>
<p style="top:318.7pt;left:62.4pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Zimmer-Biomet (USA): Institutional Support</span></p>
<p style="top:328.7pt;left:62.4pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Cartiheal (Israel): Consultant and Institutional Support</span></p>
<p style="top:338.6pt;left:62.4pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Fidia (Italy): Consultant and Institutional Support</span></p>
<p style="top:348.6pt;left:62.4pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Finceramica (Italy): Consultant and Institutional Support</span></p>
<p style="top:358.5pt;left:62.4pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Green Bone (Italy): Consultant and Institutional Support</span></p>
<p style="top:368.5pt;left:62.4pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">DSM Biomedical (USA): Institutional Support</span></p>
<p style="top:378.5pt;left:62.4pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">IGEA Clinical Biophisic: Institutional Support</span></p>
<p style="top:388.4pt;left:62.4pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">PIRAMAL/ Smith-Nephew: Institutional Support</span></p>
<p style="top:398.4pt;left:62.4pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">All the other authors declare that there are no competing interests</span></p>
<p style="top:408.4pt;left:51.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">regarding the publication of this paper.</span></p>
<p style="top:437.7pt;left:51.0pt;line-height:8.5pt"><span style="font-family:XssngvAdvTTb8864ccf.B,serif;font-size:8.5pt;color:#131313">Open Access</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> This article is distributed under the terms of the Creative</span></p>
<p style="top:447.7pt;left:51.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Commons Attribution 4.0 International License (http://</span></p>
<p style="top:457.7pt;left:51.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">creativecommons.org/licenses/by/4.0/), which permits unrestricted use,</span></p>
<p style="top:467.6pt;left:51.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">distribution, and reproduction in any medium, provided you give appro-</span></p>
<p style="top:477.6pt;left:51.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">priate credit to the original author(s) and the source, provide a link to the</span></p>
<p style="top:487.6pt;left:51.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Creative Commons license, and indicate if changes were made.</span></p>
<p style="top:537.3pt;left:51.0pt;line-height:11.0pt"><span style="font-family:XssngvAdvTTb8864ccf.B,serif;font-size:11.0pt;color:#131313">References</span></p>
<p style="top:564.2pt;left:55.3pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">1.</span></p>
<p style="top:564.2pt;left:70.5pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Nair MB, Varma HK, Menon KV, Shenoy SJ, John A (2009)</span></p>
<p style="top:574.2pt;left:70.5pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Reconstruction of goat femur segmental defects using triphasic</span></p>
<p style="top:584.2pt;left:70.5pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">ceramic-coated hydroxyapatite in combination with autologous</span></p>
<p style="top:594.2pt;left:70.5pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">cells and platelet-rich plasma. Acta Biomater 5(5):1742</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">1755</span></p>
<p style="top:605.2pt;left:55.3pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">2.</span></p>
<p style="top:605.2pt;left:70.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">He F, Chen Y, Li J, Lin B, Ouyang Y, Yu B, Xia Y, Yu B, Ye J</span></p>
<p style="top:615.2pt;left:70.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">(2015) Improving bone repair of femoral and radial defects in rabbit</span></p>
<p style="top:625.2pt;left:70.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">by incorporating PRP into PLGA/CPC composite scaffold with</span></p>
<p style="top:635.1pt;left:70.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">unidirectional pore structure. J Biomed Mater Res A 103(4):</span></p>
<p style="top:645.1pt;left:70.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">1312</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">1324</span></p>
<p style="top:656.1pt;left:55.3pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">3.</span></p>
<p style="top:656.1pt;left:70.5pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Stevens MM (2008) Biomaterials for bone tissue engineering.</span></p>
<p style="top:666.1pt;left:70.5pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Mater Today 11(5):18</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">25</span></p>
<p style="top:677.1pt;left:55.3pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">4.</span></p>
<p style="top:677.1pt;left:70.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Sarkar MR, Augat P, Shefelbine SJ, Schorlemmer S, Huber-Lang</span></p>
<p style="top:687.1pt;left:70.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">M, Claes L, Kinzl L, Ignatius A (2006) Bone formation in a long</span></p>
<p style="top:697.1pt;left:70.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">bone defect model using a platelet-rich plasma-loaded collagen</span></p>
<p style="top:707.1pt;left:70.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">scaffold. Biomaterials 27(9):1817</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">1823</span></p>
<p style="top:57.1pt;left:310.5pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">5.</span></p>
<p style="top:57.1pt;left:325.4pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Roffi A, Filardo G, Kon E, Marcacci M (2013) Does PRP enhance</span></p>
<p style="top:67.1pt;left:325.4pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">bone integration with grafts, graft substitutes, or implants? A sys-</span></p>
<p style="top:77.1pt;left:325.4pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">tematic review. BMC Musculoskelet Disord 14:330</span></p>
<p style="top:87.1pt;left:310.5pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">6.</span></p>
<p style="top:87.1pt;left:325.4pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Gazdag AR, Lane JM, Glaser D, Forster RA (1995) Alternatives to</span></p>
<p style="top:97.1pt;left:325.4pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">autogenous bone graft: efficacy and indications. J Am Acad Orthop</span></p>
<p style="top:107.0pt;left:325.4pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Surg 3(1):1</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">8</span></p>
<p style="top:117.1pt;left:310.5pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">7.</span></p>
<p style="top:117.1pt;left:325.4pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Wang W, Ouyang Y, Poh CK (2011) Orthopaedic implant technol-</span></p>
<p style="top:127.1pt;left:325.4pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">ogy: biomaterials from past to future. Ann Acad Med Singapore</span></p>
<p style="top:137.0pt;left:325.4pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">40(5):237</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">244</span></p>
<p style="top:147.1pt;left:310.5pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">8.</span></p>
<p style="top:147.1pt;left:325.4pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Lieberman JR, Daluiski A, Einhorn TA (2002) The role of growth</span></p>
<p style="top:157.1pt;left:325.4pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">factors in the repair of bone. Biology and clinical applications. J</span></p>
<p style="top:167.1pt;left:325.4pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Bone Joint Surg Am 84-A(6):1032</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">1044</span></p>
<p style="top:177.1pt;left:310.5pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">9.</span></p>
<p style="top:177.1pt;left:325.4pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Hakimi M, Grassmann JP, Betsch M, Schneppendahl J, Gehrmann</span></p>
<p style="top:187.1pt;left:325.4pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">S, Hakimi AR, Kr&#xf6;pil P, Sager M, Herten M, Wild M, Windolf J,</span></p>
<p style="top:197.1pt;left:325.4pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Jungbluth P (2014) The composite of bone marrow concentrate and</span></p>
<p style="top:207.0pt;left:325.4pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">PRP as an alternative to autologous bone grafting. PLoS One 9(6),</span></p>
<p style="top:217.1pt;left:325.4pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">e100143</span></p>
<p style="top:227.0pt;left:306.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">10.</span></p>
<p style="top:227.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Brownlow HC, Simpson AH (2000) Metabolic activity of a new</span></p>
<p style="top:237.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">atrophic nonunion model in rabbits. J Orthop Res 18(3):438</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">442</span></p>
<p style="top:247.1pt;left:306.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">11.</span></p>
<p style="top:247.1pt;left:324.9pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Di Matteo B, Filardo G, Kon E, Marcacci M (2015) Platelet-rich</span></p>
<p style="top:257.1pt;left:324.9pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">plasma: evidence for the treatment of patellar and Achilles</span></p>
<p style="top:267.1pt;left:324.9pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">tendinopathy-a systematic review. Musculoskelet Surg 99(1):1</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">9</span></p>
<p style="top:277.1pt;left:306.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">12.</span></p>
<p style="top:277.1pt;left:325.3pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Rodriguez IA, Growney Kalaf EA, Bowlin GL, Sell SA (2014)</span></p>
<p style="top:287.1pt;left:325.3pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Platelet-rich plasma in bone regeneration: engineering the delivery</span></p>
<p style="top:297.1pt;left:325.3pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">for improved clinical efficacy. Biomed Res Int. doi:</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#392a96">10.1155/2014</span></p>
<p style="top:307.1pt;left:325.3pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#392a96">/392398</span></p>
<p style="top:317.1pt;left:306.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">13.</span></p>
<p style="top:317.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Kasten P, Vogel J, Luginb&#xfc;hl R, Niemeyer P, Weiss S, Schneider S,</span></p>
<p style="top:327.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Kramer M, Leo A, Richter W (2006) Influence of platelet-rich</span></p>
<p style="top:337.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">plasma on osteogenic differentiation of mesenchymal stem cells</span></p>
<p style="top:347.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">and ectopic bone formation in calcium phosphate ceramics. Cells</span></p>
<p style="top:357.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Tissues Organs 183(2):68</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">79</span></p>
<p style="top:367.1pt;left:306.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">14.</span></p>
<p style="top:367.1pt;left:325.9pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">El Backly RM, Zaky SH, Muraglia A, Tonachini L, Brun F,</span></p>
<p style="top:377.1pt;left:325.9pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Canciani B, Chiapale D, Santolini F, Cancedda R,</span></p>
<p style="top:387.1pt;left:325.9pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Mastrogiacomo M (2013) A platelet-rich plasma-based membrane</span></p>
<p style="top:397.0pt;left:325.9pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">as a periosteal substitute with enhanced osteogenic and angiogenic</span></p>
<p style="top:407.0pt;left:325.9pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">properties: a new concept for bone repair. Tissue Eng Part A 19(1</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span></p>
<p style="top:417.1pt;left:325.9pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">2):152</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">165</span></p>
<p style="top:427.0pt;left:306.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">15.</span></p>
<p style="top:427.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">McLaughlin M, Gagnet P, Cunningham E, Yeager R, D</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2019;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Amico M,</span></p>
<p style="top:437.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Guski K, Scarpone M, Kuebler D (2016) Allogeneic platelet</span></p>
<p style="top:447.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">releasate preparations derived via a novel rapid thrombin</span></p>
<p style="top:457.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">activationp process promote rapid growth and increased BMP-2</span></p>
<p style="top:467.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">and BMP-4 expression in human adipose-derived stem cells.</span></p>
<p style="top:477.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Stem Cells Int. doi:</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#392a96">10.1155/2016/7183734</span></p>
<p style="top:487.1pt;left:306.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">16.</span></p>
<p style="top:487.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Casati L, Celotti F, Negri-Cesi P, Sacchi MC, Castano P, Colciago A</span></p>
<p style="top:497.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">(2014) Platelet derived growth factor (PDGF) contained in platelet</span></p>
<p style="top:507.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">rich plasma (PRP) stimulates migration of osteoblasts by</span></p>
<p style="top:517.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">reorganizing actin cytoskeleton. Cell Adh Migr 8(6):595</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">602</span></p>
<p style="top:527.0pt;left:306.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">17.</span></p>
<p style="top:527.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Mariani E, Filardo G, Canella V, Berlingeri A, Bielli A, Cattini L,</span></p>
<p style="top:537.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Landini MP, Kon E, Marcacci M, Facchini A (2014) Platelet-rich</span></p>
<p style="top:547.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">plasma affects bacterial growth in vitro. Cytotherapy 16(9):1294</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span></p>
<p style="top:557.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">1304</span></p>
<p style="top:567.0pt;left:306.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">18.</span></p>
<p style="top:567.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Mariani E, Canella V, Berlingeri A, Bielli A, Cattini L, Landini MP,</span></p>
<p style="top:577.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Kon E, Marcacci M, Di Matteo B, Filardo G (2015) Leukocyte</span></p>
<p style="top:587.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">presence does not increase microbicidal activity of platelet-rich</span></p>
<p style="top:597.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">plasma in vitro. BMC Microbiol 15:149</span></p>
<p style="top:607.0pt;left:306.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">19.</span></p>
<p style="top:607.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Arpornmaeklong P, Kochel M, Depprich R, K&#xfc;bler NR, W&#xfc;rzler</span></p>
<p style="top:617.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">KK (2004) Influence of platelet-rich plasma (PRP) on osteogenic</span></p>
<p style="top:627.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">differentiation of rat bone marrow stromal cells. An in vitro study.</span></p>
<p style="top:637.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Int J Oral Maxillofac Surg 33(1):60</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">70</span></p>
<p style="top:647.0pt;left:306.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">20.</span></p>
<p style="top:647.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Mooren RE, Hendriks EJ, van den Beucken JJ, Merkx MA, Meijer</span></p>
<p style="top:657.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">GJ, Jansen JA, Stoelinga PJ (2010) The effect of platelet-rich plas-</span></p>
<p style="top:667.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">ma in vitro on primary cells: rat osteoblast-like cells and human</span></p>
<p style="top:677.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">endothelial cells. Tissue Eng Part A 16(10):3159</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">3172</span></p>
<p style="top:687.1pt;left:306.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">21.</span></p>
<p style="top:687.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Perut F, Filardo G, Mariani E, Cenacchi A, Pratelli L, Devescovi V,</span></p>
<p style="top:697.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Kon E, Marcacci M, Facchini A, Baldini N, Granchi D (2013)</span></p>
<p style="top:707.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Preparation method and growth factor content of platelet</span></p>
<p style="top:33.1pt;left:51.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">234</span></p>
<p style="top:33.1pt;left:359.8pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">International Orthopaedics (SICOT) (2017) 41:221</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">237</span></p>


<p style="top:57.1pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">concentrate influence the osteogenic differentiation of bone marrow</span></p>
<p style="top:67.1pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">stromal cells. Cytotherapy 15(7):830</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">839</span></p>
<p style="top:77.1pt;left:51.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">22.</span></p>
<p style="top:77.1pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Hokugo A, Sawada Y, Hokugo R et al (2007) Controlled release of</span></p>
<p style="top:87.1pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">platelet growth factors enhances bone regeneration at rabbit</span></p>
<p style="top:97.1pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">calvaria. Oral Surg, Oral Med, Oral Pathol, Oral Radiol Endod</span></p>
<p style="top:107.1pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">104(1):44</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">48</span></p>
<p style="top:117.1pt;left:51.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">23.</span></p>
<p style="top:117.1pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Sugimori E, Shintani S, Ishikawa K, Hamakawa H (2006) Effects</span></p>
<p style="top:127.1pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">of apatite foam combined with platelet-rich plasma on regeneration</span></p>
<p style="top:137.1pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">of bone defects. Dent Mater J 25(3):591</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">596</span></p>
<p style="top:147.1pt;left:51.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">24.</span></p>
<p style="top:147.1pt;left:70.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Rai B, Oest ME, Dupont KM, Ho KH, Teoh SH, Guldberg RE</span></p>
<p style="top:157.1pt;left:70.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">(2007) Combination of platelet-rich plasma with</span></p>
<p style="top:167.1pt;left:70.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">polycaprolactone-tricalcium phosphate scaffolds for segmental</span></p>
<p style="top:177.1pt;left:70.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">bone defect repair. J Biomed Mater Res A 81(4):888</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">899</span></p>
<p style="top:187.1pt;left:51.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">25.</span></p>
<p style="top:187.1pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Kasten P, Vogel J, Geiger F, Niemeyer P, Luginb&#xfc;hl R, Szalay K</span></p>
<p style="top:197.1pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">(2008) The effect of platelet-rich plasma on healing in critical-size</span></p>
<p style="top:207.1pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">long-bone defects. Biomaterials 29(29):3983</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">3992</span></p>
<p style="top:217.1pt;left:51.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">26.</span></p>
<p style="top:217.1pt;left:70.4pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Lysiak-Drwal K, Dominiak M, Solski L, Zywicka B, Pielka S,</span></p>
<p style="top:227.1pt;left:70.4pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Konopka T, Gerber H (2008) Early histological evaluation of bone</span></p>
<p style="top:237.1pt;left:70.4pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">defect healing with and without guided bone regeneration tech-</span></p>
<p style="top:247.1pt;left:70.4pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">niques: experimental animal studies. Postepy Hig Med Dosw</span></p>
<p style="top:257.0pt;left:70.4pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">(Online) 62:282</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">288</span></p>
<p style="top:267.1pt;left:51.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">27.</span></p>
<p style="top:267.1pt;left:71.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Niemeyer P, Fechner K, Milz S, Richter W, Suedkamp NP,</span></p>
<p style="top:277.1pt;left:71.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Mehlhorn AT, Pearce S, Kasten P (2010) Comparison of mesen-</span></p>
<p style="top:287.1pt;left:71.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">chymal stem cells from bone marrow and adipose tissue for bone</span></p>
<p style="top:297.1pt;left:71.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">regeneration in a critical size defect of the sheep tibia and the influ-</span></p>
<p style="top:307.0pt;left:71.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">ence of platelet-rich plasma. Biomaterials 31(13):3572</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">3579</span></p>
<p style="top:317.1pt;left:51.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">28.</span></p>
<p style="top:317.1pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Bi L, Cheng W, Fan H, Pei G (2010) Reconstruction of goat tibial</span></p>
<p style="top:327.1pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">defects using an injectable tricalcium phosphate/chitosan in combi-</span></p>
<p style="top:337.1pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">nation with autologous platelet-rich plasma. Biomaterials 31(12):</span></p>
<p style="top:347.1pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">3201</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">3211</span></p>
<p style="top:357.1pt;left:51.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">29.</span></p>
<p style="top:357.1pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Kon E, Filardo G, Delcogliano M, Fini M, Salamanna F, Giavaresi</span></p>
<p style="top:367.1pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">G, Martin I, Marcacci M (2010) Platelet autologous growth factors</span></p>
<p style="top:377.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">decrease the osteochondral regeneration capability of a collagen-</span></p>
<p style="top:387.1pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">hydroxyapatite scaffold in a sheep model. BMC Musculoskelet</span></p>
<p style="top:397.1pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Disord 11:220</span></p>
<p style="top:407.1pt;left:51.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">30.</span></p>
<p style="top:407.1pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Kanthan SR, Kavitha G, Addi S, Choon DS, Kamarul T (2011)</span></p>
<p style="top:417.1pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Platelet-rich plasma (PRP) enhances bone healing in non-united</span></p>
<p style="top:427.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">critical-sized defects: a preliminary study involving rabbit models.</span></p>
<p style="top:437.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Injury 42(8):782</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">789</span></p>
<p style="top:447.1pt;left:51.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">31.</span></p>
<p style="top:447.1pt;left:70.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Zhang YD, Wang G, Sun Y, Zhang CQ (2011) Combination of</span></p>
<p style="top:457.1pt;left:70.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">platelet-rich plasma with degradable bioactive borate glass for seg-</span></p>
<p style="top:467.1pt;left:70.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">mental bone defect repair. Acta Orthop Belg 77(1):110</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">115</span></p>
<p style="top:477.1pt;left:51.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">32.</span></p>
<p style="top:477.1pt;left:70.4pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Parizi AM, Oryan A, Shafiei-Sarvestani Z, Bigham AS (2012)</span></p>
<p style="top:487.1pt;left:70.4pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Human platelet rich plasma plus Persian Gulf coral effects on ex-</span></p>
<p style="top:497.1pt;left:70.4pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">perimental bone healing in rabbit model: radiological, histological,</span></p>
<p style="top:507.0pt;left:70.4pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">macroscopical and biomechanical evaluation. J Mater Sci: Mater</span></p>
<p style="top:517.1pt;left:70.4pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Med 23(2):473</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">483</span></p>
<p style="top:527.1pt;left:51.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">33.</span></p>
<p style="top:527.1pt;left:70.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Oryan A, Meimandi Parizi A, Shafiei-Sarvestani Z, Bigham AS</span></p>
<p style="top:537.1pt;left:70.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">(2012) Effects of combined hydroxyapatite and human platelet rich</span></p>
<p style="top:547.0pt;left:70.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">plasma on bone healing in rabbit model: radiological,</span></p>
<p style="top:557.0pt;left:70.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">macroscopical, hidtopathological and biomechanical evaluation.</span></p>
<p style="top:567.1pt;left:70.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Cell Tissue Bank 13(4):639</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">651</span></p>
<p style="top:577.1pt;left:51.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">34.</span></p>
<p style="top:577.1pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Kasten P, Beverungen M, Lorenz H, Wieland J, Fehr M, Geiger F</span></p>
<p style="top:587.1pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">(2012) Comparison of platelet-rich plasma and VEGF-transfected</span></p>
<p style="top:597.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">mesenchymal stem cells on vascularization and bone formation in a</span></p>
<p style="top:607.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">critical-size bone defect. Cells Tissues Organs 196(6):523</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">533</span></p>
<p style="top:617.1pt;left:51.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">35.</span></p>
<p style="top:617.1pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Kim YH, Furuya H, Tabata Y (2014) Enhancement of bone regen-</span></p>
<p style="top:627.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">eration by dual release of a macrophage recruitment agent and</span></p>
<p style="top:637.1pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">platelet-rich plasma from gelatin hydrogels. Biomaterials 35(1):</span></p>
<p style="top:647.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">214</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">224</span></p>
<p style="top:657.1pt;left:51.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">36.</span></p>
<p style="top:657.1pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Filardo G, Kon E, Tampieri A, Cabezas-Rodr&#xed;guez R, Di Martino</span></p>
<p style="top:667.1pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">A, Fini M, Giavaresi G, Lelli M, Mart&#xed;nez-Fern&#xe1;ndez J, Martini L,</span></p>
<p style="top:677.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Ram&#xed;rez-Rico J, Salamanna F, Sandri M, Sprio S, Marcacci M</span></p>
<p style="top:687.1pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">(2014) New bio-ceramization processes applied to vegetable hier-</span></p>
<p style="top:697.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">archical structures for bone regeneration: an experimental model in</span></p>
<p style="top:707.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">sheep. Tissue Eng Part A 20(3</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">4):763</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">773</span></p>
<p style="top:57.0pt;left:306.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">37.</span></p>
<p style="top:57.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Zhong D, Wang CG, Yin K, Liao Q, Zhou X, Liu AS, Kong LY</span></p>
<p style="top:67.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">(2014) In vivo ossification of a scaffold combining</span><span style="font-family:TmgcryAdvTT3713a231+03,serif;font-size:8.5pt;color:#131313"> &#x3b2;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">-tricalcium</span></p>
<p style="top:77.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">phosphate and platelet-rich plasma. Exp Ther Med 8(5):1381</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">1388</span></p>
<p style="top:87.0pt;left:306.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">38.</span></p>
<p style="top:87.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Chen H, Ji XR, Zhang Q, Tian XZ, Zhang BX, Tang PF (2016)</span></p>
<p style="top:97.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Effects of calcium sulfate combined with platelet-rich plasma on</span></p>
<p style="top:107.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">restoration of long bone defect in rabbits. Chin Med J (Engl)</span></p>
<p style="top:116.9pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">129(5):557</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">561</span></p>
<p style="top:127.0pt;left:306.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">39.</span></p>
<p style="top:127.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Dallari D, Fini M, Stagni C, Torricelli P, Nicoli Aldini N, Giavaresi</span></p>
<p style="top:137.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">G, Cenni E, Baldini N, Cenacchi A, Bassi A, Giardino R, Fornasari</span></p>
<p style="top:147.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">PM, Giunti A (2006) In vivo study on the healing of bone defects</span></p>
<p style="top:157.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">treated with bone marrow stromal cells, platelet-rich plasma, and</span></p>
<p style="top:166.9pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">freeze-dried bone allografts, alone and in combination. J Orthop</span></p>
<p style="top:177.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Res 24(5):877</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">888</span></p>
<p style="top:187.0pt;left:306.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">40.</span></p>
<p style="top:187.0pt;left:325.9pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Kroese-Deutman HC, Vehof JW, Spauwen PH, Stoelinga PJ,</span></p>
<p style="top:197.0pt;left:325.9pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Jansen JA (2008) Orthotopic bone formation in titanium fiber mesh</span></p>
<p style="top:206.9pt;left:325.9pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">loaded with platelet-rich plasma and placed in segmental defects.</span></p>
<p style="top:217.0pt;left:325.9pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Int J Oral Maxillofac Surg 37(6):542</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">549</span></p>
<p style="top:227.1pt;left:306.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">41.</span></p>
<p style="top:227.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Molina-Mi&#xf1;ano F, L&#xf3;pez-Jornet P, Camacho- Alonso F, Vicente-</span></p>
<p style="top:237.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Ortega V (2009) Plasma rich in growth factors and bone formation:</span></p>
<p style="top:247.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">a radiological and histomorphometric study in New Zealand rab-</span></p>
<p style="top:257.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">bits. Braz Oral Res 23(3):275</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">280</span></p>
<p style="top:267.1pt;left:306.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">42.</span></p>
<p style="top:267.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Hakimi M, Jungbluth P, Sager M, Betsch M, Herten M, Becker J,</span></p>
<p style="top:277.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Windolf J, Wild M (2010) Combined use of platelet-rich plasma</span></p>
<p style="top:287.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">and autologous bone grafts in the treatment of long bone defects in</span></p>
<p style="top:297.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">mini-pigs. Injury 41(7):717</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">723</span></p>
<p style="top:307.1pt;left:306.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">43.</span></p>
<p style="top:307.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Nather A, Wong KL, David V, Pereira BP (2012) Allografts with</span></p>
<p style="top:317.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">autogenous platelet-rich plasma for tibial defect reconstruction: a</span></p>
<p style="top:327.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">rabbit study. J Orthop Surg (Hong Kong) 20(3):375</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">380</span></p>
<p style="top:337.1pt;left:306.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">44.</span></p>
<p style="top:337.1pt;left:325.3pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Kurikchy MQ, Al-Rawi NH, Ayoub RS, Mohammed SS (2013)</span></p>
<p style="top:347.1pt;left:325.3pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Histological evaluation of bone healing using organic bovine bone</span></p>
<p style="top:357.1pt;left:325.3pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">in combination with platelet-rich plasma (an experimental study on</span></p>
<p style="top:367.0pt;left:325.3pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">rabbits). Clin Oral Investig 17(3):897</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">904</span></p>
<p style="top:377.1pt;left:306.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">45.</span></p>
<p style="top:377.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Zhang ZY, Huang AW, Fan JJ, Wei K, Jin D, Chen B, Li D, Bi L,</span></p>
<p style="top:387.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Wang J, Pei G (2013) The potential use of allogeneic platelet-rich</span></p>
<p style="top:397.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">plasma for large bone defect treatment: immunogenicity and defect</span></p>
<p style="top:407.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">healing efficacy. Cell Transplant 22(1):175</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">187</span></p>
<p style="top:417.1pt;left:306.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">46.</span></p>
<p style="top:417.1pt;left:325.6pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Schneppendahl J, Jungbluth P, L&#xf6;gters TT, Sager M, Wild M,</span></p>
<p style="top:427.1pt;left:325.6pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Hakimi M, Windolf J, Grassmann JP (2015) Treatment of a diaph-</span></p>
<p style="top:437.0pt;left:325.6pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">yseal long-bone defect with autologous bone grafts and platelet-rich</span></p>
<p style="top:447.1pt;left:325.6pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">plasma in a rabbit model. Vet Comp Orthop Traumatol 28(3):164</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span></p>
<p style="top:457.0pt;left:325.6pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">171</span></p>
<p style="top:467.1pt;left:306.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">47.</span></p>
<p style="top:467.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Park HC, Kim SG, Oh JS, You JS, Kim JS, Lim SC, Jeong MA,</span></p>
<p style="top:477.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Kim JS, Jung C, Kwon YS, Ji H (2016) Early bone formation at a</span></p>
<p style="top:487.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">femur defect using CGF and PRF grafts in adult dogs: a compara-</span></p>
<p style="top:497.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">tive study. Implant Dent 25(3):387</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">393</span></p>
<p style="top:507.0pt;left:306.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">48.</span></p>
<p style="top:507.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Rabillard M, Grand JG, Dalibert E, Fellah B, Gauthier O, Niebauer</span></p>
<p style="top:517.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">GW (2009) Effects of autologous platelet rich plasma gel and cal-</span></p>
<p style="top:527.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">cium phosphate biomaterials on bone healing in an ulnar ostectomy</span></p>
<p style="top:537.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">model in dogs. Vet Comp Orthop Traumatol 22(6):460</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">466</span></p>
<p style="top:547.1pt;left:306.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">49.</span></p>
<p style="top:547.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Jungbluth P, Wild M, Grassmann JP, Ar E, Sager M, Herten M,</span></p>
<p style="top:557.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">J&#xe4;ger M, Becker J, Windolf J, Hakimi M (2010) Platelet-rich plas-</span></p>
<p style="top:567.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">ma on calcium phosphate granules promotes metaphyseal bone</span></p>
<p style="top:577.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">healing in mini-pigs. J Orthop Res 28(11):1448</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">1455</span></p>
<p style="top:587.1pt;left:306.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">50.</span></p>
<p style="top:587.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Batista MA, Leivas TP, Rodrigues CJ, Arenas GC, Belitardo DR,</span></p>
<p style="top:597.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Guarniero R (2011) Comparison between the effects of platelet-rich</span></p>
<p style="top:607.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">plasma and bone marrow concentrate on defect consolidation in the</span></p>
<p style="top:617.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">rabbit tibia. Clinics (Sao Paulo) 66(10):1787</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">1792</span></p>
<p style="top:627.0pt;left:306.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">51.</span></p>
<p style="top:627.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">B&#xf6;l&#xfc;kba</span><span style="font-family:TrlnccAdvTT3713a231+01,serif;font-size:8.5pt;color:#131313">&#x15f;&#x131;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313"> N, Yeniyol S, Tekkesin MS, Altunatmaz K (2013) The</span></p>
<p style="top:637.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">use of platelet-rich fibrin in combination with biphasic calcium</span></p>
<p style="top:647.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">phosphate in the treatment of bone defects: a histologic and</span></p>
<p style="top:657.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">histomorphometric study. Curr Ther Res Clin Exp 75:15</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">21</span></p>
<p style="top:667.1pt;left:306.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">52.</span></p>
<p style="top:667.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Hakimi M, Grassmann JP, Betsch M, Schneppendahl J, Gehrmann</span></p>
<p style="top:677.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">S, Hakimi AR, Kr&#xf6;pil P, Sager M, Herten M, Wild M, Windolf J,</span></p>
<p style="top:687.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Jungbluth P (2014) The composite of bone marrow concentrate and</span></p>
<p style="top:697.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">PRP as an alternative to autologous bone grafting. PLoS One</span></p>
<p style="top:707.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">20;9(6):e100143</span></p>
<p style="top:33.1pt;left:51.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">International Orthopaedics (SICOT) (2017) 41:221</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">237</span></p>
<p style="top:33.1pt;left:531.7pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">235</span></p>


<p style="top:57.1pt;left:51.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">53.</span></p>
<p style="top:57.1pt;left:70.3pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Yilmaz D, Dogan N, Ozkan A, Sencimen M, Ora BE, Mutlu I</span></p>
<p style="top:67.1pt;left:70.3pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">(2014) Effect of platelet rich fibrin and beta tricalcium phosphate</span></p>
<p style="top:77.1pt;left:70.3pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">on bone healing. A histological study in pigs. Acta Cir Bras 29(1):</span></p>
<p style="top:87.0pt;left:70.3pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">59</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">65</span></p>
<p style="top:97.1pt;left:51.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">54.</span></p>
<p style="top:97.1pt;left:71.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Malhotra R, Kumar V, Garg B, Singh R, Jain V, Coshic P,</span></p>
<p style="top:107.1pt;left:71.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Chatterjee K (2015) Role of autologous platelet-rich plasma in</span></p>
<p style="top:117.0pt;left:71.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">treatment of long-bone nonunions: a prospective study.</span></p>
<p style="top:127.1pt;left:71.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Musculoskelet Surg 99(3):243</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">248</span></p>
<p style="top:137.0pt;left:51.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">55.</span></p>
<p style="top:137.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Qi Y, Niu L, Zhao T, Shi Z, Di T, Feng G, Li J, Huang Z (2015)</span></p>
<p style="top:147.1pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Combining mesenchymal stem cell sheets with platelet-rich plasma</span></p>
<p style="top:157.1pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">gel/calcium phosphate particles: a novel strategy to promote bone</span></p>
<p style="top:167.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">regeneration. Stem Cell Res Ther 6:256</span></p>
<p style="top:177.1pt;left:51.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">56.</span></p>
<p style="top:177.1pt;left:70.7pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Emilov-Velev K, Clemente-de-Arriba C, Alobera-Garc&#xed;a M&#xc1;,</span></p>
<p style="top:187.0pt;left:70.6pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Moreno-Sansalvador EM, Campo-Loarte J (2015) Bone regenera-</span></p>
<p style="top:197.1pt;left:70.6pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">tion in experimental animals using calcium phosphate cement com-</span></p>
<p style="top:207.1pt;left:70.6pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">bined with platelet growth factors and human growth hormone. Rev</span></p>
<p style="top:217.0pt;left:70.6pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Esp Cir Ortop Traumatol 59(3):200</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">210</span></p>
<p style="top:227.1pt;left:51.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">57.</span></p>
<p style="top:227.1pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Simman R, Hoffmann A, Bohinc RJ, Peterson WC, Russ AJ (2008)</span></p>
<p style="top:237.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Role of platelet-rich plasma in acceleration of bone fracture healing.</span></p>
<p style="top:247.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Ann Plast Surg 61(3):337</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">344</span></p>
<p style="top:257.0pt;left:51.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">58.</span></p>
<p style="top:257.0pt;left:70.8pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Gumieiro EH, Abrah&#xe3;o M, Jahn RS, Segretto H, Alves MT,</span></p>
<p style="top:267.0pt;left:70.8pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Nannmark U, Granstr&#xf6;m G, Dib LL (2010) Platelet-rich plasma</span></p>
<p style="top:277.1pt;left:70.8pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">in bone repair of irradiated tibiae of Wistar rats. Acta Cirurgica</span></p>
<p style="top:287.0pt;left:70.8pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Brasileira 25(3):257</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">263</span></p>
<p style="top:297.1pt;left:51.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">59.</span></p>
<p style="top:297.1pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Souza TF, Andrade AL, Ferreira GT, Sakamoto SS, Albuquerque</span></p>
<p style="top:307.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">VB, Bonfim SR, Luvizotto MC, Louzada MJ (2012) Healing and</span></p>
<p style="top:317.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">expression of growth factors (TGF-&#xdf; and PDGF) in canine radial</span></p>
<p style="top:327.1pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">ostectomy gap containing platelet-rich plasma. Vet Comp Orthop</span></p>
<p style="top:337.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Traumatol 25(6):445</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">452</span></p>
<p style="top:347.1pt;left:51.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">60.</span></p>
<p style="top:347.1pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Chen L, Yang X, Huang G, Song D, Ye XS, Xu H, Li W (2013)</span></p>
<p style="top:357.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Platelet-rich plasma promotes healing of osteoporotic fractures.</span></p>
<p style="top:367.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Orthopedics 36(6):e687</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">e694</span></p>
<p style="top:377.0pt;left:51.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">61.</span></p>
<p style="top:377.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Neves PC, Abib Sde C, Neves RF, Pircchio O, Saad KR, Saad PF,</span></p>
<p style="top:387.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Sim&#xf5;es RS, Moreira MB, Laurino CF (2013) Effect of hyperbaric</span></p>
<p style="top:397.1pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">oxygen therapy combined with autologous platelet concentrate ap-</span></p>
<p style="top:407.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">plied in rabbit fibula fraction healing. Clin (Sao Paulo) 68(9):1239</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span></p>
<p style="top:417.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">1246</span></p>
<p style="top:427.0pt;left:51.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">62.</span></p>
<p style="top:427.0pt;left:70.6pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Hernandez-Fernandez A, V&#xe9;lez R, Soldado F, Saenz-Rios JC,</span></p>
<p style="top:437.0pt;left:70.6pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Barber I, Aguirre-Canyadell M (2013) Effect of administration of</span></p>
<p style="top:447.0pt;left:70.6pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">platelet-rich plasma in early phases of distraction osteogenesis: an</span></p>
<p style="top:457.0pt;left:70.6pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">experimental study in an ovine femur model. Injury 44(7):901</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">907</span></p>
<p style="top:467.0pt;left:51.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">63.</span></p>
<p style="top:467.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Guzel Y, Karalezli N, Bilge O, Kacira BK, Esen H, Karadag H,</span></p>
<p style="top:477.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Toker S, G&#xf6;nc&#xfc; RG, Doral MN (2015) The biomechanical and</span></p>
<p style="top:487.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">histological effects of platelet-rich plasma on fracture healing.</span></p>
<p style="top:497.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Knee Surg Sports Traumatol Arthrosc 23(5):1378</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">1383</span></p>
<p style="top:507.0pt;left:51.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">64.</span></p>
<p style="top:507.0pt;left:70.5pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Rodriguez-Collazo ER, Urso ML (2015) Combined use of the</span></p>
<p style="top:517.0pt;left:70.5pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Ilizarov method, concentrated bone marrow aspirate (cBMA), and</span></p>
<p style="top:527.0pt;left:70.5pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">platelet-rich plasma (PRP) to expedite healing of bimalleolar frac-</span></p>
<p style="top:537.0pt;left:70.5pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">tures. Strateg Trauma Limb Reconstr 10(3):161</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">166</span></p>
<p style="top:547.0pt;left:51.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">65.</span></p>
<p style="top:547.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Dallari D, Savarino L, Stagni C, Cenni E, Cenacchi A, Fornasari</span></p>
<p style="top:557.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">PM, Albisinni U, Rimondi E, Baldini N, Giunti A (2007) Enhanced</span></p>
<p style="top:567.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">tibial osteotomy healing with use of bone grafts supplemented with</span></p>
<p style="top:577.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">platelet gel or platelet gel and bone marrow stromal cells. J Bone</span></p>
<p style="top:587.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Joint Surg Am 89(11):2413</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">2420</span></p>
<p style="top:597.0pt;left:51.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">66.</span></p>
<p style="top:597.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Peerbooms JC, Colaris JW, Hakkert AA, Van Appeldorn M, Bruijn</span></p>
<p style="top:607.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">DJ, Den Oudsten BL, Gosens T (2012) No positive bone healing</span></p>
<p style="top:617.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">after using platelet rich plasma in a skeletal defect. An observational</span></p>
<p style="top:627.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">prospective cohort study. Int Orthop Oct 36(10):2113</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">2119</span></p>
<p style="top:637.0pt;left:51.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">67.</span></p>
<p style="top:637.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Lee DH, Ryu KJ, Kim JW, Kang KC, Choi YR (2014) Bone mar-</span></p>
<p style="top:647.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">row aspirate concentrate and platelet-rich plasma enhanced bone</span></p>
<p style="top:657.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">healing in distraction osteogenesis of the tibia. Clin Orthop Relat</span></p>
<p style="top:667.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Res 472(12):3789</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">3797</span></p>
<p style="top:677.0pt;left:51.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">68.</span></p>
<p style="top:677.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Samy AM (2016) The role of platelet rich plasma in management of</span></p>
<p style="top:687.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">fracture neck femur: new insights. Int Orthop 40(5):1019</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">1024</span></p>
<p style="top:697.0pt;left:51.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">69.</span></p>
<p style="top:697.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Xavier GL, Achten J, Parsons NR, Costa ML (2013) Platelet-rich</span></p>
<p style="top:707.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">therapy in the treatment of patients with hip fractures: a single</span></p>
<p style="top:57.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">centre, parallel group, participant-blinded, randomised controlled</span></p>
<p style="top:67.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">trial. BMJ Open 3(6). doi:10.1136/bmjopen-2013-002583</span></p>
<p style="top:77.0pt;left:306.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">70.</span></p>
<p style="top:77.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Wei LC, Lei GH, Sheng PY, Gao SG, Xu M, Jiang W, Song Y, Luo</span></p>
<p style="top:87.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">W (2012) Efficacy of platelet-rich plasma combined with allograft</span></p>
<p style="top:97.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">bone in the management of displaced intra-articular calcaneal frac-</span></p>
<p style="top:107.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">tures: a prospective cohort study. Orthop Res 30(10):1570</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">1576</span></p>
<p style="top:117.0pt;left:306.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">71.</span></p>
<p style="top:117.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Liebergall M, Schroeder J, Mosheiff R, Gazit Z, Yoram Z, Rasooly</span></p>
<p style="top:127.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">L, Daskal A, Khoury A, Weil Y, Beyth S (2013) Stem cell-based</span></p>
<p style="top:137.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">therapy for prevention of delayed fracture union: a randomized and</span></p>
<p style="top:147.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">prospective preliminary study. Mol Ther 21(8):1631</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">1638</span></p>
<p style="top:157.0pt;left:306.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">72.</span></p>
<p style="top:157.0pt;left:325.4pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Namazi H, Mehbudi A (2016) Investigating the effect of intra-</span></p>
<p style="top:167.0pt;left:325.4pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">articular PRP injection on pain and function improvement in pa-</span></p>
<p style="top:177.0pt;left:325.4pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">tients with distal radius fracture. Orthop Traumatol Surg Res</span></p>
<p style="top:187.0pt;left:325.4pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">102(1):47</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">52</span></p>
<p style="top:197.0pt;left:306.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">73.</span></p>
<p style="top:197.0pt;left:325.8pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Calori GM, Tagliabue L, Gala L, d</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2019;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Imporzano M, Peretti G,</span></p>
<p style="top:207.1pt;left:325.9pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Albisetti W (2008) Application of rhBMP-7 and platelet-rich plas-</span></p>
<p style="top:217.0pt;left:325.9pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">ma in the treatment of long bone non-unions: a prospective</span></p>
<p style="top:227.1pt;left:325.9pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">randomised clinical study on 120 patients. Injury 39(12):1391</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span></p>
<p style="top:237.1pt;left:325.9pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">1402</span></p>
<p style="top:247.1pt;left:306.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">74.</span></p>
<p style="top:247.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Calori GM, D</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2019;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Avino M, Tagliabue L, Albisetti W, d</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2019;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Imporzano M,</span></p>
<p style="top:257.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Peretti G (2006) An ongoing research for evaluation of treatment</span></p>
<p style="top:267.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">with BMPs or AGFs in long bone non-union: protocol description</span></p>
<p style="top:277.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">and preliminary results. Injury 37(Suppl 3):S43</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">S50</span></p>
<p style="top:287.1pt;left:306.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">75.</span></p>
<p style="top:287.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Tarallo L, Mugnai R, Adani R, Catani F (2012) Treatment of the</span></p>
<p style="top:297.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">ulna non-unions using dynamic compression plate fixation, iliac</span></p>
<p style="top:307.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">bone grafting and autologous platelet concentrate. Eur J Orthop</span></p>
<p style="top:317.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Surg Traumatol 22(8):681</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">687. doi:</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#392a96">10.1007/s00590-011-0902-y</span></p>
<p style="top:327.1pt;left:306.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">76.</span></p>
<p style="top:327.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Mariconda M, Cozzolino F, Cozzolino A, D</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2019;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Agostino E, Bove A,</span></p>
<p style="top:337.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Milano C (2008) Platelet gel supplementation in long bone non-</span></p>
<p style="top:347.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">unions treated by external fixation. J Orthop Trauma 22(5):342</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">345</span></p>
<p style="top:357.1pt;left:306.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">77.</span></p>
<p style="top:357.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Say F, T&#xfc;rkeli E, B&#xfc;lb&#xfc;l M (2014) Is platelet-rich plasma injection</span></p>
<p style="top:367.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">an effective choice in cases of non-union? Acta Chir Orthop</span></p>
<p style="top:377.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Traumatol Cech 81(5):340</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">345</span></p>
<p style="top:387.0pt;left:306.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">78.</span></p>
<p style="top:387.0pt;left:326.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Malhotra R, Kumar V, Garg B, Singh R, Jain V, Coshic P,</span></p>
<p style="top:397.1pt;left:326.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Chatterjee K (2015) Role of autologous platelet-rich plasma in</span></p>
<p style="top:407.1pt;left:326.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">treatment of long-bone nonunions: a prospective study.</span></p>
<p style="top:417.0pt;left:326.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Musculoskelet Surg 99(3):243</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">248</span></p>
<p style="top:427.1pt;left:306.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">79.</span></p>
<p style="top:427.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Go</span><span style="font-family:TrlnccAdvTT3713a231+01,serif;font-size:8.5pt;color:#131313">&#x142;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">os J, Wali</span><span style="font-family:TrlnccAdvTT3713a231+01,serif;font-size:8.5pt;color:#131313">&#x144;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">ski T, Piekarczyk P, Kwiatkowski K (2014) Results</span></p>
<p style="top:437.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">of the use of platelet rich plasma in the treatment of delayed union</span></p>
<p style="top:447.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">of long bones.Ortop. Traumatol Rehabil 16(4):397</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">406</span></p>
<p style="top:457.0pt;left:306.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">80.</span></p>
<p style="top:457.0pt;left:325.4pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Galasso O, Mariconda M, Romano G, Capuano N, Romano L,</span></p>
<p style="top:467.0pt;left:325.4pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Iann&#xf2; B, Milano C (2008) Expandable intramedullary nailing and</span></p>
<p style="top:477.1pt;left:325.4pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">platelet rich plasma to treat long bone non-unions. J Orthop</span></p>
<p style="top:487.0pt;left:325.4pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Traumatol 9(3):129</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">134</span></p>
<p style="top:497.1pt;left:306.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">81.</span></p>
<p style="top:497.1pt;left:325.4pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Sanchez M, Anitua E, Cugat R, Azofra J, Guadilla J, Seijas R,</span></p>
<p style="top:507.0pt;left:325.4pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Andia I (2009) Nonunions treated with autologous preparation rich</span></p>
<p style="top:517.0pt;left:325.4pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">in growth factors. J Orthop Trauma 23(1):52</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">59</span></p>
<p style="top:527.1pt;left:306.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">82.</span></p>
<p style="top:527.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Bielecki T, Gazdzik TS, Szczepanski T (2008) Benefit of percuta-</span></p>
<p style="top:537.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">neous injection of autologous platelet-leukocyte-rich gel in patients</span></p>
<p style="top:547.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">with delayed union and nonunion. Eur Surg Res 40(3):289</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">296</span></p>
<p style="top:557.0pt;left:306.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">83.</span></p>
<p style="top:557.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Chiang CC, Su CY, Huang CK, Chen WM, Chen TH, Tzeng YH</span></p>
<p style="top:567.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">(2007) Early experience and results of bone graft enriched with</span></p>
<p style="top:577.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">autologous platelet gel for recalcitrant nonunions of lower extrem-</span></p>
<p style="top:587.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">ity. J Trauma 63(3):655</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">661</span></p>
<p style="top:597.1pt;left:306.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">84.</span></p>
<p style="top:597.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Andriolo L, Di Matteo B, Kon E, Filardo G, Venieri G, Marcacci M</span></p>
<p style="top:607.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">(2015) PRP Augmentation for ACL Reconstruction. Biomed Res</span></p>
<p style="top:617.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Int 2015:371746</span></p>
<p style="top:627.0pt;left:306.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">85.</span></p>
<p style="top:627.0pt;left:325.6pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Filardo G, Di Matteo B, Kon E, Merli G, Marcacci M (2016)</span></p>
<p style="top:637.0pt;left:325.6pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Platelet-rich plasma in tendon-related disorders: results and indica-</span></p>
<p style="top:647.1pt;left:325.6pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">tions. Knee Surg Sports Traumatol Arthrosc. doi:</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#392a96">10.1007/s00167-</span></p>
<p style="top:657.0pt;left:325.6pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#392a96">016-4261-4</span></p>
<p style="top:667.1pt;left:306.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">86.</span></p>
<p style="top:667.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Marmotti A, Rossi R, Castoldi F, Roveda E, Michielon G, Peretti</span></p>
<p style="top:677.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">GM (2015) PRP and articular cartilage: a clinical update. Biomed</span></p>
<p style="top:687.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Res Int 2015:542502</span></p>
<p style="top:697.1pt;left:306.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">87.</span></p>
<p style="top:697.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Reichert JC, Saifzadeh S, Wullschleger ME, Epari DR, Sch&#xfc;tz MA,</span></p>
<p style="top:707.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Duda GN, Schell H, van Griensven M, Redl H, Hutmacher DW</span></p>
<p style="top:33.1pt;left:51.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">236</span></p>
<p style="top:33.1pt;left:359.8pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">International Orthopaedics (SICOT) (2017) 41:221</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">237</span></p>


<p style="top:57.1pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">(2009) The challenge of establishing preclinical models for seg-</span></p>
<p style="top:67.1pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">mental bone defect research. Biomaterials 30(12):2149</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">2163</span></p>
<p style="top:77.1pt;left:51.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">88.</span></p>
<p style="top:77.1pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Gianakos A, Zambrana L, Savage-Elliott I, Lane JM, Kennedy JG</span></p>
<p style="top:87.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">(2015) Platelet-rich plasma in the animal long-bone model: an anal-</span></p>
<p style="top:97.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">ysis of basic science evidence. Orthopedics 38(12):e1079</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">e1090</span></p>
<p style="top:107.1pt;left:51.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">89.</span></p>
<p style="top:107.1pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Tschon M, Fini M, Giardino R, Filardo G, Dallari D, Torricelli P,</span></p>
<p style="top:117.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Martini L, Giavaresi G, Kon E, Maltarello MC, Nicolini A, Carpi A</span></p>
<p style="top:127.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">(2011) Lights and shadows concerning platelet products for mus-</span></p>
<p style="top:137.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">culoskeletal regeneration. Front Biosci (Elite Ed) 1(3):96</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">107</span></p>
<p style="top:147.0pt;left:51.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">90.</span></p>
<p style="top:147.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Weibrich G, Hansen T, Kleis W, Buch R, Hitzler WE (2004) Effect</span></p>
<p style="top:157.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">of platelet concentration in platelet-rich plasma on peri-implant</span></p>
<p style="top:167.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">bone regeneration. Bone 34(4):665</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">671</span></p>
<p style="top:176.9pt;left:51.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">91.</span></p>
<p style="top:176.9pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Roffi A, Filardo G, Assirelli E, Cavallo C, Cenacchi A, Facchini A,</span></p>
<p style="top:187.0pt;left:70.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Grigolo B, Kon E, Mariani E, Pratelli L, Pulsatelli L, Marcacci M</span></p>
<p style="top:57.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">(2014) Does platelet-rich plasma freeze-thawing influence growth</span></p>
<p style="top:67.1pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">factor release and their effects on chondrocytes and synoviocytes?</span></p>
<p style="top:77.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Biomed Res Int 2014:692913</span></p>
<p style="top:88.0pt;left:306.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">92.</span></p>
<p style="top:88.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Cavallo C, Roffi A, Grigolo B, Mariani E, Pratelli L, Merli G, Kon</span></p>
<p style="top:98.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">E, Marcacci M, Filardo G (2016) Platelet-rich plasma: the choice of</span></p>
<p style="top:108.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">activation method affects the release of bioactive molecules.</span></p>
<p style="top:118.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Biomed Res Int 2016:6591717</span></p>
<p style="top:129.0pt;left:306.1pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">93.</span></p>
<p style="top:129.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Dohan Ehrenfest DM, Bielecki T, Jimbo R, Barb&#xe9; G, Del Corso M,</span></p>
<p style="top:138.9pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">Inchingolo F, Sammartino G (2012) Do the fibrin architecture and</span></p>
<p style="top:149.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">leukocyte content influence the growth factor release of platelet</span></p>
<p style="top:159.0pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">concentrates? An evidence-based answer comparing a pure</span></p>
<p style="top:168.9pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">platelet-rich plasma (P-PRP) gel and a leukocyte- and platelet-rich</span></p>
<p style="top:178.9pt;left:325.2pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">fibrin (L-PRF). Curr Pharm Biotechnol 13(7):1145</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">1152</span></p>
<p style="top:33.1pt;left:51.0pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">International Orthopaedics (SICOT) (2017) 41:221</span><span style="font-family:VjrgsxAdvTT3713a231+20,serif;font-size:8.5pt;color:#131313">&#x2013;</span><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">237</span></p>
<p style="top:33.1pt;left:531.7pt;line-height:8.5pt"><span style="font-family:SbrfrvAdvTT3713a231,serif;font-size:8.5pt;color:#131313">237</span></p>

</div>
